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Mass spectrometry (MS)-based biophysical approaches are new “tools” for protein 
characterization owing to its capability to analyze proteins and protein complexes that range in 
molecular weight from kDa to MDa. Protein characterization requires more than identifying the 
primary structure. More importantly, protein high order structures (i.e., secondary, tertiary and 
quaternary structures) are needed for biological studies. MS has become the major tool in studies 
of protein primary structure and post translational modifications (PTMs) over the past two 
decades. Because MS has high sensitivity and fast turnaround, more and more biophysical 
approaches rely on MS to generate information for protein higher order structures.  
One of the emerging biophysical approaches is MS-based protein footprinting. Protein surface 
regions can be covalently labeled by chemical reagents in a biologically relevant environment. 
These chemical labels can be read out by MS through either bottom-up or top-down MS 
proteomics analysis. The outcome provides protein conformational information. Among various 
chemical labeling strategies, hydrogen deuterium exchange (HDX) is one of the most commonly 
used approaches in MS-based protein biophysical studies.  
HDX-MS is introduced in Chapter 1 by covering the early developments and new applications 
especially in measuring interaction affinities. Although HDX-MS has been developed for 
decades, there are still many challenges in protein characterization that require new or improved 
xi 
 
HDX method development. One such challenge is characterization of protein aggregation. 
Protein aggregation leads to loss of protein function, and protein aggregates are implicated in 
several neurodegenerative diseases like Alzheimer’s and Parkinson’s diseases. A key issue in 
studies of protein aggregation is real-time monitoring under biologically relevant condition. We 
developed an HDX-MS-based approach by studying Alzheimer’s disease related Aβ aggregation, 
and we described this development in Chapter 2. Aβ proteins are labeled by deuterium in a 
pulsed way during Aβ aggregation. The extents of aggregations are monitored by MS as 
deuterium uptake. This pulsed HDX platform provides peptide-level information about Aβ 
aggregation. Ligands (drug candidates) were also evaluated with this platform to determine how 
the drug candidates affect oligomerization (Chapter 3).  
Ligand interactions can induce protein conformational changes, which are required in various 
protein functions like signaling, enzyme activity. Such interactions are fundamental to all 
biological processes. One of the often used ligands in cells is calcium. Calcium interacts with a 
variety of calcium-binding proteins, most of which have conserved sequence that form EF-hand 
motifs to bind calcium. MS-HDX has been an important tool in studies of these typical calcium-
binding proteins. Many proteins without an EF-hand motif also require calcium for their 
function. For example, protein-arginine deiminase (PAD) is an enzyme for arginine citrullination 
and binds calcium without EF-hand motif. We conducted differential HDX studies on PAD2 
protein (Chapter 4). Multiple and cooperative calcium binding of PAD2 are detected by HDX. 
HDX was further extended by applying protein-ligand titration in an HDX experiment (i.e., 
Protein-ligand interactions by mass spectrometry, titration and H/D exchange, PLIMSTEX). The 
calcium binding affinity of each binding site can be elucidated by PLIMSTEX (Chapter 5).  
xii 
 
Protein aggregation or ligand-binding induced conformational changes can also be detected by 
MS-HDX. One significant question in MS-based biophysical studies is how to generate 
structural information for proteins in the absence of a high resolution structure. In a newly 
developed platform, we combined a traditional structural biology approach, homology modeling, 
and MS-HDX to generate a structural model for diheme cytochrome c (DHCC) from 
Heliobacterium (Chapter 6), a protein for which solvent accessibility information from HDX 
experiment was used as the guide for homology modeling and used to generate a refined 
structural model of DHCC by using various computational approaches. 
In summary, we describe in this thesis development and application of several new, refined 
approaches of HDX and analyze protein aggregation, protein-ligand binding and unknown 
protein structures. We hope other scientists can apply these approaches to solve complicated and 
demanding biological problems that are difficult to investigate using traditional biophysical 
methods. 
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Chapter 1: Introduction 
 
 
 
 
 
 
 
 
This work is part of a book chapter in “Hydrogen-Deuterium Exchange Mass Spectrometry: 
Fundamentals, Techniques, and Applications” that has been submitted: 
 
Chapter 11: “Hydrogen Deuterium Exchange for Analysis of Ligand Binding and Protein 
Aggregation”, Zhang, Y.; Rempel, D.; and Gross, M.
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Different biological functions are carried out by different proteins, protein-ligand and protein-
protein complexes. Any failure in these processes, no matter how small, may lead to a 
malfunction of the whole system. To understand fully the biological processes, we first need to 
know how proteins interact with each other. There are several biophysical methods for 
uncovering these interactions, and they will be described in this chapter. One of the recent 
developments, hydrogen deuterium exchange (HDX) coupled with mass spectrometry (MS) 
approach, has become a powerful technique and is of high interest to us. In this thesis, we are 
using HDX-MS to explore different proteins and their interactions by following protein high-
order structure (HOS) changes induced by perturbations, including protein/ligand binding 
(Chapter 2-5) and temperature (Chapter 4). We also demonstrated that for homology modeling 
(HM), HDX-MS can be used to adjudicate protein structures suggested by HM and that are 
unknown so far (Chapter 6). 
In the first part of this introduction, we describe the basic principles of HDX and several factors 
that affect HDX. This section is purposefully brief as these ideas are now well-known. In the 
second part, we review in more detail the use of MS and HDX for characterization of protein-
ligand and protein-protein binding. 
1.1 Hydrogen Deuterium Exchange (HDX) 
HDX, as a powerful biophysics tool, been under development since the 1950’s1. The occurrence 
of hydrogen and deuterium exchange induces a mass shift that can be monitored by MS. When 
coupled with MS detection, its use increases profoundly because it can follow protein 
conformational changes, dynamics and folding with relative ease and high sensitivity at both the 
global or protein level, at the peptide level by using peptides released from proteolytic digestion, 
- 3 - 
 
and even at the amino-acid level. More papers covering protein HDX now report the use of MS 
as the monitoring approach than any other method. 
1.1.1  Types of Hydrogens in Proteins 
There are three types of hydrogens in a protein: the hydrogens in carbon-hydrogen bonds, those 
in side chain groups, and those that are located on the amides of peptide bonds (also called the 
backbone hydrogens). The intrinsic exchange rate of hydrogens of carbon-hydrogen bond is too 
slow to observe, and that of the hydrogen on side chain group is so fast that back-exchange (i.e., 
when the protein is returned to H2O solution) is significant. As a result, only the backbone 
hydrogens possess intermediate intrinsic rate that are readily measured, and they are excellent in 
as reporters for protein structure and dynamics because their exchange rates greatly depend on 
both hydrogen bonding and solvent accessibility.  
1.1.2  pH and Temperature Effect 
The intrinsic exchange rate of each residue is determined by primary structure of the protein (i.e., 
the nature of both the residue itself and its neighboring residues
2
). In addition, this rate is also 
determined by other factors including temperature and pH
3-5
. This is because the HDX reaction 
is controlled by both intrinsic rates of exchange and by protein dynamics. The latter is dependent 
on pH and activation energies or temperature. The higher the temperature, the lower the 
activation energy; thus, the faster the reaction occurs. As a result, one needs to be careful in 
controlling these two factors to perform proper HDX experiments. To obtain information from 
the backbone hydrogens when using MS, the HDX must be quenched so that the protein can be 
isolated, digested, and the peptides analyzed in H2O solution. This is accomplished by 
controlling temperature at 0 °C and pH at ~2.5 so that the sample can be handled without causing 
back-exchange. This process is called “quench”, and plays an important role in HDX. 
- 4 - 
 
Furthermore, one can intentionally change the temperature and pH during the HDX process to 
obtain different information. We will give a detailed example on changing temperature in HDX 
experiments in Chapter 4. 
1.1.3  HDX-MS 
Because the absolute rate of HDX at a specific peptide bond is difficult to measure, we compare 
the relative deuterium uptake rates for proteins under different conditions and report the HDX 
deuterium uptake level as a function of HDX exchange time (Figure 1.1). In the 1990s, Roder 
and coworkers
6
 applied HDX and two-dimensional nuclear magnetic resonance (NMR) to 
protein-ligand complexes and showed that the binding interface can be located because the 
extent of HDX decreases in the region of binding. HDX coupled with MS began to emerge and 
proved to be up to the task of following protein exchange
7
. Compared to NMR, MS has the 
advantages of higher sensitivity, permitting higher upper masses of the protein, and requiring no 
labeling or modification of a protein. Besides, HDX-MS should work with proteins under 
complex, biologically-relevant conditions. Sometimes proteins in the presence of impurities can 
be directly studied by HDX, as long as the impurities are not involved in the binding event. This 
advantage frees users from tedious and time-consuming protein purification. Unlike circular 
dichroism (CD) or fluorescence (we will discuss both of the methods in this chapter), HDX-MS 
can provide information at the peptide level through on-line pepsin digestion, and occasionally at 
the residue level by using electron-transfer dissociation
8
 (ETD) or electron-capture dissociation
9, 
10
 (ECD). Pepsin is widely used because it worked well with low-pH quenching condition. ETD 
or ECD experiments, however, are not routine and require careful control of the dissociation 
conditions
11
.  
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Figure 1.1 A typical HDX-MS experiment workflow comparing between the apo (A) and holo (B) states of 
Calmodulin. In the holo state, Calmodulin complexes with Ca
2+
 (shown in yellow spheres). 
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1.1.4  EX1 and EX2 
HDX occurs at two distinct regimes, EX1 and EX2
3, 12-19
. Most proteins exhibit EX2 behavior, 
where the protein folding/unfolding rate is higher than the deuterium exchange rate. On the other 
hand, EX1 behavior occurs when protein undergoes a local unfolding event, exposing all the 
backbone hydrogens in this region and allowing exchange with D2O to occur rapidly before the 
structure folds back to the native state. Under the EX2 kinetics regime, the mass of the peptide or 
protein shows a continuous increase as a single population in isotopic distribution as the 
exchanging time increases. On the contrary, in the EX1 regime, there are always two mass 
populations; the low-mass population decreases whereas high mass one increases (Figure 1.2).  
1.2 Protein-Ligand Interactions  
In this section of the introduction, we will review in depth the use of HDX and MS for 
characterization of protein-ligand/protein interaction. We will also describe briefly other non-MS 
methods that utilize indirect or direct measurements and report information from protein to 
residue level. 
All biological processes require intra- or inter-molecule recognition, interaction, and 
organization that drive the various functions of macromolecules. Proteins providing these 
functions include, for example, enzymes; molecular motors, whose conformational changes are 
involved in movement; transporters, which utilize conformational change to import or export 
ions, small molecules, and even proteins across cellular membranes; and detectors of cell signals, 
which often initiate or play an important role in signaling. All of these macromolecular functions 
are triggered by binding of various ligands, for example, metal ions, lipids, fatty acids, and 
nucleotides. Although most of these interactions are non-covalent, the affinities are usually 
strong, and, more importantly, the selectivity of these interactions is high. Most biological  
- 7 - 
 
 
Figure 1.2 Outcome of HDX under EX1 (A) and EX2 (B) regimes. 
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processes are performed by protein-ligand complexes that act in a coordinated manner. Any 
interruption in protein-ligand interaction can cause failure of the whole system. Thus, it is 
important to understand in detail how proteins and ligands interact. 
1.3 Protein-Ligand Affinity Measurements 
The key questions in studies of protein-ligand interactions are always where do the ligands bind 
and how tightly (i.e., binding affinity). In almost all protein-ligand interactions, there is 
equilibrium among the relevant species in solution (Equation 1.1), namely the free protein (P), 
free ligand (L), and protein-ligand complex (PL). Some protein-ligand complexes made up of 
non-specific interactions may also form transiently; however, usually their population is not 
significant
20
. 
on
off
P L PL
k
k
   1.1 
The on-rate constant, kon (with units of M
-1
s
-1
), depends on the concentration of both free protein 
[P] and free ligand [L]; the higher the concentration of the protein and/or the ligand, the more 
likely they will encounter each other and bind. In an ideal case (sufficient [P] and [L]), kon is 
controlled in part by the diffusion rate, the size of the protein (essentially the size of the binding 
site), and the nature of the ligand. The larger the protein, the faster the binding can occur to take 
advantage of the large surface area
21, 22
. A charged binding site on the protein can attract 
oppositely charged ligands
23-25
. In contrast, the off-rate constant, koff (with a unit of s
-1
), does not 
depend on concentration, and it represents only the probability of a protein-ligand dissociating to 
reform starting materials. 
- 9 - 
 
The rates (r, in Equations 1.2 and 1.3) are the corresponding rate constants multiplied by the 
concentration of appropriate species, and [PL] represents the concentration of the protein-ligand 
complex.  
on on[P][L]r k  1.2 
off off [PL]r k  1.3 
As is usual, the association rate of free protein and free ligand to give the complex is equal to the 
dissociation rate of the reverse reaction (Equation 1.4) when equilibrium is established. 
on off[P][L] [PL]k k  1.4 
The binding constant or association constant Ka, by definition, is the ratio of kon and koff 
(Equation 1.5).  
on
a
off
[PL]
[P][L]
k
K
k
   1.5 
The dissociation constant or binding affinity, Kd (with the unit of M) is the reciprocal of Ka and is 
more frequently used (Equation 1.6), whereas the binding affinity is a measure of the strength of 
the protein-ligand interaction. When the free protein and ligand reach the same value as the 
dissociation constant, 50% of the complex is formed. 
off
d
a on
1 [P][L]
[PL]
k
K
K k
    1.6 
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1.4 Conventional Methods for Ligand Binding 
Characterization 
Measuring protein-ligand interactions is ultimately needed for most biological studies, and 
numerous analytical and computational approaches have been developed to characterize the 
interaction. The methods make use of thermodynamics, kinetics, stoichiometry, and perturbation 
related to ligand binding. Each approach can generate specific information about the interaction. 
More importantly, information from each approach can be combined, and a comprehensive view 
can be achieved. New additions to this “tool box” are MS-based methods. A brief overview of 
existing methods is provided for perspective before we focus on the MS-based methods. 
1.4.1  Isothermal Titration Calorimetry (ITC) 
The binding events in a protein-ligand interactions always involve an enthalpy change. One 
direct measurement of an enthalpy change during ligand binding is ITC
26, 27
. In an ITC 
experiment, a certain amount of ligand is titrated into the protein solution. The mixture is stirred 
to reach equilibrium quickly. The difference in the amount of heat that required to maintain a 
constant temperature between a reference and sample cell is related to the heat released or 
absorbed in the binding event. ITC can be applied to all biochemical processes that show an 
enthalpy change. ITC is a general approach for characterizing protein-ligand interactions without 
requiring any special labeling or buffer system and can afford stoichiometry n, binding affinity 
Ka, and enthalpy H
0
. ITC has limited sensitivity, however, requiring relative large quantities of 
purified and water-soluble proteins. The approach does not directly provide any information on 
the location of the interaction.  
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1.4.2  Fluorescence 
Fluorescence-based methods have been widely applied in studies of protein-ligand interactions
28-
30
. Most commonly, binding affinity can be elucidated in a titration-type experiment in which 
fluorescence is used to measure equilibrium concentrations. Another approach is fluorescence 
anisotropy that utilizes the degree of decorrelation in the polarization of emitted and incident 
light. Such differences are induced by the free tumbling of the molecule that is reduced 
significantly upon binding to the protein.  
Another popular fluorescence-based method is Förster Resonance Energy Transfer (FRET) for 
which energy movement between an excited fluorophore, the donor, and a neighboring, ground-
state fluorophore, the acceptor, occurs and is monitored. FRET can provide the distance between 
the donor and acceptor
31
. With different labeling positions, FRET can provide some view of the 
conformational changes occurring upon ligand binding or protein-protein interactions. FRET 
requires that the protein be modified by introduction of fluorophores, which are often attached to 
reactive amino acid side chains, most frequently cysteine and lysine. One potential problem is 
that the modification could alter binding behavior. Because this is not known a priori, effort is 
often needed to ensure that the target protein is not affected. The interpretation of fluorescence 
data for systems with multiple protein-ligand interaction states could be problematic as well.  
1.4.3  Fourier Transform Infrared spectroscopy (FTIR) 
Protein-ligand interactions involve conformational changes of proteins. FTIR is able to monitor 
these changes by measuring secondary structure content (e.g., -helix and -sheet content) of the 
protein
32, 33
. Different bond types (e.g., amide I and II) have distinct infrared absorption, and 
each absorption band corresponds to different molecular vibrations. For example, amide I 
absorption contains mainly a C=O stretch, whereas amide II absorption arises from both N-H 
- 12 - 
 
bending and C-N stretching
33
. The FTIR-based methods are accurate and sensitive. The spectra 
are information-rich, recording nearly many types of molecular vibrations. To obtain spatially-
resolved information, the bands must be assigned to individual groups, usually requiring isotopic 
labeling by site-directed mutagenesis
34
. 
1.4.4  Surface Plasmon Resonance (SPR)  
Optical biosensors, like SPR, have become important tools for basic research and drug discovery. 
SPR, with its exceptional sensitivity, can be viewed as a biosensor for specific biological 
interactions (e.g., antigen-antibody binding in biopharmaceutical research). The binding kinetics 
as well as the binding affinities of protein-ligand interactions can be obtained. In a typical SPR 
experiment, the ligand is immobilized on a gold surface of an SPR chip, and the protein solution 
flows over the surface. The sensor detects changes of electromagnetic waves formed by electrons 
(i.e., surface plasmons of the gold layer) when their frequency matches the frequency of the 
incident light at a specific angle
35, 36
. The surface plasmon is influenced by its environment and 
will change upon interaction between an immobilized ligand and a protein. One limitation of this 
surface-based measurement is the need for immobilization of the ligand on the surface. A 
specific problem is that immobilizing the analyte may restrict its rotational freedom and 
diffusional properties, and these alter the thermodynamics and the kinetics of binding
37
.  
1.4.5  Enzyme-Linked Immunosorbent Assay (ELISA)  
ELISA is a popular bio-analytical assay and another spectroscopic approach to examine protein-
ligand binding. In general, the key step in ELISA is the immobilization of the antigen, which can 
be accomplished either by direct adsorption of the assay plate or indirect capture via an antibody 
that has already been immobilized on the plate. ELISA takes advantage of specific binding 
between antigen and antibody when a detectable signal from another enzyme-substrate reaction 
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(normally an absorbance change) can be observed
38, 39
. ELISA is convenient and sensitive. The 
observation must be made sufficiently fast, however, to avoid misleading results from over-
reaction between the enzyme and substrate. It can provide some information on the site of the 
interaction when the fluorophore is moved from site to site of the protein, but requires longer 
time. 
1.4.6 Circular Dichroism (CD)  
Traditional approaches in structural biology can also be used to determine protein-ligand 
interactions. CD detects the difference in absorption of left and right circularly polarized light, 
usually in protein solutions comparing between in presence and absence of the ligand. A CD 
spectrum responds to the bonds and sub structures responsible for the chirality
40
. When a ligand 
binds to a protein, the binding perturbs the protein’s chirality41, 42. CD is fast and solution-based. 
Disadvantages are low structural resolution and requirement of a pure protein sample. 
1.4.7 Nuclear Magnetic Resonance (NMR) 
NMR can provide high resolution for protein-ligand interaction in solution under near 
physiological conditions. Binding affinity, interface, and structural rearrangements 
accompanying protein-ligand interaction can be elucidated. NMR targets changes of the 
electromagnetic energy that nuclei absorb and release in a magnetic field
43, 44
. In contrast to all 
methods mentioned above, NMR is the one of few methods that can generate a high-resolution 
(atomic level) structural model of protein-ligand complexes. Another advantage is its application 
to systems with weak interactions
45
. Although NMR has low sensitivity (requiring high-
concentration of pure protein sample) and low throughput, many applications of NMR have been 
reported in studies of protein-ligand interactions
46
. 
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1.4.8 X-ray Crystallography 
Similar to NMR, X-ray reports protein structure at a molecular level. Ligand binding can perturb 
the electron density around the binding sites, which is reflected by the method
47
. One can titrate a 
protein with a metal ion, for example, and use electron density to measure metal-ion occupancy. 
The major drawback of crystallography-based approaches is that the results pertain to a solid-
state structure, and dynamics involved in protein-ligand interactions is missing. Proteins (e.g., 
apo forms) may be so dynamic that they are difficult to study by crystallography-based 
approaches. In addition, crystallography requires, of course, that the protein-ligand complex can 
be crystallized. 
1.5 Direct Mass Spectrometry Method 
All of the above approaches have limitations. Many have good sensitivity but poor or no 
structural resolution. Others have high structural resolution (e.g., NMR, X-ray crystallography) 
but low sensitivity or inability to work with large proteins or those that do not crystallize. Mass 
spectrometry has become a powerful analytical approach for proteins, thanks to the availability 
of appropriate ionization methods (e.g Electrospray Ionization (ESI) and Matrix-Assistant Laser 
Desorption/Ionization (MALDI)). An accurate and sensitive protein analysis can be done with 
relatively small samples. More importantly, a modification of ESI (called “native” MS) can 
introduce proteins directly from solutions that are similar to a protein’s native environment. In 
that case, ESI solvents are aqueous (e.g., ammonium acetate solution at pH 7), making it possible 
to observe gas-phase, protein-ligand complexes that are held together by non-covalent 
interactions. This sets up direct methods whereby MS measures equilibrium concentrations at 
both high sensitivity and perhaps with some structural resolution from MS/MS methods
48
. 
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Klassen and coworkers
49
 have played a major role in the development of a direct MS method in 
which key concentrations in Equations 1.5 and 1.6 are measured by the mass spectrometer . 
Protein-ligand complexes, as well as free proteins, are introduced by ESI into the instrument. 
The intensities of signals representing different species can be recorded at different protein-
ligand concentrations, so that information about protein-ligand interaction (e.g., binding affinity) 
can be elucidated. Various states of a complex can be isolated and studied separately. A “catch 
and release” approach, which includes isolating the complex ions, dissociating them by applying 
energy (e.g., collision-induced dissociation (CID)) and detecting the product ions by high 
resolution instrument, has also been developed and applied in drug screening and for estimating 
affinities. 
1.6 HDX-MS 
As mentioned above, HDX-MS has become an attractive complement for biophysical studies of 
protein-ligand interaction. The application of HDX-MS to protein-ligand systems can afford 
detailed information on binding regions, binding affinity, and binding order. There are several 
review articles on HDX-MS
50-54
. In the remainder of this chapter, we will focus on methodology 
and analysis for HDX-based studies of protein-ligand and protein-protein interactions. 
1.6.1 HDX-MS for Binding Regions 
Often, the first question about a protein-ligand interaction is where the binding interface lies. The 
answer can be provided by HDX approaches (e.g., continuous labeling HDX). The relative 
deuterium uptake rates (in form of an HDX kinetics curve, where deuterium uptake is plotted 
against time of exchange) are compared between ligand-free (apo) and ligand-bound (holo) 
states. Ligands can be metal ions
55
, inhibitors
56
, glycans
57
, lipids
58
, or nucleotides
59
. Regions of 
proteins affected by ligand binding usually exhibit slower deuterium uptake because hydrogen 
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bonds along certain protein back-bone amides are affected by ligand binding and the protein is 
stabilized as a complex. Those regions that exhibit differences are likely to be the binding 
interface or remote regions that change as an allosteric interaction (an application will be 
described in Chapter 4).  
1.6.2 HDX-MS for Binding Affinity 
There are two approaches based on HDX to determine protein-ligand binding affinity: Protein-
Ligand Interactions by Mass Spectrometry, Titration, and H/D Exchange (PLIMSTEX), and 
Stability of Unpurified Proteins from Rates of H/D Exchange (SUPREX). Both methods measure 
changes in deuterium uptake as a function of either ligand or denaturant concentration and can 
report quantitatively thermodynamic properties of the protein-ligand complex. The methods are 
applicable when the target protein undergoes HDX via an EX2 mechanism (i.e., the intrinsic 
rates of HDX are slower than the off rate of the ligand). Additionally, the methods require a 
predetermined incubation time when using continuous HDX labeling such that all points are 
measured at a constant time. 
1.6.2.1 PLIMSTEX 
PLIMSTEX was developed by Gross and coworkers
60
 as a means to measure binding affinities 
(Figure 1.3). It compares deuterium uptake level of the apo and holo protein, not as a function of 
HDX time, but of the total protein ligand ratios (i.e., T
T
[L]
[P]
, where [L]T represents total ligand 
concentration, and [P]T is total protein concentration) to afford protein-ligand binding affinities. 
Usually, [P]T is constant, and the only experimental variable in PLIMSTEX is [L]T
61
. The 
underlying principle of PLIMSTEX is similar to that of fluorescence but without the need to 
measure the free-ligand concentration. 
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Figure 1.3 A typical workflow for PLIMSTEX. 
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The first step of PLIMSTEX is a standard continuous labeling HDX experiment, which can 
afford kinetic curves, either global or at the peptide level. By comparing the kinetic curves 
between apo and ‘hard’ holo (i.e., the protein is completely ligand-bound) states, one can 
determine an HDX time point for which the deuterium uptake is nearly constant and there are 
relatively large differences between the apo and holo states. Under these conditions, HDX of the 
protein and protein-ligand complex are nearly steady-state so that small errors in time have little 
effect on the extent of HDX. Furthermore, the large difference in HDX between apo and holo 
also adds to the accuracy and facilitates analysis of complicated systems (i.e., proteins with 
multiple binding sites for same ligands). 
After determining the titration time for PLIMSTEX, a set of mixing experiments is conducted by 
incubating proteins with increasing [L] (i.e., titrating), from zero (i.e., apo state) to excess ligand 
(i.e., holo state) (Figure 1.4). When the protein-ligand complex has reached equilibration with 
free protein and ligand, HDX is initiated by adding a buffer in D2O. The steps for MS analysis 
are the same as those for continuous labeling HDX experiments: quench with acidic solution, 
desalt by loading onto a reversed-phase column, elute the trapped protein/peptides into the mass 
spectrometer, and measure the mass shift (D). After obtaining D, the extent of HDX as a 
function of [L] is plotted giving a “PLIMSTEX curve”. Typical results show that the deuterium 
uptake level decreases with increasing [L], reflecting increasing protection of the backbone 
amide hydrogens in the binding regions or other regions involved in allosteric interactions. Other 
binding intermediates can be monitored as well. The PLIMSTEX curve is then fit by a 
mathematical model to afford the Kd value
62
. 
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Figure 1.4 A typical PLIMSTEX curve obtained for 15 M porcine calmodulin titrated with Ca2+ in 50 mM 
HEPES. Redrawn from data in ref.
61
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A nonlinear least squares (NLLS) regression is performed by procedures implemented with 
MathCAD 14 (PTC Inc., Needham, MA). As mentioned above, the titration data are fitted using 
a 1:n = protein:ligand binding system, where n is the number of binding sites of the same ligand 
to the target protein. In PLIMSTEX modeling, D is a function of [L]T, and the cumulative 
binding constants i (i.e., product of the stepwise binding constants Ki, where i varies from 1 to n 
(Equation 1.7). 
1i iK K    1.7 
D0 is the deuterium uptake of the apo state protein, and Di is the deuterium uptake differences 
between the apo state and the intermediates i (i.e., Di = D0 - Di). Typically, Dn is the largest 
D, as ligand binding induces protection of the binding sites, so deuterium uptake decreases as 
ligand is added. D0 is treated in the modeling as a variable to minimize experimental errors. The 
best fit is obtained by searches, changing all the variable parameters (i.e., i, D0, and Di) to 
minimize the error between the fitted curve and the experimental data by iterating through many 
trials. 
1.6.2.1 .1 Examples of PLIMSTEX 
PLIMSTEX was first demonstrated by using four model proteins: rat intestinal fatty acid binding 
protein (I-FABP) interacting with potassium oleate (1:1), GDP-bound human p21
H-ras
 protein 
(Ras-GDP) interacting with Mg
2+
 (1:1), Ca
2+
-saturated porcine calmodulin (holo-CaM) 
interacting with the peptide melittin (1:1), and apo-CaM interacting with Ca
2+
 (1:4)
60
. 
PLIMSTEX was able to provide accurate Kd’s of the four systems ranging from 10
4
 to 10
8
 M
-1
. 
These early experiments also suggested that PLIMSTEX can be used for quick determination of 
binding stoichiometry and purity of the proteins
63
. 
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In an early collaborative application, we applied PLIMSTEX to a protein-DNA binding system, 
human telomeric repeat binding factor 2 (hTRF2) interacting with double-stranded telomeric 
DNA (repeats of TTAGGG)
64
. When accompanied by protease digestion, PLIMSTEX curves 
can provide binding information at the peptide level. For this system, the PLIMSTEX-
determined binding affinity is within a factor of three of a previously reported value. Sequel 
studies showed applicability to other systems as well
61, 62, 65, 66
. Another application of 
PLISMTEX on a Ca
2+
 binding protein will be described in Chapter 5. 
1.6.2.1 .2 Advantages of PLIMSTEX 
One advantage of this approach is that affinities determined are for a protein in a native, or at 
least near-native, condition during the HDX. The amount of protein required for the titration is 
small as is the concentration (M and lower in favorable cases). Unlike SUPREX, which will be 
introduced later, PLIMSTEX does not require a denaturant, which may affect protein binding. In 
addition, PLIMSTEX does not need any tagging reaction to measure the free-ligand 
concentration [L] during the titration process. It only relies on the measurement of Di. Unlike 
gas-phase direct measurements, the titration is done in solution, and the extent of HDX, although 
measured in the gas phase of a mass spectrometer, simply reports on the status of the binding. 
The approach can deal with 1:n binding systems, affording analysis of multiple macroscopic 
binding constants i, providing each binding events induces a measurable change in the 
deuterium uptake. The stoichiometry of protein-ligand complexes can also be elucidated. As 
such, PLIMSTEX complements and validates direct MS measurements where non-covalent 
protein-ligand complexes can be introduced into the gas-phase and their molecular weights 
measured to reveal stoichiometry. The direct measurement, based on the size of the complex, can 
be misleading, however, if the protein-ligand complex is not faithfully transferred from solution 
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to the gas phase. When [P] is sufficiently large (e.g., 100 times the Kd), reliable Kd values cannot 
be measured. Instead, a “sharp-break” curve is observed, reflecting the binding stoichiometry 
(Figure 1.5). In addition, these curves may also be useful to determine the purity of the protein 
by titrating with a ligand of known purity. The throughput of PLIMSTEX (e.g., in drug 
discovery) may be increased by using MALDI instead of LC/ESI-MS, but this remains to be 
demonstrated. PLIMSTEX has the potential to give peptide (regional) resolution by applying 
protease digestion and following HDX for peptides, thus locating the binding site and the Kd. 
This will be an important advance especially when a protein binds multiple ligands. We are now 
testing this prospect. 
1.6.2.1 .3 Disadvantages of PLIMSTEX 
One concern of PLIMSTEX is that protein or protein/ligand dynamics may distort the outcome. 
Intermediates (especially for a 1:n system where n > 1) may introduce problems, as multiple 
equilibria occur simultaneously (Figure 1.6). Apo (H) and apo (D) represent apo state protein, in 
the absence or presence of deuterium, respectively, whereas holo (H) and holo (D) have similar 
meanings for the complex. Based on Equation 1-2 and 1-3, both on and off rates can be 
calculated; the former is a bimolecular reaction whereas the latter is a unimolecular process. At 
the beginning of the titration, [L] is small, and the ron is relatively smaller than roff. As a result, 
much of the protein, even as complexed, will exist in the apo state if the off rate is high and 
undergo exchange characteristic of the apo (D) state. Of course, it is not possible for holo(D) to 
become holo(H). Thus, when [L] is small, there is a higher possibility of obtaining more 
deuterium than expected, introducing a distortion of the PLIMSTEX curve at the beginning of 
the titration. Therefore, [L] has to be sufficiently large to shut down the other fluxes. The 
outcome can be that the Kd calculated with the PLIMSTEX platform is too large. 
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Figure 1.5 Examples of ‘sharp break’ PLIMSTEX curves for titration of (a) melittin and (b) mastoparan of 15 M 
Ca
2+
-saturated porcine calmodulin (CaM-4Ca) in 50 mM HEPES, 100 mM KCl, 0.49 mM Ca
2+
, 99% D2O, apparent 
pH 7.4. Redrawn from data in ref.
63
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Figure 1.6 On- and off-fluxes among various species in PLIMSTEX experiments.  
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In addition, PLIMSTEX is unable to measure tight binding lower than nM. Nevertheless, for 
tight binding, it should be possible to determine the stoichiometry, as mentioned above, from a 
sharp-break curve, and put limits on the affinity. 
1.6.2.1 .4 dPLIMSTEX 
dPLIMSTEX is an adaption of PLIMSTEX incorporating a dilution strategy
67
. It was developed 
for protein-peptide systems (e.g., antibody-antigen system) to minimize sample consumption, 
which is an issue with standard PLIMSTEX and valuable proteins. The “ligand” peptide 
(antigen) is used as readout, unlike signals from proteins in the standard PLIMSTEX, taking 
advantage of the improved capacity of mass spectrometers to measure the mass of a peptide 
ligand with higher accuracy and precision than that of a large protein.  
The work flow for dPLIMSTEX starts with half volume of an equilibrated protein-peptide 
complex for measurement. The other half is diluted in aqueous buffer before incubation (Figure 
1.7). The dilution step is continued until the concentration of the peptide is too low to be 
detected. dPLIMSTEX was first demonstrated by using a model system, calcium-saturated 
calmodulin with the opioid peptide -endorphin, and it yielded a similar binding constant as 
compared to that determined by standard PLIMSTEX and other methods. It was then applied to a 
monoclonal anti-nitrotyrosine antibody, in complex with a 3-nitrotyrosine-modified peptide 
system. A binding stoichiometry of 1:2 was confirmed. In addition, a Kd in the low nM range and 
a minimum of five amino acid constituting the epitope were determined. Compared to the 
standard PLIMSTEX protocol, dPLIMSTEX has the advantage of consuming less material, and 
being less subject to error on the mass shift because it monitors, in this case, a peptide rather than 
a large protein. 
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Figure 1.7 A typical work flow for the dPLIMSTEX. Terms x and y are the initial concentrations of protein and 
peptide, respectively, and z is the dilution factor. Redrawn from data in ref.
67
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1.6.2.2 SUPREX 
Another HDX-based method, SUPREX, was developed by the Fitzgerald and coworkers
68
. It is 
analogous to chemical denaturation methods employing CD or fluorescence, which were 
previously known.  
It begins with incubating a protein (apo or holo state) in D2O buffers containing different 
concentrations of denaturant ([denaturant]), usually urea or guanidinium chloride (GdmCl), for a 
predetermined time, which is constant for all the measurements. Approximately ten different 
[denaturant] concentrations are commonly used to plot a complete SUPREX curve. After 
quenching the HDX, a measurement is made, often with MALDI-MS, although ESI can also be 
used. As [denaturant] increases, the deuterium uptake also increases, reflecting the loss of 
stability of the protein (Figure 1.8). In the presence of the ligand, the protein is stabilized, and the 
curve shifts to larger concentrations of denaturants. The difference between the apo and holo 
states is a measure of the binding constant. SUPREX reports mostly on the globally protected 
and slow exchanging regions, providing that these regions are involved in the denaturation. 
Similar to PLIMSTEX, SUPREX data are plotted as D (deuterated – undeuterated) of an 
apo/holo state protein as a function of [denaturant], and fitted using NLLS analysis. The fitted 
curve affords a transition midpoint (
1
2
SUPREXC , as a [denaturant] at this point), which can be used 
to calculate Gf and an m-value (defined as the sharpness of the transition in the fitted curve (i.e., 
f
[denaturant]
G


) (Equation 1.8).  
f [denaturant]
fold
G m
RTK e
 

  1.8 
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Figure 1.8 A typical workflow for SUPREX. Redrawn from data in ref.
69
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  1.9 
In Equation 1.8, Kfold is the equilibrium constant between the exchange incompetent and 
competent states, which are related to protein-folding dynamics (Equation 1.9). R is the gas 
constant, and T is the temperature (in Kelvin). By obtaining differences between Gf (holo) and 
Gf (apo), together with the m-value, Gf can be calculated
70-72
 and converted into a 
dissociation constant Kd (Equation 1.10). For the apo state of a protein, the result relates to 
protein dynamics, and that of a holo-state protein gives information of the stability of protein-
ligand complex. 
f
d
[L]
ln(1 )G nRT
K
     1.10 
All ligand-bound experiments are performed in a 50-100 fold excess of ligands, so that most of 
the protein is in a “hard”-holo state73. The changes of m-value, on the other hand, can be used to 
evaluate the surface area that is buried upon protein folding/unfolding or ligand binding
74
. The 
differences, if any, of the baselines before the transition between two states in SUPREX curves 
also indicate the protection of the protein when the ligand binds. The lower the baseline 
compared to that of the apo state, the less solvent-accessible the protein. This difference, which 
is crucial for the success of PLIMSTEX, does not impact SUPREX. 
For a strict two-state model (i.e., partially folded state is transient and not significantly 
populated), SUPREX provides reliable stability data (i.e., Gf and an m-value) compared to 
traditional methods (e.g., CD and fluorescence)
70-72, 75
. The difference (Gf) between apo and 
holo states of the target protein is the binding free energy of the ligand. In contrast, if the system 
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has more than two states in equilibrium, with folding/unfolding events happening cooperatively, 
the absolute values of such stability data (i.e., Gf) are less useful. Relative differences (i.e., 
Gf), however, can still accurately reflect the binding free energy. In the case of systems that 
fold/unfold uncooperatively (i.e., different domains of the same protein fold/unfold 
independently), global SUPREX cannot produce useful information. An alternative is to turn to 
the peptide level by using protease digestion
76
.  
Most SUPREX experiments have been performed on small proteins (less than 15 kDa), as 
MALDI always produce ions of +1 charge state. Instead of increasing the dynamic range of a 
MALDI instrument, Fitzgerald and coworkers
76
 developed a strategy where protease digestion is 
coupled with standard SUPREX, after the exchange and quenching steps (Figure 1.9). The 
purpose of a rapid digestion is to generate peptides that can cover different individual domains. 
Such a protocol significantly expands the application of SUPREX to larger proteins. As for all 
HDX experiments, the footprints (i.e., number of deuteriums) of each proteolytic product are 
already fixed before analysis, and this information is largely preserved until analysis. For 
success, the peptides must undergo a sufficiently large conformational change so that changes 
can be followed.  
1.6.2.2.1 Examples of SUPREX 
The thermo-stability of monomeric λ repressor variants and maltose-binding proteins were used 
in 2000
68
 to demonstrate SUPREX. The stability measurements were compared with CD 
denaturation curves of same purified samples. The experimental requirements of SUPREX, the 
back exchange rates in MALDI matrix and the deuterium uptake as function of time in different 
[denaturant] were also determined. The addition of the denaturant, in this case, GdmCl, 
dramatically increases the exchange rate through protein global unfolding. More importantly,  
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Figure 1.9 A typical workflow for SUPREX with digestion. Redrawn from data in ref.
77
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the SUPREX curves of maltose-binding protein shifts between apo and holo proteins (i.e., in 
presence and absence of maltose). The presence of maltose increases the stability by binding to 
the native state, and the protein unfolds at higher [GdmCl]. The thermodynamic stability 
information can be extracted from the deuterium uptake curves as well.  
The original SUPREX approach requires accurate MS measurement of an intact protein, 
especially in the proposed single-point SUPREX for drug candidate screening. The protease 
digestion from traditional HDX experiment can be integrated into the SUPREX protocol to 
improve the accuracy of deuterium-uptake measurement
76
. The strategy utilizes the SUPREX 
behavior of the detected peptides to report on behavior of different regions from the protein. The 
modern MS instrument can deliver high resolving power that will greatly improve the accuracy 
of SUPREX and avoid the difficulty of using direct measurements of large, intact proteins. Two 
model proteins, CypA and glyoxylate aminotransferase (ACTmi) were used as model to 
demonstrate the protease-assisted, single-point SUPREX. 
1.6.2.2.2 Advantage of SUPREX 
One advantage of SUPREX, like continuous labeling HDX and PLIMSTEX, is that it can be 
applied to proteins under biologically relevant or near relevant conditions. Competitive 
methodology, like fluorescence, often needs modifications of the target protein, to incorporate a 
fluorescent label, as discussed earlier. SUPREX can also work with unpurified samples as long 
as the other components do not interact with the protein and do not significantly suppress its 
signal in the mass spectrometer. SUPREX is a particularly appropriate choice when salt 
contamination is important because MALDI has a high tolerance of salt. 
Another advantage of SUPREX is that it is a good candidate for high throughput screening 
(HTS). As mentioned earlier in this chapter, HTS is a problem for standard HDX. With the 
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growing availability of fully automated instrumentation optimized for HTS, one can potentially 
screen up to 100,000 ligands per day, using a single-point SUPREX protocol
78
, in which one 
compares only a single D between two states: protein-target ligand complex and protein-
reference ligand complex. The greater D is, the tighter the ligand binds to the protein. The 
limitation in the data rate is the instrumentation. Nevertheless, SUPREX is well-suited for 
projects aiming at the discovery of new ligands that bind to a specific protein in drug discovery. 
1.6.2.2.3 Disadvantage of SUPREX 
The advantage of HTS comes at the expense of losing detailed structural information, which is 
often provided with continuous labeling HDX or PLIMSTEX
69
. Even with application of a 
protease-digestion protocol, the resolution can be at best a single domain of the protein
77
, instead 
of resolution at the peptide or even residue level. In addition, the requirement of denaturant is 
problematic because the denaturant may alter or even prevent protein-ligand binding; thus, 
protein folding/unfolding is not the only parameter that affects the results. SUPREX can only be 
used for a 1:1 binding system because a higher ligand binding system cannot satisfy the two-state 
assumption that is required in the Gf calculation. Nevertheless, SUPREX is an important 
method for deciphering biophysical properties of protein-ligand complexes, and it can have 
reasonable throughput. 
All of the above mentioned HDX-based methods are limited, because they require a 
conformational change or a relatively large shielding or protection to be introduced by the ligand 
binding. For the systems that do not undergo dramatic changes during complex formation, both 
PLIMSTEX and SUPREX may be useful if coupled with a competition experiment (i.e., 
performing experiments in which another ligand of known affinity competes) or with a pulsed-
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labeling strategy that allows the analyst to use short HDX times and focus on the fast-exchanging 
amide hydrogens. 
1.6.3 HDX-MS for Binding Order 
Once information is obtained on where and how tightly ligands bind to target proteins, one may 
need to follow the order of ligand binding when a protein binds more than one ligand. Here the 
question is which binding site is used first and which is last. This binding order is of importance 
because such information can guide research on drug development, particularly when the 
protein-ligand system is asymmetrical (i.e., different ligand binding regions are not identical). An 
example is aminoglycoside-N3-acetyltransferase-IIIb (AAC)
79
. Its order of substrate binding 
(either coenzyme A or antibiotic) yielded ternary complexes with different dynamic properties.  
To measure the order of binding, Gross and coworkers
65
 developed a PLIMSTEX-related 
approach. Troponin C (TnC), a Ca
2+
-bound protein, is an excellent model, because four Ca
2+
 ions 
bind to four EF hands of the protein. Because Ca
2+
 binding to EF-III and EF-IV are known to be 
high affinity, a two-step dialysis procedure was carried out to ensure a fully apo state. In the 
work flow, a “sharp break” PLIMSTEX curve is first obtained (i.e., at high protein 
concentration) to reveal the binding stoichiometry, and give an estimation of the D values to 
guide the curve fitting to obtain equilibrium constants. The binding constants for each Ca
2+
 are 
then used to calculate fractional species curves. Based on these curves, one can calculate the 
concentration of the various binding species (in this case, apo-TnC, TnC-Ca
2+
, TnC-2Ca
2+
, TnC-
3Ca
2+
, and holo-TnC) as a function of [Ca
2+
]. By applying continuous labeling HDX under 
various predetermined concentrations of Ca
2+
, one can determine when different regions bind 
Ca
2+
 as HDX reports changes caused by ligand binding at that site. In the case of troponin, the 
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determined binding order to four EF hands is III, IV, II and I (Figure 1.10), which would be 
difficult if not impossible to determine in any single experiment. 
The advantage of identifying binding order using an HDX-based method is the approach does 
not depend on accurately detecting abundances of the various binding species, but on their HD 
exchanged mass. The advantages of PLIMSTEX also apply. The equilibrium information 
obtained from the PLIMSTEX experiment is essential for the design of the subsequent kinetics 
experiments that extract deuterium distribution for different binding regions. For a tight-binding 
system, no binding order information can be obtained. Compared to traditional approaches, this 
method is time-consuming. Nevertheless, this method can be applied to proteins that bind 
multiple ligands, without mutating the protein, which may disturb the system. 
1.6.3 HDX-MS for Protein-Protein Interactions 
1.6.3.1 SIMSTEX for Protein Association 
Thus far, we have emphasized protein/ligand binding. Proteins also self-associate; sometimes, 
self-association is simple, producing small oligomers that readily dissociate. Other times, the 
protein undergoes uncontrolled aggregation and ultimately forms fibrils (amyloids) that have 
serious consequences in human health (e.g., as in Alzheimer’s disease, Parkinson’s disease).  
Insulin is an excellent model to test whether HDX can be used to assess self-association. It is a 
biologically relevant protein of modest size, but it still possesses all of the structural features of a 
large protein. It is stored in the pancreas as a hexamer, but it functions as a monomer
80, 81
. Gross 
and coworkers
82
 adapted PLIMSTEX to determine self-association equilibrium constants for 
proteins, using insulin as a model, and called the approach SIMSTEX (Self-association 
Interactions using Mass Spectrometry, self-Titration and H/D Exchange). The work flow is, in 
effect, a titration, but one in which the protein is titrated with itself. This is accomplished by  
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Figure 1.10 HDX patterns for various Ca
2+
 binding sites (obtained as peptides by peptic digestion) indicated the 
binding orders. Each column represents deuterium distribution of the peptic peptides for each EF hand: III, IV, II, 
and I (left to right). Each row represents various Ca
2+
 bound states: 0, 1, 2, 3, and 4 Ca
2+
 bound (top to bottom). 
Redrawn from data in ref.
65
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simply changing its concentration. As the concentration of the protein increases, more 
oligomerization occurs, resulting in more amide hydrogens being protected, and less deuterium 
uptake. To model the HDX data, we assumed that the oligomerization of r-human insulin occurs 
as monomer⇌dimer⇌tetramer⇌hexamer. Furthermore, different mutants of insulin were also 
compared to show that substituting amino acids B9, B13, B21 and B27 significantly impacts the 
self-association of insulin. Some of them (e.g., B13Gln) show increased tendency to self-
associate, whereas others (e.g., lispro and B9Asp) show less tendency. One concern of 
SIMSTEX is that the dissociation/association kinetics can distort the shape of the curve. In this 
example, however, the distortion is reduced, possibly owing to the slower kinetics of HD 
exchange, compared to the dissociation/association. The resulting association constants agree 
with literature values, suggesting that the SIMSTEX approach can be useful. 
The advantage of SIMSTEX is that it is not time-consuming, and it provides an accurate 
comparison between different mutants. It has potential to improve the structural resolution to the 
peptide or even single amino-acid residue level. Its limitation is the requirement that self-
association increases H bonding and decreases solvent accessibility such that the deuterium 
uptake level change can be detected. Furthermore, the approach likely cannot handle the 
complexity of aggregation of proteins like Amyloid beta. Nevertheless, the approach motivates 
continued development, not only for drug screening, but also for the study large-protein self 
aggregation. 
1.6.3.2 Pulsed HDX for Protein Aggregation 
This protein aggregation is the immediate causes of Alzheimer’s, Parkinson, and Huntington 
disease, motivating development of new biophysical approaches. Although uncontrolled 
aggregation of amyloid proteins is also a deleterious example of protein self-interaction causing 
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disease, the process is far too complex for application of SIMSTEX. Amyloid beta (A) 
(Alzheimer’s disease, AD) and -synuclein (Parkinson’s disease) are of importance because 
their propensity to aggregate affects brain function. In AD, the aggregation of the 40- and 42-aa-
long A peptide, generally called A40 or A42, as well as related peptides is proposed to be 
involved in the onset of the disease. A42 appears to be the most neurotoxic and amyloidogenic 
member of the family. 
The structures regarding the first and last stage in A aggregation have been studied 
extensively by NMR
83
, X-ray
84
 and fluorescence
85
. Nevertheless, there is still little understanding 
of the soluble aggregates of A because the aggregation gives intrinsically high heterogeneity 
of oligomers and of time-dependent behavior. Thus, a continuous labeling HDX or SIMSTEX 
strategy is of little use. Furthermore, the application of HDX in a time-dependent manner is 
challenging because both HDX and aggregation occur simultaneously. To minimize aggregation 
during the time for HDX and thereby separate the two processes, we developed a pulsed HDX 
strategy
86
, whereby A is allowed to incubate for various times and then submitted to pulsed 
HDX (1 min) followed by the standard quenching, proteolysis and analysis. More details will be 
described in Chapter 2 and 3. The advantage of the pulsed HDX approach is that it is applicable 
to studies under various experimental conditions of aggregation. Thus, it can be a general tool to 
support future efforts to characterize protein aggregation as a function of different parameters 
(e.g., concentration, presence of different ligands or protein, and pH). With the help of 
ECD/ETD, site-specific information can be obtained as well. 
Although this approach is convenient and easy to understand, one needs to predetermine the 
aggregation times carefully, as the samples are incubated separately. Different time points need 
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to be chosen for different aggregation conditions. For example, higher temperature and faster 
agitation accelerates the aggregation process, thus necessitating shorter incubation times. 
Additional efforts are needed to determine the appropriate aggregation times under conditions 
that have unknown effects. 
1.7 Conclusion 
There are three essential questions that need to be addressed in protein-ligand binding: binding 
region, affinity, and order. Various non-MS approaches are now well developed; however, they 
suffer from either low structural resolution or low sensitivity. Although direct MS can be utilized 
to study binding affinity, HDX-based approaches can be applied to answer many questions. A 
standard HDX-MS can report binding regions because it is sensitive to the slower kinetics of the 
Holo vs. the Apo state. PLIMSTEX/SUPREX experiments can be applied to measure binding 
affinity. Specifically, by applying PLIMSTEX, one can extract binding affinities for multi-
binding systems (i.e., various ligands bind to different domain of the protein), and binding orders 
if several kinetic curves are performed at various ligand concentration. Furthermore, an adaption 
of PLIMSTEX, called SIMSTEX, can be applied for investigating protein association. Even for 
complex and fast protein aggregation (e.g., for amyloid beta aggregation), a pulsed HDX 
strategy, which reports aggregation kinetics under various conditions, appears to have high 
potential. 
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2.1 Abstract 
Probing the conformational changes of amyloid beta (Aaggregation is challenging owing to 
the vast heterogeneity of the resulting soluble aggregates. To investigate the formation of these 
aggregates in solution, we designed a mass-spectrometry (MS)-based biophysical approach and 
applied it to the formation of soluble aggregates of the A42 peptide, the proposed causative 
agent in Alzheimer’s disease (AD). The approach incorporates pulsed hydrogen deuterium 
exchange (HDX) coupled with MS analysis. The combined approach provides evidence for a 
self-catalyzed aggregation with a lag phase, as observed previously by fluorescence methods. 
Unlike those approaches, pulsed HDX does not require modified A42 (e.g., labeling with a 
fluorophore). Furthermore, the approach reveals that the center region of A is first to 
aggregate, followed by the C- and N-termini. We also found that the lag phase in the aggregation 
of soluble species is affected by temperature and Cu
2+
 ions. This MS approach has sufficient 
structural resolution to allow interrogation of A aggregation in physiologically relevant 
environments. This platform should be generally useful for investigating the aggregation of other 
amyloid-forming proteins and neurotoxic soluble peptide aggregates. 
2.2 Introduction 
Protein aggregation is one of the immediate causes of Alzheimer’s disease, Parkinson’s, and 
Huntington’s disease, motivating biophysical studies of the responsible proteins. More than 
twenty small proteins undergo amyloidosis in humans. In Alzheimer’s disease (AD), the 
aggregation of the 40 or 42 amino-acid long amyloid beta (A) peptide, generally called A40 or 
A42, respectively, is proposed to be involved in the onset of the disease
1, 2
. A42 is more 
amyloidogenic and more neurotoxic than A40. Although the amyloid-cascade hypothesis 
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suggests that the A-containing amyloid plaques are responsible for neurodegeneration3-7, other 
studies suggest that soluble aggregates of A42 are more neurotoxic than the amyloid plaques
8-13
. 
The amyloid plaques in AD-affected brains contain high levels of copper, zinc and iron
14-20
. 
Among these, Cu has drawn the most attention because the Aprecursor protein (APP) is likely 
a Cu-chaperone protein
21
. Several studies of Cu
2+
-A interactions show that Cu
2+
 can promote 
A aggregation
14, 18, 19
. 
The structure of A42 and its aggregates, although studied extensively, remains of high interest. 
Studies of amyloid fibrils invoke X-ray crystallography
22-24
, electron microscopy (EM)
19, 25, 26
, 
and thioflavin T (ThT) fluorescence
19, 27, revealing the polypeptide’s global behavior, whereas 
NMR studies provide residue-level information for the fibrils
28-30
. Nevertheless, we know little 
about soluble A aggregates owing to their intrinsically high heterogeneity. 
MS should offer an opportunity for investigating soluble aggregates of A42. Thus far, there are 
no MS-based, time-dependent studies of the formation of soluble aggregates. Moreover, there are 
no other biophysical studies of A42 aggregation at the peptide (regional) level. MS, however, 
was used for analyzing the aggregated A fibrils31-33 and, with ion mobility34-36, for soluble A 
aggregates. Hydrogen deuterium exchange (HDX)
37-42
, even with top-down sequencing, can 
afford residue-level information
43, 44
 and provide insight on A42 fibril core structure
31, 32
 and its 
recycling
33, 45
. 
In light of the dearth of aggregation studies at the peptide level, we have employed herein pulsed 
HDX to study the aggregation of the Aand A42 peptides. Our platform is suitable for 
confirming the effect of temperature, agitation, and presence of Cu
2+
 ions on A aggregation. 
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Pulsed HDX, developed by Englander
46
, can be used for detecting protein folding intermediates 
47
 and membrane protein behavior
48
. Others have also applied pulsed HDX to analyze fibril
33
 and 
oligomer
43, 44
 A structures. To explain the experimental data, we used a self-catalyzed 
aggregation model, and its success suggests utility for other amyloid-forming proteins. 
2.3 Materials and Methods 
2.3.1  Chemicals 
All chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) unless stated 
otherwise. All gels, membranes, and reagents for Western blotting were purchased from 
Invitrogen (Grand Island, NY). D2O buffers were prepared by dissolving phosphate buffer (PBS) 
in D2O (Cambridge Isotope Laboratories Inc., Andover, MA). 
2.3.2  Protein Preparation 
A synthetic, wild-type human form of A40 (Keck Biotechnology, Yale University) and a 
recombinant, wild-type human form of A42 (rPeptide, Bogart, GA) were used. Sample 
preparation followed a reported procedure
49
. Both A40 and A42 were treated to remove any 
aggregated species prior to storage by dissolving the material in hexafluoro-isopropyl alcohol 
(HFIP) at 0.1 mM. The protein solution was aliquoted in low-binding tubes (Eppendorf, 
Hauppauge, NY), and the solvent was evaporated overnight. The samples were vacuum-
centrifuged (Eppendorf, Hauppauge, NY) to remove any existing HFIP, leaving an A film in 
the tubes. This A film was then stored at -80 °C for future use.  
Afilms were thawed and dissolved in dry dimethyl sulfoxide (DMSO) at 1 mM prior to 
aggregation. A aggregation studies were initiated by diluting 1:19 monomeric Aeither A40 
or A42) into PBS buffer (pH 7.4) at 25 °C. A aggregation experiments were investigated at 9 
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time points for A40 and 20 time points for A42 ranging from 1 min to 48 h. Soluble aggregates 
were enriched by centrifugation (16,000 g, 5 min at 4 °C). The centrifuged sample was then 
carefully divided into two equal-volume parts (i.e., 10 L each), referred to in all contexts as 
“top half” and “bottom half”. Only the “bottom half” solution was submitted to MS analysis to 
obtain the plots shown in the various figures. 
To study the effect of various parameters on A42 aggregation, a procedure similar to that 
described above was followed except for those involving Cu
2+
. CuCl2 was dissolved in a PBS 
buffer to give a Cu
2+
 concentration equal to the protein concentration. The stages of aggregation 
were interrogated at 13 time points by varying the incubation time from 1 min to 48 h. Prior to 
MS analysis, the sample was submitted to centrifugation under the same conditions as described 
above, and only the “bottom half” solution was collected. 
For a comparison, the process of aggregation was also monitored by varying the temperature 
(i.e., 37 vs 25 °C) and agitation (i.e., incubator rotating horizontally at 150 rpm). Experiments 
were investigated for an average of 15 time points, in absence or presence of Cu
2+
. 
A fibrils were formed following a similar procedure, but incubating at 37 °C for 3 weeks. 
After a white precipitate formed, the solution was centrifuged, and the pellet was re-dissolved in 
PBS buffer and analyzed by pulsed HDX.  
Native gel electrophoresis and Western blotting were conducted as previously described
19
. 
2.3.3  Pulsed Hydrogen Deuterium Exchange 
HDX experiments were carried out by mixing the incubated protein sample with D2O buffer in a 
1:1 ratio (pulsed labeling for 1 min at 0 °C). We chose a 1:1 dilution over, for example, 1:10, to 
minimize dilution and consequent shifts in the equilibrium of aggregation/disaggregation. 
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Importantly, the HDX time was fixed for each experiment, so the term “time” hereafter means 
aggregation time unless stated otherwise. HDX was then quenched by mixing the exchanging 
solution with 30 L 3 M urea and 1% trifluoroacetic acid (TFA) to give a pH of 2.5. The 
quenched exchanged sample was then digested by passing through an custom-packed pepsin 
column at 200 L/min, and peptic peptides were captured on a C8 trap column (2 mm x 1 cm, 
Agilent Inc., Santa Clara, CA) and desalted (total time for digestion and desalting was 3 min). 
Peptides were then separated with a linear gradient of 4% - 40% CH3CN, 0.1% formic acid, over 
5 min. Both protein digestion and peptide separation were performed at 0 °C to minimize back 
exchange. The eluted peptides were analyzed by a MaXis quadrupole time-of-flight (Q-TOF) 
(Bruker Daltonics Inc., Bremen, Germany) in the positive-ion ESI mode. All analyses were done 
in triplicate.  
2.3.4  A40 Back Exchange 
We evaluated the extent of back exchange by incubating A40 (same concentration as described 
above, starting by diluting from stock solution in d6-DMSO) in D2O buffer, with 4.5 M GdnDCl 
(GdnHCl already exchanged with D2O) to unfold fully the protein. The solution was allowed to 
stand for 2 days at 25 °C without agitation, based on a published procedure
50
. After incubation, 
the sample was treated exactly the same as described above. 
2.3.5  Data Analysis and Modeling 
Peptic peptides identification was performed as described previously
51
. The centroid mass of the 
peptides was converted by MagTran v1.03. The percent protection was calculated by using 
Equation 2.1, 
% 100% % (1 ) 100%
( 2) 0.5
HDX controlprotection D
N
m m    
 
 2.1
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where  𝑚𝐻𝐷𝑋 is the centroid mass of the deuterated peptides; 𝑚𝑐𝑜𝑛𝑡𝑟𝑜𝑙was the centroid mass of 
non-deuterated peptides; (𝑁 − 2) is the number of exchangeable amide hydrogens; and 0.5 is the 
final D2O content of the buffer system. 
The experimentally determined time-dependent data (mass shift versus incubation time) were 
characterized phenomenologically by following the recommendation of Finke and coworkers
52
 to 
use the simplest model consistent with the data. The modeling was carried out by Mathcad 14.0 
M020 (Parametric Technology Corporation, Needham, MA). The least squares fit was 
implemented with the "Minimize" function in the "Nonlinear Quasi-Newton" mode. In each trial 
of the minimization process, the postulated normalized rate constants were converted to their 
equivalent physical values by multiplication with their respective initial physical rate constants. 
The physical rate constants specified an ordinary differential equation, which was solved with 
the adaptive step-size fourth order Runge-Kutta "Rkadapt" function in Mathcad. Each reaction 
species accounted for a time-varying fraction of the total original monomer molecules in 
solution. Each fraction was weighted by a postulated percentage of protection for that species. 
The postulated rate constants and protection weights were changed for each trial of the search to 
minimize the difference between the data curve and the sum of weighted species fractions. The 
modified F-W modeling was applied to all experiments except experiments done at 37 °C, with 
agitation at 150 rpm and in absence of Cu
2+
, which shows constant increase in the curve and does 
not need modified F-W modeling. 
A bootstrap resampling method
53-55
 was then used to evaluate the uncertainty of t1/2. We 
constructed trial data sets by randomly resampling with replacement at each time point. The 
number of times for resampling equals the number of replicates at that time point. The model 
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was refitted to each of the 104 trial data sets. Analysis of the accumulated results gave a mean 
and standard deviation. 
2.4 Results and Discussion  
Our goal is to implement a general MS approach to monitor A aggregation under different 
incubation conditions. Both HDX and aggregation are time-dependent phenomena. To minimize 
aggregation during HDX and thereby separate aggregation and HDX, we used pulsed HDX 
whereby we allowed A to incubate for various times and then submitted the mixture to a rapid 
pulsed HDX (1 min) followed by the usual quench procedure. Prior to MS analysis, we 
centrifuged the sample, split it into two equal parts representing the top and bottom parts, 
respectively, and analyzed the latter aliquot that is enriched in A oligomers and aggregates. 
2.4.1  Comparison of A42 and A Aggregation by Native Gel and Western 
Blotting 
After various aggregation times, we analyzed the A40 and A42 samples by native gel and 
Western blotting to permit an accurate comparison of the aggregated species (Figure 2.1). We 
found that the top half of the solution after centrifugation showed no detectable aggregates but 
only A monomer, indicating that most of the monomer is homogeneously distributed, whereas 
larger soluble species move to the bottom half. We used the A40 peptide as a control, which 
showed only the presence of A40 monomer in all the “bottom half” samples (Figure 2.1a-c), in 
agreement with previous work
56
. A42, however, showed a quite different behavior. After only 1 
min of incubation, formation of low molecular-weight (LMW) A42 oligomers (i.e., mostly 
trimer and tetramer) was observed. With longer incubation time, high molecular-weight (HMW) 
soluble A42 oligomers in the 50-110 kDa range were observed. The amyloid fibrils, which are 
too large to enter the gel, were observed at the top of gel lanes. All these results are consistent  
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Figure 2.1 Western blotting for both A40 and A42. A40 samples are shown in a-c and A42 in (d-f). The sample 
film was dissolved in DMSO to maintain monomeric form (1 mM). The sample was diluted by 20-fold in PBS 
buffer to initiate aggregation. Aggregation was at 25 °C, no agitation, and in absence of Cu
2+
. The sample was then 
centrifuged at 16,000 g for 5 min at 4 °C. Aggregation time points were 1 min (a and d), 24 h (b and e), and 48 h (c 
and f), respectively. 
  
A40 A42Protein:
Incubation time: + +
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with previously published work showing that A42 has a greater tendency to form aggregates 
than A
34, 56
. 
2.4.2  Pulsed HDX Analysis of Soluble A Species 
To conduct a more detailed characterization of various regions of A, we applied pepsin 
proteolysis following the pulsed HDX treatment described above. As most of the soluble A 
species were on the bottom half fraction upon centrifugation, we performed all analyses on the 
bottom half solution. Seven peptides were observed: the N-terminus region (1-19 and 4-19), 
middle region (20-33, 20-34 and 20-35) and C-terminus region (35-40/42 and 36-40/42). We 
used three of these peptides (i.e., 1-19, 20-35, and 36-40/42) to analyze the HDX results because 
these fragments provide full Acoverage. 
The pulsed HDX approach used to probe the Aaggregation states as a function of incubation 
time is unlike most HDX protocols, in which the protein is incubated in D2O buffer for various 
times, quenched, and analyzed. Here the HDX time is a short (1 min) “pulse” after various 
incubation times. This pulse time is sufficient to allow the maximum exchange for this largely 
intrinsically disordered protein, yet is negligible when compared to the incubation times. We 
view this pulsed HDX as a “recording” tool to monitor aggregation without competing with it, 
allowing us to separate experimentally the aggregation from HDX. 
Initially, we followed the aggregation of A40 at 25 °C by pulsed HDX as a control experiment 
(Figure 2.2). All three peptic peptides monitored show a constant HDX extent as a function of 
incubation time. This indicates that no detectable conformational changes or self-association 
occurred from 1 min to 48 h at 25 °C. The apparent protection is likely due to two factors: (1) the 
exchange time is sufficiently short for the pulse (1 min) that HDX is not complete and (2) there  
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Figure 2.2 Pulsed HDX results for three peptides from A40. Aggregation was done at 25 °C and in the absence of 
Cu
2+
. Peptic peptides 1-19 (a), 20-35 (b), and 36-40 (c) are represented by green triangles, orange circles, and blue 
diamonds, respectively. Lines were fit by using “linear fit” in OriginPro 8.5. 
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is significant back exchange for the highly disordered A40. To evaluate the back exchange, after 
quenching the “HDX” for the fully deuterated A40, the solution was subjected to online-pepsin 
digestion, column trapping and eluting. During these processes, all the solvents are H2O based, 
which means the protein undergoes back exchange. We found only ~60% of deuterium uptake 
(an average based on the peptide level). This result shows that there is ~40% back exchange for 
this highly disorder protein on our HDX platform. Thus, the extent of HDX for A40 in the 
pulsed HDX experiment is consistent with not only our native gel and Western blotting 
experiments, but also with the common perception that A40 forms fewer aggregates than A42
57, 
58
. 
By contrast, HDX of A42 showed an appreciable increase in protection by a modified sigmoidal 
behavior (Figure 2.4, solid line, raw HDX data shown in Figure 2.3a-d). The first stage is rapid 
and exponential-like, showing a rapid increase in protection. A first plateau follows wherein no 
significant change occurs in protection. A second increase in protection appears as a sigmoidal 
upward break in the curve, followed by a second plateau, indicating that the system reaches 
equilibrium among all the species. The HMW species correspond to A42 soluble aggregates that 
concentrate upon centrifugation to the bottom half solution. Importantly, these results are 
consistent with native gel and Western blotting that show formation of HMW A42 soluble 
species on the same timescale as the pulse HDX experiments (Figure 2.4, right panel, lane 1).  
We attribute the first rapid increase in the protection level to formation of small A oligomers 
(dimer, trimer, and tetramer, etc), in line with previous work
34, 59
. The plateau that follows 
indicates no additional significant hydrogen-bond formation or conformational change. During 
this stage, larger oligomers are forming with little increase in protection as A molecules adds  
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Figure 2.3 Raw data for HDX experiments shown only for the peptide 1-19 (+4 charge). Experimental conditions: 
a) 25 °C, no agitation, in the absence of Cu
2+
; b) 25 °C, no agitation, in the presence of Cu
2+
; c) 37 °C, 150 rpm 
agitation, in the absence of Cu
2+
; d) 37 °C, 150 rpm agitation, in the presence of Cu
2+
. The black traces in each panel 
are the spectra showing isotopic distribution with no deuterium uptake, while the rest of the spectra show isotopic 
distribution with deuterium uptake at different incubation times. 
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Figure 2.4 Pulsed HDX and Western blotting results for three peptic peptides from A42  Aggregation was done at 
25 °C, and in the absence (solid line) or presence of Cu
2+
 (dashed line). Peptic peptides 1-19 (a), 20-35 (b), and 36-
42 (c) are represented by green triangles, orange circles, and blue diamonds, respectively. Straight lines were fit by 
using “linear fit” in OriginPro 8.5. Curve lines were fit by using modified F-W modeling in MathCAD. Native gel 
and Western blotting of the aggregated A42 samples (incubated at 25 °C for 48 h), in the absence (lane 1) or 
presence of Cu
2+
 (lane 2). 
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to the large soluble aggregates. After some time, the oligomers do reorganize, in an autocatalytic 
fashion, to a structure showing higher protection. The upward-breaking sigmoidal curve 
represents this reorganization and is consistent with the behavior of other amyloid-like proteins 
(i.e., they undergo nucleation, growth, and stabilization)
52
. Whereas the rate of nucleation is 
slow, giving nearly constant HDX, the growth rate is much faster, giving the sigmoidal behavior 
of HDX. Similar sigmoidal behavior was reported recently for A42 aggregation followed by a 
fluorescent tetramethylrhodamine (TMR) labeled A42 derivative
59
. Our approach has an 
advantage that it can be employed directly without the need for adding amino acids or 
fluorophores to the protein. 
2.4.3  Application of Finke-Watzky (F-W) Modeling and Bootstrap Strategy 
Amyloid-like proteins usually undergo a self-catalyzed aggregation process, which involves one 
nucleation step and one growth step. Although there are many models to describe a slow, 
continuous nucleation, we chose the simplest one to fit the time-dependent aggregation of A 
(Figure 2.4), following the recommendation of Finke and coworkers
52
. We modified the F-W 
model by adding a “dimerization” process (Equation 2.2). The model describes a reaction that 
proceeds from a monomer Ain state “A” to a “dimer” in state "B" (Equations 2.2-2.4). 
Admittedly, state “B”, consisting of a heterogeneous mix of small oligomers, is more 
complicated than can be addressed in this modified F-W model. Nevertheless, considering it as 
“dimer”, we subsequently allowed its transformation to state "C" by nucleation of large, soluble 
oligomers, heterogeneous in structure and number. The model includes a forward rate constant k1 
of oligomerization, a rate constant k-1 for the reverse reaction, a forward nucleation rate constant 
k2 from "B" to "C", and a forward self-catalysis rate constant k3 involving "B" and "C". A useful 
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parameter that can allow for a direct comparison of different aggregation curves is t1/2, which is 
the time point at which the number of A molecules in state "C" equals to the remaining A 
molecules. 
1
1
k
k
A A B


 
2.2 
2kB C  2.3 
3 2
k
B C C   2.4 
In fitting the data to the F-W model, we sought a single parameter to characterize the outcome. 
The t1/2 value (the time to reach one-half of the step height in the sigmoidal plot) for the 
transitions is likely that parameter, and it could be obtained by averaging the t1/2 values from 
three determinations. However, to obtain a better measure and utilize the full statistical value of 
the data, we evaluated the statistics by using a bootstrap resampling strategy. This gives a more 
reliable t1/2 along with its precision, permitting the use of a simple t-test for establishing 
differences. By applying the bootstrap strategy to the F-W model
53-55
 (Figures 2.5 and 2.6), we 
retrieved not only t1/2 values, but also rate-constant information and precision. Although there are 
many families of k-1, k1, k2, and k3 values that fit the experimental data, they are highly correlated 
(i.e., an increase in k2 and a commensurate decrease in k3 gives a good fit to the model). There is, 
however, a nearly constant t1/2 for all the fits for one peptide. More importantly, the t1/2 values 
corresponding to the three peptides are different. The middle region (i.e., 20-35) has the shortest 
t1/2 (1070 ± 30 min), whereas C-terminus (i.e., 36-42) and N-terminus (i.e., 1-19) regions have 
longer t1/2 values (1230 ± 30 min and 1420 ± 20 min, respectively, Figure 2.7). That these  
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Figure 2.5 A flow chart for the modified F-W modeling and bootstrap strategy. 
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Figure 2.6 A zoom in view for the outcome of application of the bootstrap strategy.  Three different lines 
(overlapping in three different colors) were randomly selected from 104 fitting results following fitting by the 
modified F-W modeling on peptide 1-19 (+4 charge). Experimental conditions: 25 °C, no agitation, in absence of 
Cu
2+
. 
  
 
 t1/2
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Figure 2.7 t1/2 distribution from bootstrap analysis for different peptide. Experimental condition: 25 °C, no agitation, 
in absence of Cu
2+
. The frequency of each peptide was calculated using the “histogram” function in Excel data 
analysis. Bin range is from 1000 to 1500, using 10 as increase interval. 
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differences among the three peptides are statistically significant is supported by the t-test at ≥ 
99.99% confidence level, made possible by employing the bootstrap strategy. Although it may be 
surprising that the outcome treats the three peptides as separate entities, we note that proteins are 
complex species and give, for example, different HDX rate constants for different regions. These 
results now establish that the middle region (i.e., residues 20-35) is the first to report entering an 
organized state. This is consistent with most molecular dynamics simulations that point to the 
middle region as either a folding nucleus or a dimerization interface
60-62
. The hinge region 
identified in the solid-state NMR results for A42 fibrils is from S26 to I31
28
, which lies in the 
middle of the region we identified here. This smaller region may also be important in initiating 
aggregation, as suggested by aggregation studies of myriad mutation forms. For example, 
Flemish (A21G)
63
, Arctic (E22G)
64
, Dutch (E22Q)
63, 65
, Iowa (D23N)
66
 and others
67
 exhibit 
different aggregation behavior compared to the wild-type A42 (WT-A42), supporting that the 
middle region of Ais important in the aggregation process. 
The C-terminus (residues 36-42) aggregates second, confirming that it plays a smaller but still 
important role in aggregation
49
. All the residues in this region (i.e., VGGVVIA) are hydrophobic, 
serving as an interface for A42 aggregation. Besides, the only differences between A40 and 
A42 are the last two residues of this region (i.e., IA) of A42.The strong differences in 
aggregation between A40 and A42 hint at the importance of the hydrophobic interaction within 
this region. As a result, we propose that without the last two residues, the hydrophobic 
interaction would be insufficient to “pull” small aggregates together and form larger aggregates. 
The N-terminus (residues 1-19) aggregates last, consistent with its hydrophilic nature. Unlike 
other approaches showing that the N-terminus is flexible
28
, our data show some ordering in this 
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region, and as expected, it is the last involved in the aggregation process. The observation that 
mice never develop AD, however, may be consistent with the importance of the N-terminus, as 
the three mutations between mouse vs human A represent amino-acid substitutions in this 
region (i.e., R5G, Y10F, and H13R). Nevertheless, the N-terminus is involved in aggregation, 
and this might be the cause for the structural difference between soluble Aaggregates and 
insoluble Afibrils. In addition, the structural difference may be relevant to the different levels 
of neurotoxicity exhibited by soluble Aaggregates vs insoluble fibrils. Thus, these pulsed HDX 
studies should have an important impact in the design of drugs that can alter the aggregation of 
Aspecies and ultimately their neurotoxicity.  
2.4.4  Pulsed HDX Analysis of A Fibrils 
Even though the LC-MS/MS identification showed full coverage for the peptides, there was 
some un-digested A observed as monomer mass in the above experiments; and its 
corresponding relative peak intensity increased with increasing incubation time. Our online 
pepsin digestion has been tested in many other projects
68, 69
, and the digestion efficiency 
approaches 100% for proteins, most of which are larger than A. The A peptide showed the 
lowest digestion efficiency, suggesting presence of amyloid fibrils or other high MW aggregates 
that are slow to proteolyze. The protection levels of these undigested species (Figure 2.8a) are 
higher than that of A species that can undergo pepsin proteolysis. Given that we observed no 
significant peaks corresponding to the monomeric mass of A40 in its aggregation experiments, 
the result for A is further evidence that the amyloid fibrils are the source of peaks representing 
undigested A. 
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Figure 2.8 Pulsed HDX results for undigested species from A42. Experimental conditions: a) 25 °C, no agitation, in 
the absence of Cu
2+
; b) 25 °C, no agitation, in the presence of Cu
2+
; c) 37 °C, 150 rpm agitation, in the absence of 
Cu
2+
; d) 37 °C, 150 rpm agitation, in the presence of Cu
2+
. 
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To study directly the amyloid fibrils, we applied pulsed HDX to the pre-formed A42 fibrils, 
which represent the final stage of A aggregation. Digestion of amyloid fibrils is difficult31, 70 
and usually requires the use of “strong” chemicals including hexafluoroisopropanol (HFIP) or 
DMSO to dissociate all aggregates into A42 monomer
49
. This time-consuming and MS-
unfriendly digestion protocol is not suitable for an HDX platform. We tested the effectiveness of 
the HDX quenching procedure (3 M urea with 1% TFA) by using TEM, and found the protocol 
was able to dissociate to some extent the amyloid fibrils, allowing us to measure the HDX of the 
fibrils (Figure 2.9).  
Upon pulsed HDX to the pre-formed fibrils we observed both the peptides formed by pepsin 
digestion (i.e., 1-19, 20-35, and 36-42) and the undigested AThe peptides and the full A 
are similarly protected (89 ± 1% for the undigested A, 85 ± 1%, 84 ± 1%, and 91 ± 2% for 1-
19, 20-35 and 36-42, respectively), consistent with the peptides being proteolytic fragments from 
the amyloid fibrils. This conclusion is consistent with a study that shows the recycling 
mechanism of A42 fibrils with the A42 monomer
45
. The monomer thus formed carries 
information of the “imprinted” fibrils because quenching HDX preserves information prior to 
MS analysis. These monomers digest well with pepsin owing to a lack of the highly packed 
structure characteristic of the amyloid fibrils. Thus, the peptide fragments are useful “fibril 
reporters” because they contain the same protection as their precursor fibrils. These amyloid 
fibrils, which become ultimately the main component in the incubation, are considerably more 
difficult to interrogate because they have a highly compact structure. Nevertheless, the highly 
organic mobile phase we used is sufficient to denature some of the fibrils and release detectable 
amounts of A42 monomer
31
. The protection level of undigested A seen in the previously  
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Figure 2.9 TEM images for effect of quenching solution on A42 fibrils. (a) A42 fibrils; (b) A42 fibrils with 3 M 
urea; (c) A42 fibrils with 3 M urea and 1% TFA (bar scale is 500 nm). 
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mentioned experiments (Figure 2.8a) is similar to that of the pre-formed fibrils, both digested 
and undigested, indicating that the full Apeptide originates from the A42 fibrils whereas the 
peptides arise from soluble species. 
To rule out a significant contribution of undigested Ato our time-dependent studies described 
earlier, we measured directly the digestion of amyloid fibrils by examining the relative peak-area 
ratios in extracted ion chromatograms (EIC) of the peptide fragments and the undigested A42. 
We used the N-terminal region (i.e., 1-19) as a measure of fibril digestion, and the ratio of its 
EIC peak area compared to that of the undigested A is 0.078, indicating that only a small 
fraction of fibrils undergo digestion. Thus, the contribution of fibril digestion to the peptide-
fragment signals is likely small because the peptide 1-19 signal area in the EIC was considerably 
greater than the EIC area corresponding to the undigested protein (see below). Because HDX 
reports an ensemble average, the protection levels seen in the digested peptides are a measure of 
soluble Aaggregates, rather than of the insoluble A species. 
2.4.5  Pulsed HDX Analysis of Factors Affecting A42 Aggregation 
One motivation for the HDX pulsed platform is to develop a tool to investigate the many factors 
that affect A oligomerization and aggregation (and of other amyloid-forming proteins). Such a 
platform should rapidly provide insight on those factors that affect A aggregation. Shifts in or 
losses of the sigmoidal behavior are a measure of the effect. One factor of high interest to us is 
that of Cu
2+
, which has been previously implicated in A42 aggregation
14, 18, 19
. Thus, we added 
Cu
2+
 to the PBS buffer before mixing with Asuch that the final stoichiometry of Cu
2+
 and 
A42 is 1:1 (molar ratio). The pulsed HDX results of A incubation in absence of Cu
2+
 provide 
the reference point for this experiment. The protection level of A incubated with Cu
2+
 is 
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remarkably linear and unchanged for the three peptic peptides (i.e., 1-19, 20-35, and 36-42, 
Figure 2.4, dashed lines, raw data shown in Figure 2.3b), in contrast to their sigmoidal behavior 
in the absence of Cu
2+
 (Figure 2.4, solid lines, raw data shown in Figure 2.3a). The plateau stage 
of protection in the presence of Cu
2+
 is similar to that represented by the first plateau for 1-19 in 
the absence of Cu
2+
 (55%). The protection is lower than that of both 20-35 and 36-42 (56% vs 
60% and 60% vs 75%, respectively). 
We hypothesize that the differences of protection in the presence and absence of Cu
2+
 is that 
Cu
2+
 stabilizes different forms of A aggregates by interacting with them. The coordination sites 
for Cu
2+
 are likely on the N-terminus (i.e., H6, H13, and H14)
14, 17
, and coordination to these 
sites would lead to more protection of that region of A. By contrast, the C-terminus, which 
can principally interact via hydrophobic forces, may be diminished to compensate for the Cu
2+
 
coordination. In addition, native gel and Western blotting of the samples corresponding to the 
largest difference on the pulsed HDX curve show much less high MW soluble aggregates (50-
110 kDa) and more low MW aggregates (i.e., mainly trimer and tetramer) in the presence vs 
absence of Cu
2+
 (Figure 2.4, right panel). This result reinforces our previous report showing that 
Cu
2+
 stabilizes the soluble A42 aggregates and inhibits formation of amyloid fibrils
14, 19
. 
We also tested the ability of our pulsed HDX approach under rapidly aggregating conditions 
such as higher temperature and with agitation. We chose a higher and more physiologically 
relevant temperature (37 °C) and agitated the solution (at 150 rpm, Figure 2.10, solid line, raw 
data shown in Figure 2.3c). Compared to the results at 25 °C in absence of Cu
2+
 and without 
agitation, the aggregation behavior speeded up considerably. The lag phase disappears, 
indicating that the transformation from low MW aggregates to high MW aggregates is expedited.  
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Figure 2.10 Pulsed HDX results for three peptides from A42. Aggregation was done at 37 °C, with agitation at 150 
rpm and in absence (solid line) or presence of Cu
2+
 (dashed line). Peptic peptides 1-19 (a), 20-35 (b), and 36-42 (c) 
are represented by green triangles, orange circles, and blue diamonds, respectively. Solid lines were fit by using 
modified FW modeling while dashed lines by simple F-W modeling in MathCAD. 
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Next, we repeated the experiment at higher temperature and subjected the solution to agitation, 
as well as added Cu
2+
 to the solution. According to the results just discussed, applying higher 
temperature and agitation should decrease the lag phase of A42 aggregation, whereas Cu
2+
 
should slow down the aggregation. Indeed, the results (Figure 2.10, dashed line, raw data shown 
in Figure 2.3d) indicate that the A42 aggregation is faster than that at 25 °C, yet a lag phase is 
observed in presence of Cu
2+
. This agrees with the hypothesis that higher temperature and 
agitation accelerate the aggregation. On the other hand, the results showed slower kinetics than 
that for A42 aggregation at 37 °C, 150 rpm, in absence of Cu
2+
, providing evidence that Cu
2+
 
slows down the A42 aggregation, even at 37 °C, yet without completely preventing it. 
As we observed in experiments of A42 incubated at 25 °C, the peaks corresponding to the A 
monomer undigested species) were observed in all experiments mentioned in this section. The 
extent of protection of the corresponding undigested species is higher than observed for peptide 
fragments in the same experiments, and similar to those of both digested and undigested pre-
formed fibrils (Figure 2.8b-d). 
The ratios of peak intensities corresponding to A that can be digested relative to that resistant 
to digestion now range from 17 to 1.1. After longer incubation times, more and more A 
becomes resistant to digestion. These ratios are 210 to 14 times higher than the ratio calculated 
from pre-formed fibrils described above (i.e., 0.078), indicating that only a very small amount of 
the fibrils was digested and thus is not expected to interfere to a large extent with the protection 
level calculated from these experiments. Importantly, this result indicates that our platform 
reports only on the soluble A species and not insoluble aggregates. 
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2.5 Conclusion 
A new implementation of the pulsed HDX technique interfaced with LC/MS provides an 
opportunity to examine the details of aggregation of the Apeptide at various stages. By using 
this method, we successfully decoupled the aggregation from the HDX process. Importantly, we 
extracted kinetic information on the A42 aggregation at 25 °C, indicating that the middle region 
of the A42 peptide (i.e., 20-35) was the “seeding” region in aggregation, followed by the C-
terminus hydrophobic region (i.e., 36-42) and then the N-terminus hydrophilic region (i.e., 1-19). 
Finally, we showed that this approach allowed us to examine directly the factors that affect the 
oligomerization of A42. For example, at 37 °C and with agitation, A42 aggregated faster than at 
25 °C. On the contrary, the presence of Cu
2+
 slowed down the A42 aggregation, presumably by 
complexing the polypeptide in the N-terminal region and stabilizing the soluble A42 species.  
We envision this approach as a general tool to support future efforts to measure rates of A42 
oligomerization and aggregation as a function of various parameters (e.g., concentration, 
presence of different ligands or proteins, and pH). We will discuss in detail on effect of ligand 
binding in Chapter 3. We also see the need for more effort in using MS site-specific ion 
activation (i.e., electron-transfer dissociation, ETD) to obtain information at the amino-acid level 
and probe in more detail the aggregation interface and the Cu
2+
 binding sites. Alternative 
footprinting approaches including fast photochemical oxidation may also offer complementary 
views to understand amyloid formation. Moreover, the method described herein is applicable to 
the study of various experimental conditions on the oligomerization and aggregation of other 
amyloid-forming proteins involved in neurodegenerative diseases. 
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Chapter 3: Structural Analysis of Amyloid 
Beta Peptides Interacting with Different 
Ligands by Pulsed Hydrogen Deuterium 
Exchange Mass Spectrometry 
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3.1 Abstract 
The study of amyloid  (A) peptide aggregation in Alzheimer’s Disease (AD) has been 
hampered by the high heterogeneity of soluble A aggregates. To extend the ideas of Chapter 2, 
we further applied the pulsed HDX platform to investigate the effect of different compounds on 
the A aggregation process. Three ligands are included in this study, L1, L2, and 
amentoflavone (AMF). The pulsed HDX technique reveals that the three ligands interfere with 
A aggregation process differently. L1 and L2 stabilize small oligomers when Cu
2+
 is absent. 
When Cu
2+
 is present, L2 accelerates the structural reorganization and formation of large A 
oligomers more than does L1. On the contrary, when AMF interacts with A, the presence of 
Cu
2+
 does not have a significant impact on the Aaggregation behavior. Overall, these studies 
demonstrate that the pulsed HDX platform described in the previous chapter is applicable to 
study the effect of different conditions and additives that affect amyloid protein aggregation. 
3.2 Introduction 
There are more than twenty small proteins that undergo amyloidosis in humans. Such protein 
aggregation events play a role in neurodegenerative diseases including Alzheimer’s, Parkinson’s 
and Huntington’s, and has gained the attention of many researchers in biochemistry and 
biophysics. In general, only one protein is responsible for each type of amyloidosis; for example, 
amyloid beta (A) peptide aggregation is involved in Alzheimer’s disease (AD). There are two 
main forms of the A peptide, A40 and A42, which are 40 and 42 amino acids long, 
respectively
1, 2
. A40 is dominant, whereas A42 is more neurotoxic and amyloidogenic. Previous 
studies suggest that mature A fibrils or A plaques are responsible for memory loss and neuro 
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degeneration
3-8
. Recent in vitro and in vivo studies, however, suggest that the soluble aggregates 
of A42 are more neurotoxic than the amyloid plaques
9-14
. 
The AD-affected brain contains remarkably high levels of metal ions including copper (Cu), zinc 
(Zn), and iron (Fe)
15-20
. Among these metal ions, Cu has drawn the most attention because it has 
a putative role of the amyloid-beta precursor protein (APP) as a Cu chaperone protein
21
. The 
Cu
2+
-A interaction can promote formation of small A oligomers
19, 20, 22
.  
Recent efforts to control A aggregation via metal ion-A interactions were focused on small 
molecules (e.g., bifunctional chelators (BFCs) that bind to both metal ions and Apeptides20, 23-
28
). Most of these studies investigated the interaction of A40 with BFCs. That interaction causes 
significantly different aggregation pathways to be followed than those of the more pathological-
relevant A42. In addition, natural compounds, for example, amentoflavone (AMF) and 
epigallocatechin gallate (EGCG), have drawn serious attention recently as affecting the 
occurrence of AD
29, 30
.  
The structures of A42 and its aggregates have been studied extensively. Electron microscopy 
(EM)
20, 31, 32
 and thioflavin-T (ThT) fluorescence
20, 33
 can be employed to investigate the global 
aggregation behavior, whereas X-ray crystallography
34-36
 and solid state NMR
37-39
 studies 
provide residue-level information on the amyloid fibrils. Not much is known about the structure 
of the soluble A aggregates, however, owing to their low concentration and vast heterogeneity.  
Most mass spectrometry (MS) measurements of A have been performed on the complete 
aggregated stage (A fibrils)40-42. We are motivated to study soluble A aggregates by MS 
methods as they require very little sample and can afford both sensitivity and resolution. 
Hydrogen deuterium exchange (HDX)-MS can afford information on hydrogen-bond formation 
and conformational changes due to protein/ligand or protein/protein interaction
43-48
. MS has 
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already been utilized in determining A42 fibril core structure
40, 41
 and recycling mechanism
42, 49
. 
Studies on the A oligomers are scarce, surprising because residue-level structural information 
of aggregates can be achieved by using both HDX and top down sequencing
50, 51
.  
Pulsed HDX, in which the deuterium labeling time is constant, was first developed by 
Englander
52
 and used by Konermann
53
 for detecting protein-folding intermediates and 
membrane-protein behavior. Our groups have used this approach to elucidate the aggregation 
kinetics of A under different conditions, including the presence of Cu
2+
 and different 
temperature
54
. Other MS studies have utilized ion mobility MS (IM-MS)
55-57
 and provided size 
information of soluble A42 oligomers, which cannot be achieved by HDX. 
Herein, we describe the pulsed HDX platform and its applicability to the aggregation behavior of 
A42 with different metal-binding BFCs, in the presence and absence of Cu
2+
. We were able to 
probe the structural interference of different ligands on A42 aggregation behavior at the peptide 
level. We observed different effects from the three ligands tested, further validating the 
sensitivity of the platform. Overall, these studies demonstrate that the pulsed HDX platform that 
we described in the previous chapter is applicable to different conditions and additives that affect 
amyloid protein aggregation. 
3.3 Materials and Methods 
3.3.1  Chemicals and Protein Preparation 
All of this information is covered in the previous chapter (Chapter 2). 
3.3.2  Pulsed HDX 
The pulsed HDX was as described in the previous chapter (Chapter 2). In brief, A films were 
thawed and dissolved in dry dimethyl sulfoxide (DMSO) at 1 mM before aggregation. A 
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aggregation studies were initiated by diluting 1:19 (vol/vol) monomeric A into PBS buffer 
(pH 7.4) at 37 
°
C with agitation (i.e., incubator rotating horizontally at 150 rpm). Aggregation 
was allowed to occur over various incubation times ranging from 1 min to 48 h (13 time points) 
under various experimental conditions (i.e., complexing with different ligands). Soluble 
aggregates were enriched by centrifugation (16,000 × g, 5 min at 4 
°
C). The centrifuged sample 
was then carefully divided into two equal-volume parts (i.e., 10 L each). Only the lower half of 
the sample was submitted to MS analysis to obtain the plots shown in various figures, following 
the general approach described in the previous chapter. 
To study the effect of different ligands on A42 aggregation, a similar procedure was followed 
except that the protein was incubated in the presence of ligand (i.e., L1, L2, and AMF). For 
experiments in the presence of ligand and the absence of Cu
2+
, A42 was co-incubated with each 
one of the ligands (pre-diluted in PBS buffer) in a 1:1 ratio. For the experiments in the presence 
of both ligand and Cu
2+
, A42 was incubated with the ligand and Cu
2+
 in 1:1:1 ratio. 
3.3.3  LC/MS, Data Analysis, and Finke-Watzky (F-W) modeling 
All of this information is covered in the previous chapter (Chapter 2). 
3.4 Results and Discussion 
We chose three ligands to study their effect on A aggregation and the formation of soluble 
A oligomers (Figure 3.1). Both L1 and L2 are metal-binding BFCs, and AMF is a natural 
product that is also expected to interact with metal ions. L1 contains a 2-
phenylbenzothiazole/vanillin group for Aβ binding and a 1,4-dimethyl-1,4,7-triazacyclononane 
molecular fragment for metal chelation, whereas L2 has metal-binding donor atoms integrated 
within a molecular framework modeled on the amyloid-binding fluorescent dye thioflavin T 
(ThT)
27
.  
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Figure 3.1 Molecular structures of the BFCs L1 and L2 and amentoflavone (AMF) described in this work. For L1 
and L2, the A binding frame and metal binding parts are highlighted in red and blue, respectively. 
  
 
 
 A B C
L1 L2 amentoflavone (AMF)
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The pulsed HDX approach employed in this study probes the samples as a function of incubation 
time and, unlike other typical HDX protocols in which the protein is incubated in D2O buffer for 
various times, quenched, and analyzed. Here the HDX time is a short “pulse” (1 min) taking 
place after various incubation times. The pulse time is sufficient to allow the maximum exchange 
for the largely intrinsically disordered Aβ peptide, yet is negligible when compared to the 
incubation times. We view this pulsed HDX as a “recording” tool to monitor aggregation without 
competing with it, thus allowing us to separate the effects of aggregation from those of HDX. 
To investigate A aggregation at higher structural resolution, we applied pepsin digestion 
following pulsed HDX labeling and preceding mass spectrometry analysis, so that all the HDX 
information is retained, yet available at the peptide level. As most of the soluble A aggregates 
were on the bottom half fraction upon centrifugation (see Materials and Methods sections), we 
performed all analyses following the reported protocol
54
 on the bottom half of the solution. 
Seven peptides were observed: the N-terminus region (1-19 and 4-19), middle region (20-33, 20-
34 and 20-35) and the C-terminus region (35-42 and 36-42). We used three of these peptides 
(i.e., 1-19, 20-35, and 36-42) to analyze the HDX results because these fragments provide full 
coverage. We already observed that Aaggregation has three stages from Chapter 2: formation 
of small Aβ oligomers (~40% protection) from monomeric Aβ, formation of larger Aβ oligomers 
to afford ~50-60% protection, and a structural reorganization leading to fibrillar species (~80% 
or more protection)
54
.  
3.4.1  Pulsed HDX for L1 
Addition of L1 to an Asolution causes the Aaggregation kinetics to change significantly 
(Figure 3.2). For example, all three regions of the protein, as seen in the peptic peptides, show 
significant longer lag phases in the presence of L1 and absence of Cu
2+
 (Figures 3.2A, 3.2B, and  
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Figure 3.2 Pulsed HDX results for three peptic peptides from A42.interacting with L1. Aggregation was done at 37 
0
C, with agitation at 150 rpm, in presence of L1, either in the absence (upper panel) or presence of Cu
2+
 (lower 
panel). Peptic peptides 1-19 are represented in A and D, 20-35 in B and E, and 36-42 in C and F, respectively. All 
lines are fits using a modified F-W model in MathCAD.  
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3.2C) compared to the previously reported results in the absence of both L1 and Cu
2+
 (see 
Chapter 2). This result helps establish the sensitivity of the pulsed HDX platform on reporting 
the Aaggregation behavior in presence of small organic compound and other additives. In 
addition, the presence of an extended lag phase indicates that L1 interferes with Aaggregation 
by stabilizing small, soluble Aoligomers that show a low protection level (i.e., 40% to 50%). 
The t1/2 values from all peptides (~250 min), however, are similar to those when comparing 
between the two conditions, indicating that L1 can also accelerate the structural reorganization to 
form large aggregates with a high protection level (i.e., ~80%). 
When both L1 and Cu
2+
 are present (Figures 3.2D, 3.2E, and 3.2F), the Aaggregation kinetic 
curves are similar compared to the condition where only L1 is present (Figures 3.2A, 3.2B, and 
3.2C). The only difference is a slightly longer lag phase in the presence of Cu
2+
 (~300 vs. ~250 
min); this is consistent with the hypothesis that Cu
2+
 decelerates the aggregation process by 
stabilizing small oligomers
20, 27, 54
. Comparing the results obtained for the presence of L1 and 
Cu
2+
 (Figures 3.2D, 3.2E, and 3.2F) compared to those with only Cu
2+
 (Chapter 2), we observe 
that the lag phase is significantly shorter (~300 vs. ~700 min). Whereas the presence of L1 alone 
increases the lag phase by interacting with A, L1 appears to interact also with Cu
2+
 (through 
the metal-binding portion of L1 highlighted in blue in Figure 3.1) and interfere with the 
Cu
2+
coordination to A, thus leading to a different Aaggregation structure. This structure is 
likely a small oligomer, because it exhibits a lower protection level (~45%, see Figures 3.2D, 
3.2E, and 3.2F) compared to the larger oligomers formed in the absence of L1 (~60%-70% 
Chapter 2). These small oligomers are slightly more favored vs. the larger oligomers when L1 is 
present, thus leading to the shorter lag phase compared to that obtained in the absence of L1. 
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Figure 3.3 Pulsed HDX results for three peptic peptides from A42 interacting with L2. Aggregation was done at 37 
0
C, with agitation at 150 rpm, in presence of L2, either in the absence (upper panel) or presence of Cu
2+
 (lower 
panel). Peptic peptides 1-19 are represented in A and D, 20-35 in B and E, and 36-42 in C and F, respectively. All 
lines are fits using an F-W model in MathCAD.  
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3.4.2  Pulsed HDX for L2 
The Abinding part of L2 is similar to that of L1. Thus, we expect to see L2 exert a similar 
effect on the Aaggregation in the absence of metal ions. Indeed, when L2 is added to an 
Asolution, significantly longer lag phases for aggregation are observed when compared to the 
absence of any ligand (Figures 3.3A, 3.3B, and 3.3C vs. Chapter 2) in all regions. The t1/2 values 
of the peptides shown in the presence of L2 are longer than under the other conditions of no 
ligands and in the presence of L1 (~500 vs. ~250 min), most likely due to the presence of the 
extended lag phase. During this lag time, Astays mostly as small oligomers corresponding to 
the section of the curve showing protection levels of ~40%. This result thus indicates that L2 can 
stabilize small Aoligomers, similar to L1.  
By comparison, the structural reorganization of the large aggregates corresponding to the rapid 
increase in the protection level from 40% to 80% is accelerated in the presence vs. the absence of 
L2, similar to L1. We suggest that in the presence of ligands (L1 or L2), the small A 
oligomers are slightly more stabilized, and this leads to a slower reorganization to form large 
aggregates. 
The metal-binding fragment of L2, however, is significantly different than that of L1, leading to 
different Aaggregation kinetic curves in presence of Cu
2+
. Unlike L1, no lag phase is 
observed for A aggregation in the presence of L2 and Cu
2+
 (Figures 3.3D, 3.3E, and 3.3F). 
This result further indicates that the BFCs bind to both Aand Cu
2+
. In this case, L2 does not 
stabilize the small A oligomers vs. the larger aggregates, affording significantly smaller t1/2 
values for all regions than those in the absence of L2 and presence of Cu
2+
 (~100 vs. ~700 
min)
54
. 
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3.4.3  Pulsed HDX for AMF 
AMF is a natural product and does not have any structural similarity to L1 or L2, and we 
expected that the aggregation kinetic curves should reflect this feature. Indeed, the curves in all 
regions show a rapid increase and a leveling in protection level in the presence of AMF alone 
(Figures 3.4A, 3.4B, and 3.4C). Unlike in the presence of L1 or L2, the aggregation curves in the 
presence of AMF do not show a significant lag phase, indicating that the small Aoligomers 
readily reorganize themselves into large aggregates with a high protection level, and thus AMF 
does not stabilize to any extent these small oligomers. In addition, the protection levels at the 
final stage in the presence of AMF (~80-90%) is higher than those in the presence of L1 or L2 
(~80%), indicating that large, fibrillar Aaggregates ultimately form in the presence of AMF
54
. 
In addition, compared to the aggregation curves obtained when no ligands were present, the 
aggregation curves corresponding to the presence of AMF show similar t1/2 values yet with 
different curvatures, further suggesting that AMF directly affects the A aggregation
Similarly, in the presence of both AFM and Cu
2+
, the Aaggregation kinetic curves do not 
show a significant lag phase (Figures 3.4D, 3.4E, and 3.4F), nor does the presence of Cu
2+
 
change the t1/2 values for any of the peptides. Importantly, these results strongly suggest that 
AMF eliminates the “Cu effect” (i.e., the Cu-mediated stabilization of small A oligomers
20, 22
) 
observed in the absence of any ligand. Overall, these results indicate that AMF efficiently binds 
to A, even in the presence of Cu
2+
, and promotes the Astructural reorganization to form 
large, fibrillar aggregates.  
3.5 Conclusion 
We applied herein the pulsed HDX-MS approach described in Chapter 2 to investigate further 
the effect of different ligands on Aaggregation. We utilized the on-line pepsin digestion  
- 97 - 
 
 
Figure 3.4 Pulsed HDX results for three peptic peptides from A42 interacting with AMF. Aggregation was done at 
37 
0
C, with agitation at 150 rpm, in presence of AMF, either in the absence (upper panel) or presence of Cu
2+
 (lower 
panel). Peptic peptides 1-19 are represented in A and D, 20-35 in B and E, and 36-42 in C and F, respectively. All 
lines are fits using an F-W model in MathCAD.  
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protocol that was introduced in Chapter 2 to examine the binding effects on a peptide level. 
Importantly, we obtained Aaggregation kinetic parameters for peptides corresponding to 
different regions of A. In particular, BFCs L1 and L2 bind to Aand stabilize small A 
oligomers in the absence of Cu
2+
, suggested by a shortening of the lag phases in the aggregation 
process. The kinetic curves indicate that BFCs accelerate the Astructural reorganization 
process to form large aggregates. When both BFC and Cu
2+
 are present, the kinetic curves show 
a significant lag phase for L1, but no lag phase for L2, suggesting that these two ligands interact 
differently with Aand Cu
2+
. In addition, in the presence of the natural product AMF, A 
aggregation kinetic curves show no significant lag phase, and are identical in the absence and 
presence of Cu
2+
, suggesting that AMF binds Asignificantly differently compared to the two 
BFCs. Most importantly, it seems that AMF eliminated the “Cu effect” of stabilizing the small 
oligomers and promotes the formation of large A aggregates. 
In conclusion, we envision this approach to be general for investigating various protein 
aggregation processes. Moreover, this method could be used to screen lead compounds as 
potential drug candidates for AD. To do this, we need to compare the outcome of the aggregation 
with biological effects of these putative drug candidates in animal testing. In addition, by 
applying electron capture dissociation (ECD) or electron transfer dissociation (ETD), we can 
obtain residue level information to guide further drug development. Furthermore, alternative 
footprinting methods, for example, fast photochemical oxidation of proteins (FPOP) may provide 
complementary information. Our hope is that others can apply this approach to investigate 
protein aggregation processes involved in other neurodegenerative diseases. 
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4.1 Abstract 
We applied differential hydrogen deuterium exchange mass spectrometry (HDX-MS) to 
understand the calcium dependence of the protein arginine deiminases or peptidylarginine 
deiminase (PADs), a family of enzymes whose activity is dys-regulated in inflammatory disease 
and cancer. Calcium binding triggers conformational changes, both within the active site cleft 
and at distal regions, and these increase PAD activity by at least 10,000 fold. Although PADs 
play an important role in regulating human gene transcription via the citrullination of histone 
arginines, their activation in cells is not understood because the calcium concentration required 
for activity is >10 times higher than physiologically relevant concentration. In this chapter, we 
describe the use of HDX-MS in a study of protein-ligand interaction, especially in calcium 
binding proteins. Wild type PAD2 and a PAD2 C647A mutant were analyzed by HDX-MS to 
monitor the calcium binding-induced protein conformational changes and to show that HDX-MS 
is sensitive to the dynamics of calcium binding. Multiple regions in PAD2 are located that have 
conformational changes upon calcium binding. The results of HDX-MS are consistent with the 
crystal structures and provide dynamic information for PAD2-calcium binding in solution. 
4.2 Introduction 
Mammals encode five PAD isozymes, PADs 1-4 and 6, which convert arginine into citrulline 
(Arg→Cit) (Figure 4.1). Given that arginines are important for protein-protein and protein-
DNA/RNA interactions, the scope and importance of citrullination to human physiology is likely 
to be broad, especially when one considers that this post-translational modification (PTM) 
converts a positively charged guanidinium group into a neutral urea. Consistent with this 
statement is the fact that PAD activity influences multiple cellular processes, including 
apoptosis, gene regulation, and cell growth
1-3
.  
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Figure 4.1 Function of PAD. 
  
PAD
Ca2+
arginine
(positively charged)
citrulline
(neutral)
- 107 - 
 
The PAD family is made up of four active enzymes (PAD1-4) and catalytically inactive PAD6. 
They share 50-55% sequence identity
1
. The physiological roles of the individual isozymes and 
how they relate to disease remains poorly understood at the molecular level. The most well 
established connection to disease is overexpression of PADs 2 and 4 in the joints of Rheumatoid 
arthritis (RA) patients; overexpression induces formation of antibodies towards citrullinated 
proteins and localized activation of the immune system
4
. Although PADs 2 and 4 are most often 
associated with disease, PADs 1 and 3 are also involved in regulation of epidermal functions
5
, 
respectively, suggests that all active isozymes in PAD family represent potential therapeutic 
targets. 
Based on previous reported crystal structure of calcium-free wild type PAD4
6
, this enzyme 
adopts an “elongated shape that N-terminal domain forms two immunoglobulin-like subdomains, 
and the C terminal domain forms an α/β propeller structure consisting of five ββαβ modules 
arranged circularly in a pseudo-five-fold symmetric” structure7. Approximately 67% of sequence 
homology on the C terminus of all PADs suggests that the structures of these C-terminal 
domains are similar. Five calcium binding regions were identified in the holo form of PAD4. All 
five calcium binding regions do not have typical EF-hand motif (helix-loop-helix motifs) found 
in common calcium-binding proteins like Calmodulin. Among five calcium binding regions, Ca1 
and 2 are at the bottom of the active site cleft, whereas Ca3-5 are positioned near the molecular 
surface of sub-domain 2 in the N terminal domain. Based on their positions, Ca1 and 2 are 
crucial for substrate binding and enzyme activity. By comparing calcium-free and bound PAD4, 
we can conclude that calcium binding induces conformational changes that generate the active 
site cleft in the C terminal domain where the target substrate, arginine, is converted to citrulline. 
In PAD4, a nucleophilic cysteine, C645, hydrolyzes the guanidinium of an arginine residue to 
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form citrulline. Interestingly, Ca3-5 binding regions are well-conserved among all PAD family 
members. The protein structures surrounding Ca3-5 shifted from disorder to order when calcium 
ions are bound, inducing significant conformational changes. Thus, the structure of the holo form 
of PAD is stabilized. On the contrary, Ca3-5 does not affect PAD enzymatic activity.  
Unlike PAD4, there is no high resolution structure published for PAD2 that is also present in the 
synovial tissues of RA patients
4
. Beside RA, highly expressed PAD2 in luminal breast cancers 
have been reported
8
. As potential drug target, PAD2 have been studied by comparing its 
distribution, catalytic activities, calcium dependency, optimal pH range of activities and substrate 
specify with PAD4
9, 10
. Recent studies proposed that PAD2 uses a new substrate-assisted 
mechanism of catalysis
11
. Biological importance of PAD2 has promoted the deep structural 
studies of PAD2.  
In this collaborative project, we planned to use X-ray crystallography, mutagenesis and HDX-
MS to determine the location, order of calcium binding and the dissociation constants for the 
individual calcium-binding regions. These studies may identify the key calcium binding regions 
that are required for the high calcium dependence of the enzyme. The Thompson lab has 
developed a cell line for expressing pure PAD2 protein and crystallization method for holo form 
of PAD2. This crystallization-based approach can provide high resolution structure model for 
holo form of PAD2. However, it lacks information about PAD2 in solution phase, which can be 
obtained through HDX-MS. 
As I presented in the introduction chapter (Chapter 1), HDX-MS is a new powerful biophysical 
approach in study of protein-ligand interactions. Proteins in their native state (solution phase) 
were labeled by deuterium in buffer solution. The protein conformational information as 
- 109 - 
 
represented by deuterium uptake is recorded by mass spectrometry in an LC-MS experiment. 
Our group has reported several HDX-MS studies of calcium-binding proteins including 
Calmodulin
12, 13
 and Troponin C
14
. In this chapter, we started with HDX-MS investigation of 
PAD2-Ca
2+
 interactions. Both apo and holo forms of PAD2 were analyzed by HDX at seven 
exchange time points at two temperatures, 4 °C and 25 °C, respectively. HDX kinetic curves for 
each identified peptic peptides of PAD2 were plotted in both the apo and holo forms. Calcium 
binding induced conformational changes (either direct or allosteric interactions) were identified 
for both wild type and mutant PAD2. This HDX-MS approach provides a solid basis for HDX-
MS based calcium binding affinity studies, our PLIMSTEX approach, as will be described in the 
following chapter. 
4.3 Methods and Materials 
4.3.1  Chemicals and Proteins 
All chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) unless stated 
otherwise. Calcium free PAD2 was provided by the Thompson lab. 
4.3.2  HDX-MS 
We examined the effects of calcium-binding to PAD2 at the peptide level by using HDX. The 
protein sample (14 μM PAD2 in 20 mM Tris pH 7.6, 0.5 M NaCl, 0.5 mM TCEP, 10% glycerol) 
was pre-incubated with either 0.5 mM EDTA or 2.5 mM CaCl2 for 60 min at 4 
0
C. All HDX 
experiments were carried out at either 4 °C or 25 °C in D2O (20 mM Tris in D2O, 0.5 M NaCl, 
0.5 mM TCEP, pD 7.6) where 4 L protein solution was mixed with 16 μL D2O buffer. HDX 
was analyzed at eight time points (0, 0.17, 0.5, 1, 2, 15, 60, 240 min). HDX was quenched by 
adding 30 μL of 3 M Urea, 1% TFA at 4 °C. A total of 50 μL of quenched protein sample was 
injected for proteolysis with on-line desalting and digestion (immobilized pepsin) and analysis 
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with a fast gradient HPLC (5 min). The HPLC was coupled to an LTQ-Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA). MS/MS experiments were also performed with 
the LTQ Orbitrap as preliminary for the HDX to identify the peptides produced by pepsin 
proteolysis. Product-ion spectra were acquired in a data-dependent mode, and the six most 
abundant ions were selected for product-ion analysis. 
4.3.3  Peptide Identification and Data Processing 
The raw data files were converted to *.mgf files (MassMatrix Mass Spectrometric Data File 
Conversion Tools, Version 3.9) and then submitted to MassMatrix (Version 2.4.2) for peptide 
identification
15, 16
. Peptides included the set used for PLIMSTEX to be described in the following 
chapter had a MassMatrix score of 10 or greater, when using peptide and MS/MS tolerance as 10 
ppm and 0.8 Da, respectively. The MS/MS MassMatrix search was also performed against a 
decoy (reverse) sequence, and ambiguous identifications were ruled out. The product-ion 
(MS/MS) spectra of all peptide ions from the MassMatrix search were manually inspected, and 
only those verifiables were followed in the HDX experiments.  
For the HDX experiments, the centroid masses of isotopic envelopes were calculated with HDX 
WorkBench
17
: deuterium level (%) = ((m(P) – m(N))/(m(F) – m(N))) x 100%, where m(P), 
m(N), and m(F) are centroid values of partially deuterated peptides, nondeuterated peptides, and 
fully deuterated peptides, respectively. To accommodate the situation where a fully deuterated 
control is not available, m(F) was determined as m(F) = m(N) + (n-p-2)/z, where n is the number 
of amino acids in the peptide, p is the number of prolines, and z represents charge. Prolines, with 
no amide hydrogen, were not considered. The value “2” is subtracted in the equation because the 
first two amino acids do not retain deuterium upon back exchange. No correction was made for 
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back exchange because all values are relative and reflect the same back exchange, thus giving 
reliable trends. 
In addition, we compared the HDX results at different temperature. It is well known that HDX 
rate is affected by temperature (Equation 4.1)
18
. Thus, to compare HDX at two temperatures, the 
HDX exchange time scales of the experiments must be adjusted; for example, by increasing time 
at the lower temperature. 
1
1 2 1
2 2
( )exp
exp
exp
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a a
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ch RT RT
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k



   Equation 4.1 
The calculated reaction rate at 25 °C is 9.3 times faster than that at 4 °C. We modified the 
timescale of HDX data at 25 °C. All time points are adjusted to 9.3 times longer than the original 
scale. For example, the extents of HDX at the seven 25 °C time points of 0.17, 0.5, 1.0, 2.0, 15, 
60, 240 min were converted to same extents but at 1.55, 4.65, 9.3, 18.6, 139.5, 558, 2232 min. 
4.4 Results and Discussion  
We identified ~280 peptic peptides from the outcome of the LC-MS/MS experiments. These 
peptides cover 96% sequence of PAD2 (Figure 4.2). Thus, almost all PAD2 regions can be 
monitored in HDX studies. More importantly, there are many overlaps of peptic peptides from 
proposed calcium binding regions.  
4.4.1  HDX Studies of Apo and Holo Wild-Type (WT) PAD2 at 4°C 
In the first set of experiments, both apo and holo forms of PAD2 were incubated in D2O buffer at 
4 °C. The kinetic curves for both apo and holo forms were plotted for seven time points (Figure 
4.3). Data from apo form of PAD2 at 4 °C are highlighted on the dynamic maps of PAD2  
- 112 - 
 
 
Figure 4.2 HDX peptide coverage map for WT PAD2 (96%). 
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Figure 4.3 HDX kinetic curves for WT PAD2 (4 °C) of both apo (solid line) and holo (dash line) states. Numbers in 
parentheses with “+” sign are the charge states of the peptides. 
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structure obtained from unpublished data from the Thompson lab (Figure 4.4). The 
conformational changes on smaller regions of the protein can be mapped from the HDX data of 
multiple overlapping peptides. PAD2 regions with different dynamic features can be identified 
on the map. Several regions (highlighted in blue in Figure 4.4) are still protected from HDX even 
for 240 min, indicating the rigidity of the structure and the strong H bonds in that region. The 
least dynamic regions of PAD2 are β sheets (4, 17 and 18, represented by several peptides in 
regions 40-51, 266-273 and 290-300) of the N-terminal domain (residues 1-295), other β sheets 
(22, 23 and 34, represented by several peptides in regions 355-369 and 565-573) and an α12 
helix (represented by peptides in region 538-555) of the C-terminal domain (residues 296-665). 
All the numbers for the secondary structure are based on PAD4
6
. Those regions exhibit less than 
10% deuterium uptake after 240 min incubation in D2O buffer. On the contrary, all calcium 
binding regions undergo more HDX in the apo state (highlighted in warm color in Figure 4.4). 
Calcium-binding motifs, containing many acidic residues, exhibit higher dynamic features in the 
apo state relative to the holo. In general, calcium binding proteins take advantage of these 
flexible regions to interact rapidly with free calcium ions in solution and form stable 
conformations through non-covalent interactions. 
For PAD2, five of the six calcium binding regions overlapped (Ca1-5) in the sequence (Table 
4.1). Residues 156-171 are shared by Ca3-5 binding regions, and 352-355 by Ca 1 and 2 binding 
regions. Only five regions, 349-351 and 406-449 for Ca1, 370-384 for Ca2, 152-155 for Ca3, 
385-391 for Ca4, and PAD2 121-131 for Ca6, are not shared by multiple calcium binding 
regions (Table 4.1). We compared the HDX kinetic curves of peptides from the above regions 
for both apo and holo WT PAD2 to examine calcium binding-induced conformational changes. 
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Figure 4.4 Dynamics map for HDX of PAD2 (4 °C). The deuterium uptake levels for the apo state of WT PAD2 are 
mapped with color for each exchange point. Color codes are shown on the right edge. 
  
No 
Data
<0.1
<0.2
<0.3
<0.4
<0.5
<0.6
≥0.6
0.17 min 0.5 min 1 min
240 min60 min15 min
2 min
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Table 4.1 Calcium binding regions in PAD2. “Y” represents that this region is involved in the corresponding Ca 
binding region. 
 
  
regions Ca1 Ca2 Ca3 Ca4 Ca5 Ca6
121-131 Y
152-155 Y
156-171 Y Y Y
172-180 Y Y
349-351 Y
352-355 Y Y
370-384 Y
385-391 Y
406-449 Y
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For the Ca1 binding region, there are no significant differences between the HDX kinetic curves 
for the apo and holo states at PAD2 406-449 (Figure 4.3), which is the region involved only in 
Ca1 binding and is not overlapping with other Ca binding regions. HDX data from shared region 
between Ca1 and 2 binding regions, PAD2 349-355, show similar trends. Thus, no calcium 
binding-induced conformational change is identified for Ca1 binding region from the HDX data 
at 4°C. 
Peptic peptides covering Ca 2-5 binding regions are heavily overlapped. Overlapped peptides 
from region 156-171 (for Ca3-5 binding) show a significant decrease in deuterium uptake when 
Ca
2+
 is added, indicating that these regions undergo large conformational changes upon calcium 
binding. We observed slight HDX differences in PAD2 250-257, a region that is involved only in 
Ca5 binding and is not overlapping with other Ca binding regions, between apo and holo states. 
Based on sequence identity and similarity of PAD4 and PAD2 (Figure 4.5), the active site, as 
well as regions surrounding calcium binding regions Ca2-5, are strongly conserved. Such high 
conserved sequences suggest that PAD2 and PAD4 share similar binding capability for these 
four calcium binding regions. Our HDX data confirmed calcium binding on these four regions in 
PAD2, which is consistent with an unpublished X-ray crystallography data from the Thompson 
lab. The published X-ray crystallography data for PAD4 point to these four regions as Ca 
binding regions as well
6
. PAD4 showed significant conformational changes particularly in Ca3-5 
binding regions going from disordered in the apo state to become ordered in the holo state. 
Consistent with this are the significant differences in deuterium uptake in our PAD2 HDX 
experiment, indicating that similar structural changes from disorder to order in Ca3-5 binding 
regions occur for the solution protein. 
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Figure 4.5 Sequence alignment of PAD2 and PAD4. Symbols below represents degree of identity or similarity of 
the residues between the two sequences. For example, “*” stands for identity in the sequence, “:” for better 
similarity than “.” based on the algorithm from ref19. PAD4 sequence lies above and PAD2 lies below. Different Ca 
binding sites are color coded as shown at bottom. 
  
MAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHSPPAKK 60 
MLRERTVRLQYGSRVEAVYVLGTYLWTDVYSAAPAGAQTFSLKHSEHVWVEVVRDGEAEE 60 
* :   :*:   . ..** ****    *: *:** .. :**:: *  * *::.:.  *:: 
 
KST-GSSTWPLDPGVEVTLTMKAASGSTGDQKVQISYYG--PKTPPVKALLYLTAVEISL 117 
VATNGKQRWLLSPSTTLRVTMSQASTEASSDKVTVNYYDEEGSIPIDQAGLFLTAIEISL 120 
 :* *.. * *.*.. : :**. ** .:..:** :.**.   . *  :* *:***:**** 
                                   
CADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDL 177 
DVDADRDGVVEKNNPKK--ASWTWGPEGQGAILLVNCDRETPWLPKEDCRDEKVYSKEDL 178 
 .*  * * *: ... *   :***** ************:.   .  **.*::* ..*** 
  
QDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHY 237 
KDMSQMILRTKGPDRLPAGYEIVLYISMSDSDKVGVFYVENPFFGQRYIHILGRRKLYHV 238 
:*** * * ** *. : :.: :**::: *: *** ** . .  :..:   :** :   *  
              
LMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWI 297 
VKYTGGSAELLFFVEGLCFPDEGFSGLVSIHVSLLEYMAQDIPLTPIFTDTVIFRIAPWI 298 
:  .**. :: *:**.*.*** .*.**::: :***:    ::* : :* *:*:**:**** 
                                                   
MTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYI 357 
MTPNILPPVSVFVCCMKDNYLFLKEVKNLVEKTNCELKVCFQYLNRGDRWIQDEIEFGYI 358 
****  ** .*:.*.: :*  ***.*..*. *::*:*.:* :  * .*:*:***:*:*** 
           
QAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVT 417 
EAPHKGFPVVLDSPRDGNLKDFPVKELLGPDFGYVTREPLFESVTSLDSFGNLEVSPPVT 418 
:**** :***:****: .**:**:*.::********* *   .::.************** 
 
VRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLS 477 
VNGKTYPLGRILIG-SSFPLSGGRRMTKVVRDFLKAQQVQAPVELYSDWLTVGHVDEFMS 477 
*.** *******:* *.:* ...*:* :.::***.********:******:*******:* 
 
FVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIK--KKKQQKIKNILSNKTL 535 
FVPIPGTKKFLLLMASTSACYKLFREKQKDGHGEAIMFKGLGGMSSKRITINKILSNESL 537 
*** *. * * **:**. :*****:*:*::*****::*:*:   ..*: .*::****::* 
 
REHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKH 595 
VQENLYFQRCLDWNRDILKKELGLTEQDIIDLPALFKMDEDHRARAFFPNMVNMIVLDKD 597 
 :.* :.:**:****::**:****:*.****:* ***:.*  :*.*********:**.*. 
 
LGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFS 655 
LGIPKPFGPQVEEECCLEMHVRGLLEPLGLECTFIDDISAYHKFLGEVHAGTNVRRKPFT 657 
********* :: .**** :* .*******:****:*: :**   ****.*********: 
 
FKWWNMVP 663 PAD4   Ca1 Ca2 Ca3 Ca4 Ca5 Ca6 Ca3-4 
FKWWHMVP 665 PAD2 
****:*** 
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For the Ca6 binding region, only three peptic peptides from PAD2 121-151 cover this region. 
There are significant HDX differences observed between the apo and holo PAD2 for peptide 
121-131, indicating that this region becomes protected upon calcium binding. Peptide 121-151 
shows less but still significant differences that are reduced owing to an averaging effect from 
other residues (132-151) that are not involved in Ca binding. A previous X-ray structure shows 
that PAD4 only binds five calciums and lacks a 6
th
 Ca binding region
6
. The X-ray structure of 
PAD2 from the Thompson lab, however, also confirmed a 6
th
 Ca coordination contacts that fit 
well within standard calcium bond lengths (2.3-2.5 Å)
20
.  
We also observed deuterium uptake difference between apo and holo WT PAD2 at several 
regions that are not calcium-binding (Figure 4.3). Interestingly, we observe increased deuterium 
uptake for peptides 5-18 and 273-287 upon calcium binding. These regions may involve in 
PAD2 dimerization. PAD2 dimer dominates in the apo form (unpublished native spray mass 
spectrometry data from Gross lab) but may subject to change in the holo form. Multiple regions, 
PAD2 78-117, 203-226, 336-348 and 631-657, are protected (show less HDX) upon calcium 
binding, which may relate to PAD2 active cleft formation. The PAD4 study shows that there are 
no structural differences between PAD4-Ca and PAD4-Ca-substrate complex, indicating that the 
active cleft is already formed upon Ca binding
6
. 
In summary, the differential HDX experiments detected significant changes in Ca2-6 binding 
regions between apo and holo form of WT PAD2. On the contrary, there are no calcium-induced 
conformational changes identified at the Ca1 binding region (Table 4.1 and Figure 4.3). There 
might be two reasons for such observation: (1) this region does not bind calcium in WT PAD2 at 
2.5 mM Ca
2+
 concentration; (2) calcium binding at this region is weak and still as dynamic as it 
is in the apo state. To examine the second possibility, we need to perform HDX at a higher 
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temperature to obtain higher extent of hydrogen deuterium exchange in the apo state, thus 
making the differences between apo and holo states more significant and available to measure. 
4.4.2  HDX Studies of Apo and Holo WT PAD2 at 25°C 
We also performed HDX at a higher temperature. We increased the HDX incubation temperature 
to 25°C to identify weak calcium binding interactions that we may have missed at 4 °C. These 
data are presented also as kinetic curves for both apo and holo PAD2 (Figure 4.6). A dynamic 
map was generated by using HDX data from apo PAD2 (Figure 4.7). As expected, we observe 
faster deuterium exchange at 25 °C than 4 °C, as seen by comparing the dynamic maps under 
these two conditions (Figure 4.7 vs. Figure 4.4). Most of PAD2 regions have more than 30% 
deuterium uptake after 240 min incubation at 25 °C, larger than what we observed at 4 °C. The α 
helix and β sheets regions on either N- or C-terminal regions that are found to exhibit low level 
deuterium uptake in 4 °C experiments (i.e., peptides in regions 40-51, 266-273, 290-300, 355-
369, 543-555, and 565-573) take less than 30% deuterium uptake in 25 °C experiments. We 
conclude that these regions are consistently the least dynamic region among PAD2 at both 
temperatures. 
Kinetic curves of the peptides covering the calcium-binding regions were compared between apo 
and holo PAD2 at the two temperatures. For the Ca1 binding region, there are no significant 
changes upon Ca binding (Figure 4.6) at either temperature. For PAD4, the Ca1 binding region is 
at the bottom of an active-site cleft where the substrate arginine binds. The citrullination of the 
substrate arginine is initiated by a nucleophilic cysteine (C645 in PAD4 and C647 in PAD2) 
hydrolyzing the guanidinium group of arginine. This reaction is induced by a conformational 
change on residue C645 in PAD4, C645 is far away from active site cleft in calcium free PAD4 
but it moves ~5 Å and be close to the cleft upon Ca1 binding from inactive to active state
6
. The  
- 135 - 
 
5
-1
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
-1
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
8
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
-2
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
9
-2
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
4
-2
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
-3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
-3
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
-3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-4
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-4
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-5
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-5
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
-5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
-6
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
-6
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 136 - 
 
5
2
-6
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
2
-6
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
-7
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-6
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-7
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-7
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-7
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
7
-8
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
7
-8
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-8
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-8
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-8
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
8
5
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
8
8
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
9
2
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
9
8
-1
1
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
9
8
-1
1
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
1
2
-1
1
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 137 - 
 
1
1
3
-1
1
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
1
6
-1
2
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
2
1
-1
3
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
2
1
-1
5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
2
1
-1
5
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
2
-1
5
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
2
-1
5
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
2
-1
6
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
6
-1
7
6
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
6
-1
8
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
6
-1
8
0
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
3
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
0
-1
8
3
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
0
-1
8
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 138 - 
 
1
7
3
-1
8
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
3
-1
8
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
3
-1
8
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
7
-1
8
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
4
-1
9
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
4
-1
9
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
4
-1
9
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
6
-2
0
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
0
-2
0
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
3
-2
1
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
4
-2
1
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 139 - 
 
2
1
5
-2
2
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
1
6
-2
2
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
1
6
-2
3
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
8
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
3
2
-2
4
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
4
9
-2
5
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
0
-2
5
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
1
-2
5
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
1
-2
6
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
2
-2
5
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
5
-2
6
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
5
-2
6
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
8
-2
6
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
6
-2
7
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
6
-2
7
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
6
-2
7
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 140 - 
 
2
7
3
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
4
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
6
-2
8
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
6
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
6
-2
8
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
7
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
8
7
-2
9
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
8
8
-2
9
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
0
-3
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
0
-3
0
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
2
-3
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
2
-3
0
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
2
-3
1
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
0
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
1
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
1
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
1
5
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
1
-3
1
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
1
-3
1
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 141 - 
 
3
1
4
-3
1
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
4
-3
2
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
5
-3
1
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
5
-3
1
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
3
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
3
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
3
5
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
1
-3
3
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
2
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
2
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
3
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
3
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
3
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
3
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
4
-3
3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
6
-3
4
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
6
-3
4
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
1
-3
4
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
9
-3
5
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
5
-3
6
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 142 - 
 
3
5
5
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
6
-3
6
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
6
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
7
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
7
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
7
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
7
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
7
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
8
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
8
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
8
-3
9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
8
-3
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
8
0
-3
9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
8
5
-3
9
1
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
9
1
-3
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
9
2
-3
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 143 - 
 
3
9
2
-4
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
1
-4
0
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
4
9
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
4
9
 (
+
6
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
1
-4
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
3
-4
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
5
-4
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
0
-4
5
8
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
0
-4
6
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
0
-4
6
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
2
-4
6
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
3
-4
6
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
3
-4
7
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
7
-4
7
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
7
-4
7
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 144 - 
 
4
6
7
-4
7
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
5
-4
7
8
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
5
-4
9
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
5
-4
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
6
-4
9
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
6
-4
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
6
-4
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
1
-4
9
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
1
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
4
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
9
-5
1
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
9
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 145 - 
 
5
0
1
-5
1
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
5
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
3
-5
3
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
5
-5
3
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
5
-5
3
7
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
6
-5
3
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
6
-5
3
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
3
8
-5
4
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
3
-5
4
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
3
-5
5
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
3
-5
5
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
3
-5
6
5
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
4
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
5
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
6
5
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
5
-5
5
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
8
-5
5
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 146 - 
 
5
4
8
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
0
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
4
-5
6
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
4
-5
6
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
5
-5
6
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
5
-5
7
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
6
-5
6
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
6
-5
7
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
0
-5
7
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
8
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
8
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
9
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
1
-6
1
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
2
-6
1
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 147 - 
 
 
5
9
2
-6
1
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
5
-6
1
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
5
-6
1
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
4
-6
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
4
-6
2
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
5
-6
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
5
-6
2
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
7
-6
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
1
-6
2
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
1
-6
3
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
2
-6
3
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
4
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
4
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
7
 (
+
5
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
9
-6
5
9
 (
+
6
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 148 - 
 
Figure 4.6 HDX kinetic curves for WT PAD2 (25 °C) of both apo (solid line) and holo (dash line) states. Numbers 
in parentheses with “+” sign are the charge states of the peptides. 
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Figure 4.7 Dynamics map for HDX of PAD2 (25 °C). The deuterium uptake levels for the apo state of WT PAD2 
are mapped with color for each exchange point. Color codes are shown on the right edge. 
  
0.17 min 0.5 min 1 min
240 min60 min15 min
2 min
No 
Data
<0.1
<0.2
<0.3
<0.4
<0.5
<0.6
≥0.6
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highly conserved sequence of Ca1 binding region between PAD2 and 4 suggests C647 of PAD2 
undergoes similar conformational change upon Ca1 binding. In the parallel X-ray based studies 
from Thompson lab, the residue C647 of PAD2 is inactivate and far away (12 Å apart) from the 
active site cleft when PAD2 is incubated with 10 mM calcium. No conformational change in 
HDX is in consistence with the inactive state PAD2 observed in X-ray. The absence of calcium 
on Ca1 binding site of holo PAD2 may suggest the different activation mechanism between 
PAD2 and PAD4.  
For the other five calcium-binding regions (Ca 2-6), significant decreases in deuterium uptake 
are observed upon calcium binding at 25 °C, and these results are consistent with HDX data at 4 
°C. There are several other regions that are not involved in calcium binding but still undergo 
conformational changes in the holo states according to the HDX experiment at 4 °C. For 
example, regions 7-18 and 274-286, exhibit increasing deuterium uptake in the holo state at 25 
°C, and they may be involved in forming a PAD2 dimer interface as discussed previously. We 
also observed decreased deuterium uptake at other regions at 25 °C. Regions 78-87, 113-117, 
336-348 and 632-657 undergo decreased HDX as was observed at 4 °C. 
4.4.3  Comparing HDX Studies (4 °C vs. 25 °C) of Apo WT PAD2 
We adjusted the HDX data at 25 °C experiment and plotted them with the HDX data at 4 °C 
(Figure 4.8). In general, we do not observe significant changes upon increasing the temperature 
for apo PAD2. Almost all regions show the same trends in the kinetic curves. There are no 
significant changes or breaks between curves taken at the two temperatures. If PAD2 has 
conformational changes at 25 °C, the kinetic curves should show significant differences. That 
little change occurs indicates that PAD2 remains as a highly conserved structure at higher  
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Figure 4.8 HDX kinetic curves for WT PAD2 apo state comparison between two temperatures. 4 °C was shown in 
black dots and 25 °C in red. Numbers in parentheses with “+” sign are the charge states of the peptides. 
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temperature (4 °C vs. 25 °C). In addition, these data speak to the good precision and high 
consistency of our experimental data. 
4.4.4  HDX Studies of Mutant PAD2 
The enzyme activity of PAD2, arginine deimination, requires several residues in the binding 
pocket to interact with the substrate. Based on proposed mechanism of PAD2 catalysis, two 
aspartic acid residues (Asp351 and 473) formed hydrogen bonds with Arginine substrate while 
the active site thiolate of C647 (equal to C645 in PAD4) attacks the guanidinum carbon of 
arginine to initiate the Arg→Cit conversion11. In previous structural studies of PAD4-substrate 
complex, the key residue, C645, for Arg→Cit conversion is replaced by Alanine. This PAD4 
C645A mutant is catalytically inactive and form stable calcium bound PAD4-substrate 
complexes
21
. Similarly, PAD2 C647A mutant results in a loss of PAD2 enzyme activity. 
Evidence from unpublished X-ray crystallography data from the Thompson lab demonstrated 
that PAD2 C647A mutant still binds to the substrate, but no conversion from arginine to 
citrulline occurs. The PAD2 C647A mutant likely has a different higher order structure in the 
active site cleft than does WT PAD2. Calcium binding-induced conformational changes of 
PAD2 C647A remain unknown. The HDX data from PAD2 C647A mutant could provide such 
conformational differences. Thus, we extended our HDX studies to PAD2 C647A mutant and 
compared the calcium binding-induced conformational changes between the mutant and WT 
PAD2. 
Sequence coverage of PAD2 mutant is similar to WT PAD2. Multiple overlapped peptic peptides 
cover all six proposed calcium binding regions (Figure 4.9). To provide a view of the dynamics 
of the protein, we show a map with color coding for the extent of HDX for the apo state of the 
mutant (Figure 4.10). Unlike for WT PAD2, there is a significant decrease in deuterium uptake  
- 164 - 
 
5
-1
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
-1
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
-1
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
8
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
-1
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
-2
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
-2
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
9
-2
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
4
-2
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
-3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
-3
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
-3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
-3
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-4
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-4
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-5
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
-5
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 165 - 
 
6
1
-7
6
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-7
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
-7
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-8
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-8
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-8
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
7
8
-9
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
8
4
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
8
5
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
8
8
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
9
2
-9
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
9
8
-1
1
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
9
8
-1
1
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
1
3
-1
1
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
1
6
-1
2
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
2
1
-1
3
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
2
1
-1
5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
2
5
-1
3
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 166 - 
 
1
2
5
-1
5
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
3
4
-1
4
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
2
-1
5
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
3
-1
6
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
5
6
-1
6
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
7
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
3
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
6
8
-1
8
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
0
-1
8
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
3
-1
8
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
3
-1
8
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
7
7
-1
8
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
4
-1
9
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
5
-1
9
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 167 - 
 
1
8
5
-1
9
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
1
8
7
-1
9
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
0
-2
0
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
3
-2
1
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
4
-2
1
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
7
-2
1
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
0
7
-2
1
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
1
5
-2
2
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
1
6
-2
2
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
2
7
-2
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
0
-2
5
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
1
-2
5
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
1
-2
6
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
5
-2
6
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
5
5
-2
6
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 168 - 
 
2
5
8
-2
6
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
6
-2
7
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
6
-2
7
3
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
6
6
-2
7
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
3
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
4
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
5
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
6
-2
8
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
6
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
6
-2
8
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
7
-2
8
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
7
-2
8
6
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
7
8
-2
9
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
8
8
-2
9
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
0
-3
0
0
(+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
2
-3
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
0
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
0
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
2
9
3
-3
1
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 169 - 
 
3
0
1
-3
0
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
1
-3
0
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
1
-3
1
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
0
1
-3
1
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
0
-3
1
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
4
-3
1
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
5
-3
1
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
1
5
-3
2
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
2
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
2
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
3
3
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
3
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
0
-3
3
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
2
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
2
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
2
2
-3
3
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
0
-3
3
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
4
-3
3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
4
-3
4
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
5
-3
3
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 170 - 
 
3
3
5
-3
4
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
6
-3
4
0
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
3
6
-3
4
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
0
-3
4
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
0
-3
5
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
0
-3
5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
0
-3
5
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
1
-3
4
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
1
-3
5
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
1
-3
5
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
4
9
-3
5
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
2
-3
5
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
3
-3
5
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
5
-3
6
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
5
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
6
-3
6
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
6
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
7
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
5
8
-3
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
7
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 171 - 
 
3
7
0
-3
7
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
7
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
8
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
8
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
0
-3
9
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
8
-3
9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
8
-3
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
7
8
-3
9
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
8
0
-3
9
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
8
5
-3
9
1
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
9
1
-3
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
9
2
-3
9
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
3
9
2
-4
0
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
0
-4
0
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
1
-4
0
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
0
6
-4
1
1
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 172 - 
 
4
1
2
-4
3
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
2
-4
3
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
1
4
-4
3
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
1
-4
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
1
-4
5
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
3
-4
5
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
3
6
-4
4
9
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
0
-4
5
8
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
0
-4
6
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
0
-4
6
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
2
-4
6
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
2
-4
6
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
5
9
-4
6
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
3
-4
6
6
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
7
-4
7
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
7
-4
7
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
6
7
-4
7
5
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 173 - 
 
4
6
7
-4
7
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
5
-4
7
8
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
5
-4
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
6
-4
9
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
6
-4
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
7
9
-4
9
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
1
-4
9
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
2
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
8
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
9
-5
1
2
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
4
9
9
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
2
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
2
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
2
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
0
1
-5
1
4
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 174 - 
 
5
0
1
-5
1
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
3
-5
3
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
5
-5
3
5
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
5
-5
3
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
5
-5
3
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
6
-5
3
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
1
6
-5
3
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
3
8
-5
4
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
3
8
-5
4
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
3
8
-5
4
4
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
3
-5
4
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
3
-5
4
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
4
9
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
4
-5
5
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
5
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
5
-5
5
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
4
8
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
0
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
0
-5
6
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 175 - 
 
5
5
1
-5
5
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
5
-5
6
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
4
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
4
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
5
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
5
6
-5
6
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
5
-5
6
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
5
-5
7
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
6
-5
6
9
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
6
6
-5
7
2
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
0
-5
7
3
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
5
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
5
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
8
8
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
9
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
7
3
-5
9
1
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
8
8
-6
0
2
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
2
-6
0
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 176 - 
 
5
9
2
-6
1
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
2
-6
1
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
2
-6
1
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
5
-6
0
9
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
5
-6
1
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
5
-6
1
1
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
5
9
5
-6
1
1
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
4
-6
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
4
-6
2
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
4
-6
2
8
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
5
-6
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
5
-6
2
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
7
-6
2
7
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
1
7
-6
2
7
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
1
-6
3
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
2
-6
3
7
 (
+
1
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
0
 (
+
2
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
0
 (
+
3
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
0
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
6
3
8
-6
5
7
 (
+
4
)
0
.1
1
1
0
1
0
0
1
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
T
im
e
 (
m
in
)
Deuterium (%)
- 177 - 
 
 
Figure 4.9 HDX kinetic curves for PAD2 C647A mutant of both apo (solid line) and holo (dash line) states at 4 °C. 
Numbers in parentheses with “+” sign are the charge states of the peptides. 
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Figure 4.10 Dynamics map for HDX of C647A PAD2 (4 °C). The deuterium uptake levels for the apo state of 
PAD2 C647A are mapped with color for each exchange point. Color codes are shown on the right edge. 
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for Ca1 binding regions (PAD2 340-354 and 406-411) of PAD2 C647A mutant as indicated by 
the peptic peptides covering these regions. These results indicate that the Ca1 binding region 
undergoes conformational changes upon calcium binding. As suggested by unpublished X-ray 
crystallography studies by the Thompson lab, the Ca1 binding region in WT PAD2 may resist 
change in conformation by interactions with C647. For C647A, the lack of C647 clearly releases 
such inhibition and makes the Ca1 region available for calcium binding.  
For the Ca 2-5 binding regions of PAD2 C647A mutant, similar decreases in deuterium uptake 
are observed upon calcium binding as for WT. Thus, the HDX experiments on PAD2 C647A 
mutant provide evidence that the five calcium-binding regions, Ca1-5, are occupied by calcium 
in the holo form. These data are consistent with a highly dynamic apo state, particularly for the 
Ca2-5 regions, that become constrained upon calcium-binding, consistent with the unpublished 
X-ray crystal structure from the Thompson lab. For Ca6, there is no significant difference in 
deuterium uptake between the apo and holo forms of the mutant, strongly suggesting there is 
little or no calcium binding at Ca6 binding region of the mutant. 
There are several regions that are not involved in calcium binding but that show higher 
deuterium uptake in the holo form than in the apo form of the PAD2 C647A mutant. As 
discussed for the WT PAD2, those regions may be involved as an interface in PAD2 dimer 
reorganization. In addition, some regions, 227-249, 310-329 and 431-478, show significant 
decrease in deuterium uptake upon calcium binding in the mutant but not the WT (Figure 4.9). 
Those conformational changes may be involved in deactiviation of PAD2 function by C647A 
mutation. 
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4.5 Conclusion 
We conducted differential, solution HDX experiments to study PAD2 upon Ca binding. Several 
regions show dramatic decreases in deuterium uptake upon addition of Ca
2+
. Four calcium 
binding sites, Ca2-5, has similar conformational changes upon calcium binding, which is 
consistent with previous studies of PAD4 and unpublished X-ray studies on PAD2. Calcium 
binding on those regions induces the order on protein conformation and stabilized the following 
substrate binding and citrullination. Solid state structure suggests Ca1 binding, but this is not 
seen in solution by HDX at 2.5 mM Ca
2+
 concentration. This suggests different activation 
mechanism between PAD families and requires further investigation. HDX data represents not 
only conformational changes on calcium binding regions, but also the potential dimer interface 
of PAD2. Information from our extended HDX studies of PAD2 at elevated temperature and on 
mutant PAD2 has similar trends on most regions. The only difference between WT and mutant 
PAD2 was on the Ca1 and 6 binding sites. It indicates conformational differences induced by the 
mutation.  
PAD2 is a complicated enzyme system that contains up to six calcium binding regions. Detailed 
interpretation of the calcium binding in each region requires more information including Ca’s 
binding affinity and binding order. The unpublished x-ray data provide only a crude estimation 
of the calcium dissociation constants for the individual region, and based on comparison to the 
concentration of calcium required for half maximal activity, these values are shifted substantially 
from that occurring in solution, a deviation that may be due to crystal artifacts. In the following 
chapter, we will use PLIMSTEX methodology to confirm the order of calcium binding and 
estimate the dissociation constants for the individual binding in solution. 
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Chapter 5: PLIMSTEX studies of calcium 
binding of protein arginine deiminase 2 
(PAD2) 
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5.1 Abstract 
The Protein Arginine Deiminase (PAD) family plays important roles in inflammatory diseases 
and cancer. One of the family members, PAD2, is involved in the onset and progression of 
neurodegenerative human disorders and multiple sclerosis. Although PAD2 is an attractive 
therapeutic target, its calcium binding-induced activation mechanism is poorly understood. In the 
previous chapter, we described calcium binding-induced conformational changes that were 
determined by differential HDX-MS. A total of six calcium binding sites were identified in WT 
PAD2 and PAD2 C647A mutant. In this chapter, we focus on WT PAD2 and extended our 
HDX-MS studies by applying a Protein–Ligand Interactions by Mass Spectrometry, Titration, 
and H/D EXchange (PLIMSTEX) strategy coupled with online-pepsin digestion to study binding 
affinity of each Ca
2+ 
binding site. The calcium titration experiment was designed based on the 
differential HDX-MS kinetic results described in the previous chapter. In the PLIMSTEX study, 
PAD2 protein was incubated with different concentration of calcium ions in a titration format. 
The deuterium uptake measured by MS is plotted as a titration curve to afford information of 
binding affinity. Such information further improves our understanding about the calcium-
induced activation of PAD2.  
5.2 Introduction 
PADs are enzymes that catalyze a post-translational modification called arginine deimination or 
citrullination, which alters a positive charge to neutral on Arginines. These proteins are often up-
regulated in inflammatory diseases and cancer
1, 2
. There are five members in the family, PAD1-4, 
and 6, and PAD4 is the only that is well characterized. PAD2 is involved in citrullination of 
histones H3 and H4. This post-translational modification causes activation or repression of genes 
that are regulated by estrogen receptor (ER) and p53
3-5
. Although PAD2 is an attractive 
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therapeutic target, the mechanism of enzyme activation is poorly understood. We do know that 
PAD2 needs to bind several Ca
2+ 
ions to carry out the enzymatic reaction. Understanding the 
details of calcium binding for each PAD2 calcium binding region will further improve our 
knowledge about calcium binding and the subsequent activation of PAD2.  
As discussed in the introduction, information about protein conformational changes can be 
obtained by comparing two states of a protein, apo and holo states, by using HDX-MS. We 
reported an investigation of the PAD2-calcium interaction by differential HDX-MS in the 
previous chapter (Chapter 4), and we used this approach to identify the calcium binding-induced 
conformational changes and to infer binding sites. Such traditional HDX is a powerful 
footprinting method, but it provides little information about binding affinity at each of the 
calcium binding sites of PAD2. Previous x-ray crystal studies on PAD4 raise the question about 
the functions of the five calcium binding sites in PAD4
6
. Similar to PAD4, there are five calcium 
binding sites, as identified by our HDX-MS experiments, on WT PAD2. The Ca1 binding region 
was not identified by differential HDX-MS at a 2.5 mM Ca
2+
 concentration. An important 
extension to this work is to obtain detailed information like calcium binding affinity in these 
regions.  
There are several HDX-MS approaches to determine protein-ligand binding affinity
7, 8
. One 
development by our group
8
 is PLIMSTEX. A detailed introduction of PLIMSTEX is covered in 
the introduction (Chapter 1). Thus, we will only give a brief description here. In a typical 
PLIMSTEX experiment, one compares deuterium uptake level of two states of the protein, not as 
a function of HDX incubation time, but of the ratio between total ligand and total protein 
concentration
9-11
. By fitting the ligand titration curve, the binding affinity can be elucidated. 
When accompanying by pepsin digestion, PLIMSTEX curves can generate binding information 
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for peptide or even residue specific level
9
. Herein, we conduct PLIMSTEX studies on peptide 
level for PAD2-Ca
2+
 binding system. Based on our HDX experiments, we conducted the 
PLIMSTEX titration at 4 
o
C and at 30 sec of exchange. We titrated apo PAD2 at 41 different 
concentrations of calcium to afford a deuterium uptake on the peptide level as was monitored by 
LC-MS coupled with online pepsin digestion. Information from this further provides an estimate 
of the binding in PAD2-Ca
2+
 system.  
5.3 Materials and Methods 
5.3.1  Expression of WT-PAD2; Peptide Level HDX; Peptide Identification 
and HDX Data Processing 
All of this information is covered in the previous chapter (Chapter 4). 
5.3.2  PLIMSTEX 
PLIMSTEX experiments were done similarly as the differential solution HDX experiments 
except that a 3 M PAD2 after incubation with different concentrations of Ca2+ or 
ethylenediaminetetraacetic acid (EDTA), to obtain higher binding affinity information and avoid 
the “sharp break” curve discussed in the introduction (Chapter 1). In total, the PLIMSTEX 
experiments were interrogated at two concentrations of EDTA ([EDTA]:[PAD2] = 36 or 198) 
and 41 concentrations of Ca
2+
 ([Ca
2+
]:[PAD2] = 0 to 3968) to obtain a full binding profile. We 
chose an incubation temperature at 4 
o
C based on the HDX-MS experiment discussed in the 
previous chapter. In the PLIMSTEX experiments, the protein sample was incubated with Ca
2+
 or 
EDTA at 4 
o
C for exactly 1 h, followed by D2O incubation at the same temperature for 30 s. A 
standard quench, desalting and online-digestion procedures were performed following a 
procedure described in Chapter 4. The resulting peptic peptides were analyzed by LC-MS on an 
Orbitrap XL LC/mass spectrometer (Thermo, San Jose, CA). 
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5.3.3  PLIMSTEX Curve Fitting 
All of this information is covered in a previous chapter (Chapter 1). In brief, a nonlinear least 
squares (NLLS) regression is performed by procedures implemented with MathCAD 14 (PTC 
Inc., Needham, MA). The PLIMSTEX data are fitted using a 6:1 ([ligand]:[protein]) binding 
system. The best fit is obtained by searches, changing all the variable parameters (i.e., i, D0, and 
Di) to minimize the error between the fitted curve and the experimental data by iterating 
through many trials. 
5.4 Results and Discussion  
Our goal is to determine the binding affinities of the PAD2-Ca
2+
 binding system by PLIMSTEX. 
In all of these experiments, the protein was labeled in in solution with Tris buffer. The 
conformational changes were revealed by following the deuterium uptake as a function of the 
concentration ratio of the calcium ions and WT PAD2 under the same conditions. We conducted 
a total of 129 experiments (including biological triplicates) at 41 different calcium concentrations 
and two different EDTA concentrations to ensure that the PLIMSTEX results can reliably report 
the conformational changes induced by any perturbations (i.e., ligand concentration changes).  
In a typical PLIMSTEX experiment, one first performs a standard HDX-MS experiment, to 
select a D2O incubation time that permits a maximum deuterium uptake difference between the 
apo and holo states. In this case, the D2O incubation time is 30 s based on our previous 
differential HDX-MS results (Chapter 4). Consequently, all PLIMSTEX experiments were done 
at an exactly 30 s of D2O incubation time, with only the EDTA or Ca
2+
 concentrations as 
variables. Adding EDTA titration into our experiment is to assure an apo state of PAD2.  
Although we designed to keep protein (PAD2) concentration constant and change the ligand 
(Ca
2+
) concentration, selection of the protein concentration requires careful consideration. The 
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protein concentration needs to be low enough to follow binding at high affinity sites and avoid 
“sharp break” curves (as discussed in Chapter 1), but sufficiently high to obtain decent MS 
signals for peptides representing the ligand-binding regions. Fortunately, the ligand-binding 
regions for Ca binding protein have many acidic residues, making the peptides hydrophilic and 
more readily detected by MS than hydrophobic peptides. Based on these two criteria, we 
conducted a series of pilot experiments and selected 3 M PAD2 for all PLIMSTEX 
experiments. As usual, we plotted deuterium uptake level as a function of [Ca
2+
]/[protein] ratio 
to obtain PLIMSTEX curves.  
To assure our PLIMSTEX experiments were reproducible and no systematic error were 
introduced, HDX PAD2-Ca
2+ 
titration
 results from “control region of PAD2” were analyzed. We 
plotted deuterium uptake level from three peptides as a function of [Ca
2+
]/[protein] ratio (e.g., 
18-25, 61-69, and 266-272, Figure 5.1), which covered “control region” that are remote from the 
Ca
2+
 binding sites. These three peptides also range from protected area (showing no deuterium 
uptake) to flexible regions (showing extensive deuterium uptake). We did not observe any 
significant deuterium uptake difference with increasing the [Ca
2+
]/[protein] ratio for any of these 
three peptides, suggesting there is no significant systematic error. More importantly, these results 
suggest that the changes observed in our PLIMSTEX experiments can reflect effectively and 
accurately any conformational changes induced by Ca
2+
.  
For Ca
2+
 binding, we chose a total of four peptides that covered Ca2, 3/5, 4, and 6 binding sites 
(370-391, 168-183, 378-391, and 121-151, respectively) to investigate the binding by 
PLIMSTEX. These choices reflect that Ca3 and Ca5 bind in the same region (based on the 
unpublished X-ray results from the Thompson lab and HDX results from Chapter 4). We did not  
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Figure 5.1 PLIMSTEX data for regions that do not show deuterium uptake decrease.  
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cover Ca1 because we did not observe any significant deuterium uptake changes in that binding 
region at 2.5 mM Ca
2+
, as discussed in Chapter 4.  
Unlike the control experiments, we observed significant decreases in deuterium uptake for these 
peptides upon increasing the [Ca
2+
]/[protein] ratio (Figure 5.2), which agrees with the HDX 
kinetics data in Chapter 4 that show deuterium uptake differences between apo and holo states in 
almost all Ca
2+
 binding regions. Surprisingly, all PLIMSTEX curves corresponding to different 
regions show similar trends, indicating of a high level of cooperativity or regulatory interactions. 
These results agree with the unpublished X-ray structure from the Thompson lab, which shows 
that the Ca3, 4 and 5 (called a “tripartite calcium switch”, TCS) bind cooperatively, whereas the 
TCS can regulate binding of Ca2. It may also affect the low-affinity binding at Ca1. The TCS 
apparently plays a key role in PAD2 enzymatic activity by releasing the active site for the 
substrate arginine to interact. Thus, even if Ca1 and Ca2 binding is not cooperative with the 
TCS, it is still understandable why all binding curves look similar.  
Unfortunately, we cannot obtain the binding order of these calcium ions because the PLIMSTEX 
curves are similar in shape and location. To assign the binding affinities to each individual Ca, 
we start with the unpublished X-ray crystallography data. We divide all the curves into three 
deuterium uptake decrease stages. The curves all start with a sharp turn at [Ca
2+
]/[protein] ratio 
less than one, follow by two immediate decreases in deuterium uptake level with the second one 
less significant than the first. After these three stages there is a plateau, suggesting that Ca 
binding is complete for PAD2. We then fit three of the four binding curves (including 370-391 
for Ca2, 168-183 for Ca3/5 and 378-391 for Ca4) simultaneously and obtain binding affinities 
following procedures described in Chapter 1 (Figure 5.2). The reason for leaving out peptide 
121-151 representing Ca6 is that the deuterium uptake decrease is less than 5%, which causes  
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Figure 5.2 PLIMSTEX data for five Ca
2+
 binding regions. Dashed lines are curve fitting for obtaining the binding 
affinities, based on the 1-3-1-1 binding pattern. 
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difficulties for identifying the best fitting parameters. We set the total number of bound Ca
2+
 as 
six during the fitting process, and we enabled a “cooperative binding” function in the fitting 
program, where we can specify which sites bind Ca
2+
 cooperatively (Table 5.1). In this function, 
we specify how many calcium ions
 
bind to the protein cooperatively, and how many bind 
independently. In addition, we order the binding system by binding affinity (i.e., higher binding 
affinity occurs “before” lower). For example, 1-3-1-1 binding pattern indicates to the fitting 
program that there are three Ca
2+
 bind fully cooperatively with second highest affinity, whereas 
the other sites bind Ca
2+
 independently.  
We tested all possibilities for six Ca
2+
 binding by fitting the three curves using different binding 
patterns (Table 5.2). We applied several criteria to pre-mark some of the binding patterns 
“untrue”. For example, we observed a sharp break when [Ca2+]/[protein] ratio is less than 1, 
which means the first Ca
2+
 binding should not be cooperative with any other Ca
2+
 binding, and it 
does have high binding affinity (less than 3 M). Thus, the first number in the binding pattern is 
“1”, which means all the possible binding patterns start with a number larger than one (i.e., two 
to six) should not be considered. In addition, the third turn of the curve is not as sharp as the 
second, so we need less than Ca
2+
 for the fitting of the last stage of the curve. Unfortunately, 
current PLIMSTEX data analysis and fitting process cannot deal with partially cooperative 
binding behavior (i.e., the binding of one Ca
2+
 partially affects or regulates the binding behavior 
of at another Ca
2+
 binding site). Such fitting and simulation requires larger computational 
capacity than we currently have. 
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Table 5.1 Examples of the Ca binding cooperativity 
 
  
Ca binding order 1
st
 Ca 2
nd
 Ca 3
rd
 Ca 4
th
 Ca 5
th
 Ca 6
th
 Ca
A 1 1 1 1 1 1
B 2 1 1 1 1
C 1 2 1 1 1
D 1 2 2 1
A: All calcium ions bind PAD2 independently.
B: Only the first two calcium ions bind PAD2 cooperatively.
C: Only the 2nd and 3rd calcium ions bind PAD2 cooperatively.
D: The 2nd and 3rd calcium ions bind PAD2 cooperatively; as well as 4th
and 5th calciums ions. However, these two groups of calcium ions (i.e., 
2nd and 3rd vs. 4th and 5th) do not have cooperativity.
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Table 5.2 All tested binding patterns for Ca binding cooperativity 
 
  
1
st
 Ca 2
nd
 Ca 3
rd
 Ca 4
th
 Ca 5
th
 Ca 6
th
 Ca
1 1 1 1 1 1
2 1 1 1 1
3 1 1 1
4 1 1
5 1
2 2 1 1
2 1 2 1
2 3 1
3 2 1
1 2 1 1 1
1 3 1 1
1 4 1
1 1 2 1 1
1 1 1 2 1
1 1 3 1
1 2 2 1
1 1 1 1 2
1 2 1 2
1 3 2
1 1 2 2
1 1 1 3
1 1 4
1 5
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By comparing the shape of the fitted curves, we determined that the best fit for a binding pattern 
is 1-3-1-1. We plotted the fits together with the data in Figure 5.2. In addition, we obtained 
binding affinities for each individual site in the 1-3-1-1 binding profile.  
Parallel studies are needed to generate complementary information; for example, if we knew the 
binding order, we may be able to resolve more fully the complicated calcium binding system. 
The Thompson lab has investigated a calcium titration experiment by using X-ray 
crystallography (unpublished) to estimate the affinities. To define the calcium activation pathway 
and determine the binding order of six calcium binding sites, they generated an eight-point 
crystallographic dose response curve. PAD2 crystals were soaked with increasing concentrations 
of calcium (0-10 mM), including the concentration required for half-maximal activity (K0.5 = 180 
μM) as determined from an enzymatic activity assay. The peak electron density for each calcium 
ion was quantified as a reporter in the titration and normalized against the density of a conserved 
water molecule. Using the binding order from the crystallography data, we assign that Ca6 has a 
Kd of less than 3 M whereas Ca3, 4 and 5 sites have affinities approximately 420 M. Ca2 has 
an affinity of 1 mM whereas Ca1 has an affinity around 8 mM. These results are in approximate 
agreement with the crystallography data (Table 5.3) except on Ca1 binding region, even though 
the crystallography data refer to a solid-state structure. 
We assign the lowest binding affinity (8 mM) for Ca1 because it agrees with the differential 
HDX results. At 2.5 mM Ca
2+
 concentration, only 24% of PAD2 bound to Ca
2+
 at Ca1 binding 
region, which may not be sufficient to be observed by differential HDX. Unfortunately, peptides 
that are involved in Ca1 binding region do not provide enough MS signal. Thus, we are not able 
to use these peptides for PLIMSTEX analysis. It is noted that according to the unpublished X-ray  
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Table 5.3 Comparisonof the data between PLIMSTEX and X-ray crystallography (unpublished) 
 
  
Ca binding regions
Binding affinity 
measured by 
PLIMSTEX
Binding affinity 
measured by X-ray
crystallography
Ca6 < 3 M < 1 M
Ca3, 4, and 5 420 M 280 M
Ca2 1 mM N/A
Ca1 8 mM 630 M
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crystallography data from the Thompson lab, Ca1 binding behavior is affected by the TCS. Thus, 
it is reasonable to postulate that the PLIMSTEX curve in Ca1 binding region, if can be 
monitored, will have similar shape as the others. In addition, it is very suspicious of the 
biological relevant function of Ca1 binding site if it has such a low binding affinity.  
Furthermore, we did analysis of two different ratio of [EDTA]/[protein], 36 and 198, to assure a 
that the apo state of PAD2 was completely free of Ca
2+
. We observed no significant changes in 
any peptide when EDTA was added. The deuterium uptake levels for Ca 2, 3/5, 4, and 6 were 
approximately 47%, 42%, 38%, and 26%, respectively, for all three conditions: no EDTA, 
[EDTA]/[protein] ratio = 36 and = 198. These outcomes suggest that either the native state 
PAD2 (the original sample state) is pure apo state and does not bind to Ca
2+
 ions or that the first 
binding of Ca
2+
 to PAD2 is sufficiently strong that it is unaffected by EDTA. If such a high-
affinity binding of Ca
2+
 to the protein occurred, we cannot determine the binding affinity with 
present mass spectrometry-based technology even if we use more EDTA to remove all the 
calcium ions from the protein. 
5.5 Conclusion 
In this study, we applied HDX-based mass spectrometry biophysics approach to a protein 
calcium-binding system. This study is challenging because six calciums bind to PAD2 and their 
binding behaviors are highly cooperative. We modified the PLIMSTEX fitting program was 
respond to the complexities of PAD2 and then applied it to investigate the Ca
2+
 binding affinities 
for different sites on the protein. Although the results are not completely convincing, it is worth 
noting that this would be difficult by any other equilibrium tool except for X-ray crystallography. 
- 199 - 
 
 Unlike other calcium binding proteins we studied in our group
11-14
, PAD2 does not have a 
typical EF-hand motif for each binding site. The cooperative binding to calcium ions of PAD2 
has been identified by previous studies including differential HDX-MS (Chapter 4). All these 
factors in the PAD2 system pose difficulties for our PLIMSTEX experiment. The PLIMSTEX 
curves for each binding site indeed show similar trends and are consistent with the cooperative 
binding scheme we propose. Combining the data from the X-ray crystallography-based binding 
order studies done in the Thompson lab, we successfully obtained binding affinities for each 
binding sites, and confirmed that Ca6 has the highest binding affinity whereas Ca1 has the 
lowest.  
We envision the peptide level PLIMSTEX to be useful for other protein ligand binding systems. 
It certainly provides more detailed information than global-level PLIMSTEX. In addition, a 
bootstrap strategy can be used in data analysis to obtain precision of binding affinities. Further 
investigations including electron capture or electron transfer dissociation can also be carried out 
to give even residue-level information, giving this approach unique capability. 
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Chapter 6: Structural Analysis of Diheme 
Cytochrome c by Hydrogen Deuterium 
Exchange Mass Spectrometry and Homology 
Modeling 
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6.1 Abstract 
Chapter 4 and 5 describe development and application of HDX-MS approaches on protein or 
protein-ligand complex based on known structures. A lack of X-ray or NMR structures of 
proteins, however, can inhibit their further study and characterization, motivating the 
development of new ways of analyzing structural information without crystal structures. The 
combination of hydrogen deuterium exchange mass spectrometry (HDX-MS) data in conjunction 
with homology modeling (HM) can provide improved structure and mechanistic predictions. 
Here a unique diheme cytochrome c (DHCC) protein from Heliobacterium mosdesticaldum is 
studied with both homology modeling and HDX to bring some definition of the structure of the 
protein and its role. Specifically, HDX data were used to guide the homology modeling to yield a 
more functionally relevant structural model of DHCC.  
6.2 Introduction 
Cytochromes c are essential metalloproteins in the electron-transfer chain of most living 
organisms, including all photosynthetic taxa. Metalloproteins move electrons around the cell to 
produce energetic compounds that drive cellular metabolism. Many of the photosynthetic 
electron-transfer proteins of interest belong to the cytochrome c family. Understanding their 
structure and function will contribute not only to understanding photosynthesis, its evolution, and 
its role in early Earth history but also to harnessing solar energy. 
Cytochrome c’s are electron-transport hemoproteins that are covalently bound through two 
thioether bonds between the vinyl groups of a heme macrocycle and the sulfhydryls of a 
CXXCH heme-binding motif
1
. Two heme propionate groups are exposed and can participate in 
hydrogen bonding. The main function is to mediate single-electron transfer reactions between 
protein electron donors and acceptors via reversible oxidation/reduction of Fe
2+
 and Fe
3+
. The 
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axial coordination of the heme iron and its effect on other parts of the larger protein environment 
play key roles in determining redox, electron transfer, and other properties of cytochrome c
2, 3
.  
Prokaryotic diheme cytochrome c’s, as representatives of electron-transfer proteins with two iron 
centers, have been studied mainly with various spectroscopic methods
4-6
. For example, 
cytochrome c4 from Pseudomonas stutzeri, which shares the same origin and has a similar 
amino-acid sequence as DHCC
7
, possesses a strong hydrogen bond involving the heme 
propionate groups, and the protein facilitates intramolecular, inter-heme electron transfer
8
. Both 
hemes contain hexa-coordinated iron involving histidine and methionine axial ligands. The 
hydrogen bond in P. stutzeri closes one edge of the heme, allowing it to act as the donor and the 
other as the acceptor. 
DHCC from Heliobacterium modesticaldum, an early-evolving, gram-positive phototrophic 
anaerobic prokaryote, plays a role as the terminal electron acceptor in the high-potential electron-
transfer chain of the cytochrome bc complex. This complex participates in the photosynthetic 
electron-transport cycle by oxidizing the quinone pool, sending electrons to the reaction center 
and pumping protons to establish an electrochemical gradient that drives ATP production. 
DHCC replaces the canonical monoheme cytochrome c1 in the cytochrome bc1 complex, or 
cytochrome f in the cytochrome b6f complex
9, 10
. DHCC has two c-type hemes that are predicted 
to reside in similar c-type cytochrome folds. The heme 1 domain is closer to the N-terminal 
helix, whereas the heme 2 domain begins approximately halfway through the sequence. The 
unusual diheme architecture is an interesting contrast with those of the more common mono-
heme cytochromes. In general, an electron transfer of one metal center induces conformational 
changes in the site of the other, and that usually enhances the rates of subsequent steps
11
. 
Studying the structure, function, and redox properties of this protein is crucial to the 
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understanding of the function of the entire heliobacterial cytochrome bc complex. Furthermore, 
an understanding of the Heliobacterium electron transport chain (ETC), which is simpler and 
smaller than later evolved organisms, can provide clues to how life and photosynthesis evolved 
on Earth and possibly on other planets. Similarly, the simple nature of the ETC makes it an 
attractive target for biomimicry in solar energy production
12-15
.  
Redox-dependent conformations of cytochrome c’s have been studied extensively for decades by 
using various biochemical and biophysical approaches
16-23
. Although some comparative X-ray 
crystallographic studies of tuna-heart cytochromes c show little or no difference between the 
backbone structures
24
, almost all solution-based studies show a clear conformational change 
between the two redox states
25-27
. Specifically in the case of horse heart cytochrome c, the radius 
of the oxidized state is significantly larger than that of the reduced one
25
. Despite the success of 
these approaches, there is a need for other methods. For example, many biophysical techniques 
usually require a large amount of sample
28-30
, which is not always available, and their structural 
resolution is relatively low
28
. In contrast, mass-spectrometry (MS) approaches have high 
sensitivity and moderate structural resolution. For studying protein conformations, hydrogen 
deuterium exchange (HDX) coupled with MS is an effective and now commonly employed 
approach
31-35
. The exchange rates for HDX are good readouts for hydrogen bonding and solvent 
accessibility at global, peptide and even amino acid levels
36
. It is also possible to use HDX data 
to adjudicate protein subunit docking and ligand-binding structural models
37-39
. 
In HDX studies, one often compares the exchange rate of the same protein regions for two 
different states that are produced by some protein perturbation (e.g., ligand binding, change in 
redox status, formation of a complex). Although each amino acid has different intrinsic 
deuterium exchange rate constants, this causes no problem because the experimental exchange 
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rates between two states of the protein are compared. Previously, HDX coupled with infrared 
spectroscopy was used to study the conformations of reduced and oxidized horse heart 
cytochrome c
40
. Viala and co-workers
41
 reported an HDX-MS study of the same system, 
indicating of a more open structure in the oxidized state. Thus far, however, there are no HDX-
MS studies of the DHCC system. To test our proposed mechanism of the DHCC subunit of the 
heliobacterial cytochrome bc complex, which involves a more closed conformation upon 
reduction
42
, we designed an HDX study of both the reduced and oxidized states of the 
heliobacterial DHCC in an effort to achieve peptide-level resolution of structural changes. 
Homology Modeling (HM) is another common approach to protein structure and function 
especially when data from other structural approaches (e.g., X-ray crystallography and NMR) are 
not available. Although HM statistics for assigning model quality do not necessarily reflect the in 
vivo structure of the protein, the approach should be more accurate when coupled with 
experimental approaches. HDX-MS with HM was used previously to investigate docking and 
binding studies in combination with Electron Microscopy
43-46
. These semi-quantitative 
approaches rely on heavy computational techniques and assess quaternary structure of the 
protein. Here, we are using HDX-MS results to direct HM to obtain a low resolution 
understanding of protein tertiary structure and to predict a reaction mechanism for the complex. 
Our method relies on readily available applets for modeling and HDX for making qualitative 
structural distinction between a buried or exposed region to adjudicate the models, quite unlike 
the previous studies that use HDX to study the docking of ligands or subunits. Success will not 
only provide insight to DHCC but also to establish the utility of the combined approach for other 
protein systems.  
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6.3 Materials and Methods 
6.3.1  Protein Expression and Purification 
The diheme cytochrome c subunit from Heliobacterium modesticaldum bc complex was 
expressed in Escherichia coli with the cytochrome c insertion plasmid and purified as previously 
described, yielding only the holo-protein
42
. The N-terminal transmembrane helix region was 
truncated to express only the fully soluble portion of the protein. Post-processing did not 
eliminate the hemes, both being covalently bound to the protein. 
6.3.2  HDX of Reduced and Oxidized DHCC 
Differential, solution HDX experiments were performed at 4 °C. DHCC in 20 mM Tris-HCl 
buffer, pH 7.5 solution was incubated with either sodium dithionite (reductant), or potassium 
ferricyanide (oxidant) at a final concentration of 25 M for both the protein and the 
reductant/oxidant. The samples were equilibrated for 1 h prior to initiating HDX. Continuous 
labeling was initiated by incubating 2 μL of the mixture with 18 μL of D2O for seven 
predetermined times (0.17, 0.5, 1, 2, 15, 60, and 240 min). The exchange reaction was quenched 
by mixing the D2O solution with 30 μL of 3 M urea, 1% trifluoroacetic acid (TFA) at 0 °C. The 
quenched solution was then flash-frozen in liquid nitrogen and stored at -80 °C for less than 48 h 
prior to analysis. 
The quenched sample was then digested by passing it through a custom-packed pepsin column (2 
mm x 2 cm) at 200 L/min; the peptides were captured on a C8 trap column (2 mm x 1 cm, 
Agilent Inc., Santa Clara, CA, USA) and desalted with a 3 min flow. Peptides were then 
separated by using a C18 column (2.1 mm x 5 cm, 1.9 m Hypersil Gold, Thermo Fisher 
Scientific, Waltham, MA, USA) with a 5 min linear gradient of 4% - 40% CH3CN in 0.1% 
formic acid. Protein digestion and peptide separation were carried out in an ice-water bath to 
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minimize back exchange. All analyses were with a hybrid LTQ Orbitrap (Thermo Fisher 
Scientific, San Jose, CA, USA) at an ESI capillary temperature of 225 °C. Each experiment was 
performed in duplicate. 
6.3.3  Peptide Identification and HDX Data Processing 
All of this information is covered in the previous chapter (Chapter 4). 
6.3.4  Homology Modeling and Model Refinement 
Homology modeling of DHCC was carried out with three different modeling platforms. The first 
was with Modeller
47
 v9.10 and v9.12 using alignment algorithms ClustalW2 and ClustalΩ, 
respectively, with both pdb files 1ETP
8
 and 3MK7c
48
 generating 100 models from each run. The 
best models from each run were selected based on the molpdf, GA341 and DOPE scores. The 
best model from each run was then tested by taking the experimental HDX data for each peptide 
as a measure of the secondary and tertiary structure of that portion of the protein. The amount of 
exchange in each section was compared to the secondary and tertiary structure predicted by the 
model. For regions that disagreed, the template to DHCC alignment was manually adjusted and 
another round of models with the new alignment was generated until the best match was 
obtained with the HDX data.  
The second approach used models that were generated using the Phyre2
49
 and I-TASSER
50
 on-
line modeling suites. The models generated from these two suites were compared to each other 
because they do not allow for manual adjustment of the alignments or parameters or further 
analysis options. Disorder prediction was run on the best model in Phyre2. The top resulting 
model was compared to the HDX data and to the Modeller generated models.  
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The third approach was built on previous work
10
 where a complete model of the cytochrome bc 
complex was built using the Phyre2 server to analyze the whole complex structure and predict 
mechanism for electron transfer within the complex.  
6.3.5  Solvent Accessible Surface Area (SASA) Assessment of Homology 
Models 
SASA was calculated for all four homology models using the program Get Area
51
. The SASA 
for the backbone only was chosen as the value to be used in our assessment because the only 
HDX that was counted was of the backbone hydrogens not the whole residue. The backbone 
SASA was calculated for each residue and is reported in square Angstroms. To compare to the 
HDX data, the SASA was averaged for all residues in each of the MS peptic peptides. The 
percent of deuterium uptake was reported calculated by taking the average of the initial and final 
point. 
6.4 Results and Discussion  
Prior to conducting HDX, we tested whether charge-state distributions of the intact protein could 
provide coarse structural data to distinguish the reduced and oxidized states of DHCC. 
Experiments revealed that the conditions of native ESI are sufficiently oxidative to preclude 
obtaining mass spectra for the pure reduced species. Expression of the protein with the 
covalently bound heme precluded any comparisons with the apo state. Thus, we turned to HDX 
footprinting to obtain structural data for the DHCC protein. 
6.4.1  HDX Shows the Oxidized Form of DHCC is More Flexible 
An on-line pepsin digestion of expressed and purified DHCC afforded hundreds of peptides, of 
which 69 detected with high signal/noise ratio and validated MS/MS information were chosen  
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Figure 6.1 HDX peptide coverage map  for DHCC showing 95% coverage. The same peptides with different charge 
states are also shown. 
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for the subsequent peptide mapping. The coverage is 95% (shown in Figure 6.1), allowing us to 
assess nearly fully the protein in both of the redox states. As mentioned before, no correction for 
back exchange of the protein was made because all data were used in two-state comparisons of 
the redox-state samples under identical conditions. All samples are subjected to back exchange 
after quench and processing, and this converted any side chain deuteriums (e.g., on -NH2) back 
to hydrogens. Thus, it is the back-bone deuteriums that remain on the polypeptide for the LC/MS 
analysis. Changes in protein dynamics, as reflected by HDX, reflect changes to the protein 
induced by reduction. The resulting perturbations alter the conformation of the protein backbone 
and its H bonding as reflected by changes in HDX. Therefore, all fluctuations in HDX rates 
reflect only reduction-induced changes. For example, we expect that less constrained regions 
should exhibit relatively fast HDX, whereas structured and buried regions exchange slowly. 
We plotted the HDX kinetic curves for each of the peptides from both the reduced (Figure 6.2, 
solid lines) and oxidized (Figures 6.2, dashed lines) states of the DHCC. When peptides of 
different charge cover the same region, we found that the results were nearly identical, indicating 
that the HDX results have good precision. More importantly, we conducted each experiment in 
duplicate and show the error bars (average deviations) in each plot. To show more clearly the 
precision, we enlarged one of the typical HDX plots to show the precision of the experiments 
(Figure 6.3). In summary, all the HDX experiments afforded a 0-3% relative average deviation 
for duplicate determinations. 
The extents of HDX for most regions of the protein are different for the two states (oxidized and 
reduced), indicating that the structural conformation of DHCC is redox-state-dependent. For 
those regions that show differences, the oxidized state always shows greater deuterium uptake 
compared to the reduced state, indicating that the oxidized state is more flexible (less structurally  
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Figure 6.2 Kinetic curves of all the peptides used for HDX mapping for reduced (solid line) and oxidized (dash line) 
states of the DHCC. The peptides involved in heme c binding pockets are highlighted in red frames. Numbers in 
parentheses with “+” sign are the charge states of the peptides.  
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Figure 6.3 Selected HDX kinetic curves for demonstration of the precision for each experiment. The curves are 
typical through the sequence. 
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constrained). This is consistent with other horse-heart-cytochrome c HDX studies that show that 
the oxidized state is more dynamic and flexible than the reduced
41
. The largest differences in 
HDX kinetics occur near the heme-binding CXXCH motif (i.e., for peptides 1-29 and 109-127) 
(Figure 6.2). These differences indicate that conformational opening in the heme-binding region 
accompanies oxidation. This result suggests that redox-dependent conformational changes begin 
at the metal center. Comparing the changes in HDX for the oxidized and reduced states at the 
two heme binding pockets, we find similar outcomes. Specifically, the oxidized protein 
undergoes between 30 and 50% HDX at the two sites whereas the reduced protein undergoes 
between 20 and 40% exchange (Figure 6.2). Our previous reported potentiometric titration of 
DHCC
42
 shows a single observable midpoint potential, which is consistent with the conclusion 
that the two heme binding pockets have similar chemical environments.  
6.4.2  HDX Reflects Secondary Structure 
Although four regions display no changes upon reduction (e.g., 45-49, 130-138, 143-149, and 
169-172, Figures 6.2), they can be viewed as controls because they indicate that regions 
insensitive to oxidation do not show differences in HDX. Importantly, these regions also show 
no detectable HDX as a function of time, indicating that these regions are heavily H-bonded 
and/or buried in the protein. We assign these four regions to be involved in tertiary structural 
helix bundles (Category I). We take this result to indicate that the core structural components of 
DHCC do not change dramatically upon reduction, whereas flexible regions are more likely to be 
affected and participate in the conformational changes that accompany redox changes. In 
contrast, region 173-208 undergoes extensive exchange, even at short time (Figure 6.2). We 
categorize regions of this type to be part of loops (Category II). 
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Regions that constitute a third category also show increasing HDX with time but at a more 
modest extent (none showed 90% or higher deuterium uptake). This lower HDX occurs in part 
because the peptides are long and likely cover regions containing both H-bonded helices and 
flexible loops, thus reporting an “average” of these structural elements. For example, the 
peptides for region 78-108 show deuterium uptake ranging from 20-50% for the reduced state 
and 30-60% for the oxidized state (Figure 6.2). The helix region undergoes less HDX, whereas 
the peptide bonds in the flexible loop exchange more readily. Similarly, regions 78-91 and 92-
108, also comprise helix and loop structures and, thus, show an intermediate level of deuterium 
uptake (~ 60%). This intermediate exchange also pertains to region 109-127, and 150-168. 
We also identified a fourth category where HDX at the shortest times in near zero but increases 
slowly with time (Figures 6.2). We assigned these regions, including 38-44, 50-57, and 128-142, 
to be likely helices but not part of buried helix bundles. 
6.4.3  Homology Model Building and Assessment 
A series of homology models were generated with the software Modeller and PHYRE2 (Figure 
6.4 and Table 6.1). To begin, we chose template 1ETP because it is a bacterial cytochrome c4 
protein, and the evolutionary origin of DHCC may be the cytochrome c4 protein family
42
. 
Likewise, 1ETP undergoes electron transfer from a donor to an acceptor protein
8
. We selected 
3MK7c as the second template on the basis of bioinformatic analysis. A BLAST search of the 
Protein Data Bank (PDB) with DHCC’s sequence returns 3MK7c as the most similar protein by 
alignment statistics. Functionally, 3MK7c is a soluble member of a protein complex, but it 
resides in the cytoplasm and accepts electrons from a cytoplasmic donor and shuttles them into 
the complex, the opposite direction from which DHCC should function
48
. Both 1ETP and 
3MK7c have hemes with two different redox potentials. Although the generated homology  
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Figure 6.4 Homology models A to D. Regions that are highlighted in red do not agree with HDX results. 
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Table 6.1 Homology modeling data. 
Model Template 
Alignment 
Algorithm 
Percent 
Similarity 
Percent 
Identity 
Modeling 
Software 
Molpdf score 
Model 
A 
1ETP ClustalW2 
49% 
(100/205) 
15% 
(32/205) 
Modeller v9.10 
0.24 
(0.49- 
highest) 
Model 
B 
 
1ETP Clustal Omega 
45% 
(92/205) 
16% 
(33/205) 
Modeller v9.10, 
v9.12 
0.12 
(0.28-
highest) 
Model 
C 
3MK7c Clustal W2 
57% 
(116/205) 
28% 
(68/205) 
Modeller v9.10 
0.46 
(highest) 
Model 
D 
 
3MK7c Phyre2 
57% 
(116/205) 
28% 
(58/205) 
I-TASSER, 
PHYRE2 
3.2Å 
Resolution 
N/A 
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models do not incorporate the cofactor heme by nature of the program, the templates we chose 
do include the cofactors within the protein. Even though we did not add the hemes in the HM 
modelling, the protein structure should still be representative. Functional considerations of the 
template are a way to assess model quality.  
Homology Modeling (HM) statistics assess model quality in a more quantitative way. The 
percent similarity and percent identity examine the alignment of the template and model 
sequences. Amino-acid residues that align are examined to see if they are identical or in the same 
category. The percent identity increases from Model A to Model B as a result of manual 
alignment changes implemented on the basis of the HDX data. Further increases in both percent 
similarity and percent identity occur for models C and D, which use 3MK7 as a template (Table 
6.1). The higher these values, the more similar a model is to the template, and the more faithful is 
the homology model. The 28% identity achieved for Models C and D is just under that preferred 
for HM, but it is sufficient for further consideration. We also view it as acceptable because there 
are so few diheme cytochromes with solved structures in the PDB. After running HM in 
Modeller, score reports are generated for each model. The molpdf score can be used to compare 
models across runs. Model C has the highest molpdf score indicating it is the better homology 
model. Model B may be a better model functionally as discussed below, but it has a lower 
molpdf score because manual alignment changes were made (Table 6.1). Homology modeling 
data indicate that Models C and D are better models; therefore, 3MK7c is the better template. 
This result is only based on alignment and threading algorithms, however, and does not speak to 
function or biochemical properties of the models and templates. Thus, biochemical and/or 
biophysical data are needed to assess further these models.  
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6.4.4  HDX Analysis of DHCC with Homology Models 
HDX data generated by MS can provide biophysical data that, when mapped onto the four 
homology models, should be able to test the correctness of secondary and tertiary structures 
generated by the models (Figure 6.4 and Table 6.2). For Model A, most of the regions that show 
discrepancies between the HDX results and the HM outcomes are the helical regions (Figure 
6.4A and Table 6.2). For example, peptides in Category I show almost no deuterium uptake in 
either of the states (Figures 6.2), suggesting they participate in forming tertiary structure, most 
likely a helix bundle. In Model A, however, only region 143-149 has the helix-bundle motif. 
Peptides 45-49 and 130-138 are modelled to be a loop or a singular helix structure. After 
manually adjusting the alignment based on this observation, Model B and C show better fits for 
45-49, 143-149, and 169-172, as these regions are predicted to be helices in helix bundles. 
Furthermore, Model A HM did not identify the second heme binding motif and the alignment 
and subsequent modeling are poor in this region, 109-127.  
To resolve regions for which there is a lack of agreement, we generated Model B (Figure 6.4B 
and Table 6.2) by manually adjusting the alignment based on the results of Model A as evaluated 
by HDX. Model B showed improved agreement between HDX and the HM structure. The helix 
bundle and 2
nd
 heme regions predicted by Model B are consistent with the experimental results, 
but achieving these improvements sacrificed other regions that had agreed with Model A. For 
example, 33-37 shows as a loop, but it takes up only ~50% of possible deuterium. On the 
contrary, a mostly loop region, 173-208, does show ~70% HDX. In addition, residues 173-205 
show the poorest agreement with HDX results compared to other models, as the sequence does 
not align with the template. 1ETP is a smaller protein, and in adjusting for the heme regions, 
residues at the end of DHCC were left without template residues. As a result, this region is  
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Table 6.2 Comparison of HDX data and Homology models. 
 
a. Regions that determined by HDX. Most of the regions are covered by multiple peptides, and 
they give similar results. 
b. Different regions are signed in four categories based on their HDX behavior. 
c. Secondary/tertiary structure elements in each model. “h” stands for helix, “l” stands for loop, 
“h/l” stands for mixture of helix and loop, and “h bundle” stands for helix bundle. 
d. Measures of agreement degrees between HDX and modeling results. “**” stands for 
agreement, “*” stands for agreement with restrictions (information from order prediction by 
Phyre2), and blank cells represent lack of agreement.  
  
A B C D
1-29 III h/l h/l h/l h/l ** ** ** **
33-37 III h/l l l l ** *
38-44 IV h bundle h/l h/l h/l *
45-49 I h h bundle h/l h bundle ** **
50-57 IV l l h bundle h/l *
58-65 II l l l l ** ** ** **
78-91 III h/l h/l h/l h/l ** ** ** **
92-108 III h/l h/l h/l h/l ** ** ** **
109-127 III l l h/l h/l ** **
128-142 IV h/l l l l * *
143-149 I h bundle h bundle h h bundle ** ** * **
150-168 III h/l h/l h/l h/l ** ** ** **
169-172 I h h bundle h bundle h bundle ** ** **
173-208 II h/l l h/l h/l ** ** ** **
Region
a
HDX agreement on the models
d
Model A
c Model B  Model C Model DCategory
b
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unstructured according to Model B. Even though this region shows the highest HDX for the 
whole protein (~70%), it still should have some secondary structure. Despite these areas of 
disagreement, Model B is better than Model A because the active regions of the protein are 
consistent with the outcomes of both HDX and HM. Overall, the transition from Model A to 
Model B demonstrates that HDX data can inform the manual refinement and improve homology 
models.  
Model C (Figure 6.4C and Table 6.2) was developed in the same manner as Models A and B, but 
used 3MK7c as a template. Model C gives better agreement for the second heme-binding region, 
109-127, than do Models A and B (Table 6.2). It also decreased the number of regions of 
disagreement. The model points to a highly open structure, however, and it does not form the 
expected two cytochrome c-type folds as seen in the other models. Thus, Model C, although 
affording better agreement in the second heme region, is not a good model overall for DHCC.  
Model D (Figure 6.4D and Table 6.2) was generated from the online suites I-TASSER and 
Phyre2, and nearly identical results were obtained from running both I-TASSER and Phyre2. 
Both packages identified 3MK7c as the best template, gave highly similar alignments and 
consequently identical models. Model D is presented as that obtained by using Phyre2. It is 
consistent with the HDX results in all regions of the subunit except 38-44, 50-57, and 130-138 
(Figure 6.4D and Table 6.2). These regions are loops in Model D; however, they undergo lower 
HDX, more typical of a rigid region. The Phyre2 software includes a disorder prediction, 
identifying secondary and tertiary structure (Figure 6.5), and a disorder prediction analysis was 
performed on Model D. More order is predicted for all three regions of disagreement, suggesting 
that, although they are not alpha helices, there is more order in the region than can be explained 
by a loop. The order in these regions is likely caused by the interaction of the chains across the  
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Figure 6.5 Model D with disorder prediction data Warmer color and larger number indicates more disordered 
region. Color codes are shown on the right edge.  
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domains, as these regions are in the middle where the two domains interact. Thus, the regions of 
disagreement are actually areas of partial agreement. The region containing residues 130-138 is 
the only region that is inconsistent with all four models and across the three software packages, 
suggesting that the region is different than that seen in the templates. Taking all the evidence 
together, we conclude that Model D best agrees with the HDX data.  
6.4.5  SASA Calculation Shows Model D Correlates Best with the HDX Data 
A correlation of SASA at the peptide level (calculated as an average of the SASA for the 
individual amino acids comprising the region) and the average extents of HDX for the 
corresponding peptide regions confirmed our assignment of model D as the best homology 
model of DHCC (Figure 6.6). This model gave the best correlation coefficient in comparison to 
correlations with Models A-C. In fact, the SASA analysis only disagreed in only one area with 
Model D. Model C has the most open structure, thus with larger SASA values. Overall, the 
SASA analysis is a more quantitative assessment to illustrate that Model D is the best model 
presented thus far. 
6.4.6  HDX Data Mapping Onto Model D 
To view the two redox states at the protein level, we mapped the HDX differences between the 
two redox states of DHCC taken as an average of the differences for each time point onto 
homology Model D (Figure 6.7). The most prominent difference occurs for the short helix in the 
heme 2 domain (colored in blue in Figure 6.7). In agreement with the kinetic traces, most helical 
and loop regions around the heme sites have larger differences, indicating that structural changes 
accompany the redox chemistry. Adding credibility to this conclusion is that the cores of the two 
helix bundles show no significant changes. 
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Figure 6.6 Correlation of HDX and SASA data for all models A (A), B (B), C (C) and D (D). The Pearson 
correlation coefficients R’s are shown in red. 
  
0% 25% 50% 75%
0
5
10
15
20
25
 S
A
S
A
 (
Å
2
)
HDX extent (%)
0% 25% 50% 75%
0
5
10
15
20
25
 S
A
S
A
 (
Å
2
)
HDX extent (%)
0% 25% 50% 75%
0
5
10
15
20
25
 S
A
S
A
 (
Å
2
)
HDX extent (%)
0% 25% 50% 75%
0
5
10
15
20
25
 S
A
S
A
 (
Å
2
)
HDX extent (%)
A B
C D
R: 0.5994 R: 0.691
R: 0.6958 R: 0.9472
228 
 
 
Figure 6.7 The deuterium uptake differences between the oxidized and reduced states of DHCC are mapped onto 
Model D. Color codes show the differences (reduced state subtracted by the oxidized state). 
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Figure 6.8 The deuterium uptake levels for all peptides mapped onto Model D with color for each exchange point. 
The figures for oxidized state are in (a) and reduced in (b). Color codes are shown on the right edge.  
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We also mapped the extent of HDX for all the peptide regions onto our best model, Model D, 
with a color scheme indicating the amount of exchange at each time point (Figure 6.8). Instead of 
an overall picture of kinetics information as in Figure 6.7, these maps show the dynamics of the 
protein at each time point. By comparing the same state at different times, we see that most of 
the regions of the oxidized state are dynamic, acquiring more and more deuterium as seen by the 
increasingly warmer colors.  
General features of the protein’s secondary structure are seen by the different HDX extents. 
Loop regions achieve either a higher level of HDX than helices or a similar level at an earlier 
time. Those loops undergoing less HDX are more ordered and constrained by interactions within 
the protein. The core regions within the helix bundle are always seen as cold colors, indicating 
they are so inflexible that HDX is small even after 4 h of incubation. The data reveal important 
trends about the impact of changing redox states as well as the secondary and tertiary structural 
and solvent accessibility changes of DHCC. 
6.4.7  Proposed Function of DHCC 
HDX provides kinetics and dynamics information on the peptide-level of DHCC in both reduced 
and oxidized states, whereas HM provides a potential protein structure even in the absence of a 
crystal structure. HM can only yield models that are as good as the information entered, and they 
cannot provide the high-resolution structural information of a crystal structure. The approach 
described here takes HM statistics and complements them with HDX results to assess model 
agreement. We used HDX data to refine Model A and correct areas of disagreement to generate 
Model B. Likewise, we used HDX to determine if Model B were more informative, and we 
found that it is in better agreement with HDX than Model A, demonstrating the utility of HDX 
data for testing and refining a homology model. Comparing all four models, we found that 
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Model D had the highest HM statistics and the best agreement with HDX, including a good 
correlation with SASA. We subsequently selected it as the best model for the protein structure.  
Functionally, the choice of templates will bias the model predicted. The DHCCs 1ETP and 
3MK7c are the best templates for structural alignments and are both soluble proteins that contain 
two c-type hemes. Neither protein has been chemically oxidized or reduced; thus, the template 
structure is probably a mix of both forms. 1ETP, from Pseudomonas stutzeri, is a periplasmic 
diheme cytochrome c4. It does not belong to a complex but instead shuttles electrons between 
complexes in an electron-transport chain. The two hemes are located in different protein 
environments, yielding two distinct redox potentials and allowing for inter-heme electron 
transfer. The protein 3MK7c, from P. stutzeri, is a subunit of the cbb3 cytochrome oxidase. Like 
DHCC, 3MK7c is a soluble subunit with an N-terminal anchor. The cytochrome cbb3 complex, 
however, moves electrons in the opposite direction of the cytochrome bc complex. As for 1ETP, 
3MK7c has two distinct redox potentials, but they differ to a greater extent than do those of 
1ETP. Inter-heme electron transfer is still observed. Based on their biological roles, 3MK7c is 
closer functionally to DHCC. This agrees with the observation that Model D accommodates 
better the HM parameters and the HDX data.  
Numerous solution-based spectroscopic and computational studies have shown that there is a 
conformational change between the reduced and oxidized states of horse heart cytochrome c
40, 41
. 
These results are in apparent conflict with high-resolution crystallographic data that show the 
crystal structures of the two states are similar
52
. One explanation is that the solid-state X-ray 
structure does not reflect the solution structure, which is likely to be dynamic. It was proposed 
that the oxidized state undergoes lower-frequency and larger-amplitude motions than the reduced 
state
53
. Our HDX results for DHCC suggest that there are significant structural differences 
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between the two different redox states. It is also possible that both X-ray structures represent the 
reduced form of the protein, produced by X-ray irradiation. 
Just as the HDX kinetics suggest a redox-dependent conformational change for DHCC, they also 
indicate areas that are likely more solvent-accessible (less H-bonded). The heme 2 domain 
particularly exhibits faster exchange. It follows that the heme 2 domain interacts with the soluble 
electron acceptor cytochrome c553. Similarly, in vivo, the heme 1 domain would have an N-
terminal helix anchoring the protein to the b and IV subunits of the bc complex. Heme 1 would 
also then interact with the Rieske subunit. These subunit-subunit interactions would lower the 
HDX rates in the heme 1 region, as is observed.  
For monoheme cytochromes, electron transfer is a two-step process. After the electron donor 
binds with and reduces the cytochrome, the cytochrome binds the electron acceptor and passes 
the electron to it. DHCC, as other diheme cytochrome c’s, adds one more step, the 
intramolecular inter-heme electron transfer. In DHCCs from other species, the two hemes usually 
possess two distinct macroscopic redox potentials (e.g., 240 mV and 330 mV for cytochrome c4 
from P. stutzeri). The values are consistent with the negative and positive electrostatic charges of 
the two domains
11
. The direction of the electrostatic field within the protein gives rise to the 
distinct heme redox potentials and directs the flow of the electron from the lower to higher 
potential heme. The DHCC from Heliobacterium cytochrome bc complex, as studied here, 
however, has only one redox mid-potential
42
, indicating similar chemical environments around 
the two heme-binding pockets. The HDX kinetics data are consistent with this observation. The 
significant conformational changes upon reduction, as revealed by HDX, may work to facilitate 
an inter-heme electron transfer despite the observation of a single mid-point potential in vitro. 
Our results point to formation of a closed structure upon reduction of the protein, providing a 
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closer distance between the two hemes. In P. stutzeri, the inter-heme electron transfer occurs 
upon hydrogen-bond formation between the heme propionate groups and a surrounding 
hydrogen-bond network established by a conformational change to the reduced state, producing 
the closer heme-heme distance and an altered heme environment. Such alterations change the 
redox potential and facilitate inter-heme electron transfer. It is likely that only one redox 
potential is observed in vitro because the heme environments are sensitive to the truncated N-
terminal helix and subunit interactions that are missing in the expressed DHCC. Thus, our 
prediction is consistent with the in vitro data.  
On the basis of the evidence discussed above, we can propose a potential complex mechanism 
for the H. modelsicaldum bc complex (Figure 6.9). As for other bc1 or b6f complexes, 
menaquinol enters at the Qo site
54, 55
. Two electrons and two protons are removed, one at a time 
in a bifurcated electron transfer. The first electron is transferred quickly to the Rieske iron-sulfur 
cluster, reducing the Rieske cluster and causing it to move towards the periplasm, preventing 
rapid back transfer of the electron to Qo. The Rieske cluster is then in position to transfer an 
electron to heme 1 of DHCC. Docking of the Rieske cluster is probably the first step in inducing 
the redox-based conformational changes of DHCC. Based on the mechanism of interheme 
electron transfer within other diheme cytochrome c’s, reducing heme 1 changes the conformation 
and causes formation of a hydrogen-bonding network that permits rapid inter-heme electron 
transfer. Heme 2 then donates the electron to soluble cytochrome c553, which departs, allowing 
the Rieske to return to Qo. The second electron would then travel down the b heme pathway, 
reducing menaquinone at the Qi site. Another menaquinol docks and the process repeats, 
completing one turnover of the bc complex and translocating a net of two protons to the 
periplasm.  
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Figure 6.9 Proposed function of diheme cytochrome c. (A) and (B) Assumed dimer of the H. modesticaldum 
cytochrome bc complex. Blue- cytochrome b subunit, Purple- Fe-S subunit, Green- cytochrome f subunit. A) 
Imagined left half of dimer shown as homology modelled subunits of the H. modesticaldum cytochrome bc 
complex. B) Right side of the dimer shown as the solved crystal structure of the cytochrome bc1 complex from R. 
sphaeroides used as the template for 7A. Heme cofactors highlighted in red. (C) Proposed H. modesticaldum 
cytochrome bc complex bifurcated electron transfer steps and mechanism. Q- quinones, Qo- quinone oxidation site, 
Qi- quinone reduction site, R- Rieske Fe-S, bL,H- b-type hemes, H1,2- DHCC c-type hemes, c553- electron acceptor 
soluble cytochrome c553.  
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Such a mechanism is efficient for many species with a monoheme but not with a diheme 
cytochrome. Dihemes often result from gene duplication that could be random
6
. However, multi-
heme systems in nature serve to transport electrons rapidly or to store electrons
56
. In the 
mechanism proposed here, the diheme is fulfilling both of these functions. The interheme 
electron transfer has been observed to be very rapid compared to transfer to a donor and can be 
used to prevent back reaction with the Rieske cluster. Additionally, if cytochrome c553 is scarce 
or turning over at a slower rate than the bc complex, the diheme can store an electron and wait 
for cytochrome c553 without significantly hindering the turnover rate of the bc complex. Further 
study, particularly crystallographic information and inhibitor studies, will clarify these 
mechanistic proposals.  
6.5 Conclusion 
HDX data, when used in conjunction with HM and verified by SASA, improves protein structure 
models and allows mechanistic predictions. For DHCC, HDX kinetic analysis reveals that the 
oxidized state is more dynamic and open than the reduced one. This is seen in loop regions that 
generally undergo more extensive HDX at shorter times. The bundle core regions do not show 
significant differences between the redox states, suggesting that they are stable and undergo little 
conformational change during redox cycling. Redox-dependent conformational change facilitates 
the formation of potential hydrogen bonds, permitting inter-heme electron transfer. The 
dynamics data reveal faster uptake on the heme 2 domain, suggesting that it is the site of electron 
donation to cytochrome c553. This evidence is used to predict the mechanism for the bc complex 
of H. modesticaldum.  
The study provides insight on the relation of conformational change to the binding of the 
electron donor Rieske subunit and soluble electron accepter, cytochrome c553, and on the 
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function of the DHCC subunit within the bc complex of H. modesticaldum photosynthetic 
electron-transfer chain. In addition, we believe that the combined approach of modeling and 
protein footprinting will be useful in other problems in structural biology where protein crystal or 
NMR structures are lacking. Information at the amino-acid level, such as that can be provided by 
HDX with electron-capture dissociation or electron-transfer dissociation or by OH radical 
footprinting (e.g., FPOP), will improve the ability to distinguish models. 
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Mass spectrometry (MS)-based biophysical approaches are new “tools” for protein structure 
characterization owing to their sensitivity and fast turnaround rate. One of the emerging MS-
based biophysical approaches is protein footprinting. One can obtain information such as protein 
high-order structure or dynamics through protein footprinting by counting the number or extent 
of the covalent labels. Such information can be readout on peptide level through bottom-up 
strategy where the target proteins undergo enzymatic digestion process. One of the MS-based 
protein footprinting methods is hydrogen deuterium exchange (HDX). 
In this thesis, we focused on developments and applications of HDX. Basic principles of HDX-
MS and description of HDX-MS-based strategies on characterization of protein-ligand binding 
are introduced in Chapter 1. Chapters 2 and 3 focused on development of a pulsed HDX-MS 
platform on characterization of protein aggregation, and its extension on investigation of drug 
candidate for Alzheimer’s Disease. Chapters 4 and 5 investigated on a protein and six Ca2+ ions 
binding system, focusing on both mapping of binding regions and measuring binding affinities. 
In the last Chapter, we used a combined approach of HDX-MS and homology modeling (HM) to 
determine protein structure when high-resolution X-ray or NMR data are not available. 
HDX-MS is a powerful technique and is widely used in characterization of protein structures. 
We can monitor structural behavior of every single residue except proline through HDX-MS. By 
combining with pepsin digestion and dissociation approaches such as electron capture 
dissociation (ECD) and electron transfer dissociation (ETD), residue-level information can be 
elucidated. In addition, automatic procedures provide better reproducibility and less user effort 
compared to the traditional HDX-MS platform. Furthermore, several available software packages 
ease the users from tedious data analysis process. 
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HDX-MS still requires efforts, however, in its basic understandings. HDX is a reversible labeling 
technique. One must perform the experiment fast between the quenching and LC-MS analysis 
steps, usually within 3-10 min for desalting and peptide trapping. Thus, this disadvantage limits 
application of HDX-MS in analyzing complex samples, which typically requires long-time 
separation and digestion procedures before MS. Other MS-based footprinting approaches, such 
as fast photochemical oxidation of proteins (FPOP) and carboxyl group labeling (GEE), are 
irreversible labeling techniques that allow the labeled proteins to be separated and digested using 
different techniques. Thus, HDX, FPOP, and GEE labeling can be complementary and provide 
complete view of the system better than each of them separately. 
In addition, HDX report solvent accessibility and hydrogen bonding because the backbone 
hydrogen atoms are sensitive to both conditions. Thus, it is difficult to extract reliably the solvent 
accessibility information only. On the contrary, FPOP and GEE reaction is only sensitive to the 
movement of the side chain groups, thus, reporting only the solvent accessibility information. 
Again, one needs to combine these three techniques together for a complete structure analysis. 
 
 
 
245 
 
Curriculum Vitae 
Ying Zhang 
CB1134, One Brookings Dr., St. Louis, MO, 63130 
314-805-3381 
ying.zhang@wustl.edu 
SUMMARY 
 Ph.D. trained in Prof. Michael L. Gross lab. Research assistant 
with 5+ years’ experience in mass spectrometry (MS)-based 
protein structural characterization.  
 Diverse background in MS-based protein structural 
characterization approaches, including hydrogen deuterium 
exchange (HDX-MS) and hydroxyl radical footprinting coupled 
with bottom-up analysis. 
ACHIEVEMENTS 
 Able to handle multiple projects simultaneously, including 
collaboration with Genentech Inc. (Protein Analytical Chemistry) 
on mass spectrometry based structural characterization of protein 
therapeutics. 
 Developed an HDX-MS based platform in studies of protein 
aggregation. 
EDUCATION 
Ph.D. in Chemistry 
Washington University in St. Louis, St. Louis, MO 
Advisor: Profs. Michael L. Gross and Liviu M. Mirica  
2015 
Spring 
 B.S. in Chemistry 
Nanjing University, Nanjing, Jiangsu, China 
2009 
   
PUBLICATIONS 
8. Zhang, Y., Rempel, D.L., Zhang, H., and Gross, M.L. An Improved Fast Photochemical Oxidation of 
Proteins (FPOP) Platform for Protein Therapeutics. (Accepted by JASMS) 
 
7. Zhang, Y., Majumder, E., Yue, H., Blankenship, R.E., and Gross, M.L. (2014). Analysis of Diheme 
Cytochrome c by Hydrogen Deuterium Exchange Mass Spectrometry and Homology Modeling. 
Biochemistry, 53, 5619-5630. 
 
6. Wang, Y.Y., Zhang, Y., Wang, F.D., Giblin, D.E., Hoy, J., Rohrs, H.W., Loomis, R.A., and Buhro, W.E. 
(2014). The Magic-Size (CdSe)34 as a Low-Temperature Nucleant for Cadmium Selenide Nanocrystals; 
Room-Temperature Growth of Crystalline Quantum Platelets. Chemistry of Materials, 26, 2223-2243. 
 
246 
 
5. Zhang, Y., Rempel, D.L., Zhang, J., Sharma, A.K., Mirica, L.M., and Gross, M.L. (2013). Pulsed Hydrogen-
Deuterium Exchange Mass Spectrometry Probes Conformational Changes in Amyloid Beta (A) Peptide 
Aggregation. Proc Natl Acad Sci U S A, 110, 14604-14609. 
 
4. Wang, Y.Y., Liu, Y.H., Zhang, Y., Kowalski, P.J., Rohrs, H.W., and Buhro, W.E. (2013). Preparation of 
Primary Amine Derivatives of the Magic-Size Nanocluster (CdSe)13. Inorg Chem, 52, 2933-2938. 
 
3. Tang, F.Z., Zhang, Y., Rath, N.P., and Mirica, L.M. (2012). Detection of Pd(III) and Pd(IV) Intermediates 
during the Aerobic Oxidative C-C Bond Formation from a Pd(II) Dimethyl Complex. Organometallics, 31, 
6690-6696. 
 
2. Khusnutdinova, J.R., Qu, F.R., Zhang, Y., Rath, N.P., and Mirica, L.M. (2012). Formation of the 
Palladium(IV) Complex [(Me3tacn)Pd(IV)Me3]+ through Aerobic Oxidation of (Me3tacn)Pd(II)Me2 
(Me3tacn = N,N',N''-Trimethyl-1,4,7-Triazacyclononane). Organometallics, 31, 4627-4630. 
 
1. Wang, Y.Y., Liu, Y.H., Zhang, Y., Wang, F.D., Kowalski, P.J., Rohrs, H.W., Loomis, R.A., Gross, M.L., 
and Buhro, W.E. (2012). Isolation of the Magic-Size CdSe Nanoclusters [(CdSe)13(n-octylamine)13] and 
[(CdSe)13(oleylamine)13]. Angew Chem Int Edit, 51, 6154-6157. 
 
MANUSCRIPT 
8. Zhang, Y., Wecksler, A., Molina, P., Deperalta, G., Ling, V., and Gross, M.L. Epitope Mapping of an 
Antibody-Antigen System using Fast Photochemical Oxidation of Protein (FPOP). 
 
7. Zhang, Y., Wecksler, A., Cui, W., Zhang, H., Molina, P., Deperalta, G., Ling, V., and Gross, M.L. Native 
Electrospray and Top-Down Studies of an Intact Antibody-Antigen Complex by FT-ICR Mass 
Spectrometry.  
 
6. Zhang, Y., and Gross, M.L. "Protein-Ligand Binding Study by Hydrogen Deuterium Exchange Mass 
Spectrometry" In Hydrogen-Deuterium Exchange Mass Spectrometry: Fundamentals, Techniques, and 
Applications. (Book Chapter) 
 
5. Zhang, Y., Sharma, A.K., Mirica, L.M., and Gross, M.L. Pulsed Hydrogen-Deuterium Exchange Mass 
Spectrometry Monitors Aggregation Kinetics of Amyloid Beta (A) Peptide Controlled by Bifunctional 
Compounds. 
 
4. Zhang, Y., Rempel, D.L., Slade, D.J., Thompson, P.R., and Gross, M.L. Investigation of Protein Arginine 
Deiminase 2 and Calcium Binding by Hydrogen Deuterium Exchange Mass Spectrometry. 
 
3. Wang, Y.Y., Zhou, Y., Zhang, Y., and Buhro, W.E. Magic-size II-VI Nanoclusters as Synthons for Flat 
Colloidal Nanocrystals. (Submitted to Inorg. Chem.) 
 
2. Slade, D.J., Zhang, X., Fang, P., Dreyton, C.J., Zhang, Y., Rempel, D.L., Gross, M.L., Guo, M., Coonrod, 
S.A., and Thompson, P.R. A Tripartite Calcium Switch Regulates Protein Arginine Deiminase 2 Activity 
and Nuclear Localization. (Submitted to ACS Chem. Biol.) 
 
1. Lindner, K., Pierson, N.A., Zhang, Y., Petre, B-A., Karreman, C., Schildknecht, S., Leist, M., Kipping, M., 
Desor, M., Gross, M.L., Clemmer, D.E., and Przybylski, M. Fragmentation and Aggregation in 
Physiological and Pathophysiological Synuclein Differentiated by the Key Tripeptide VVT (70-72) of -
Synuclein. 
 
 
